Pendahuluan
Halaman ini memberikan analisis komprehensif tentang sejarah perdagangan orang dalam yang diketahui dari Perceptive Advisors Llc. Orang dalam adalah pejabat, direktur, atau investor signifikan dalam suatu perusahaan. Adalah ilegal bagi orang dalam untuk melakukan perdagangan di perusahaan mereka berdasarkan informasi spesifik yang tidak dipublikasikan. Ini tidak berarti bahwa mereka dilarang melakukan perdagangan apa pun di perusahaan mereka sendiri. Namun, mereka harus melaporkan semua perdagangan kepada SEC melalui Formulir 4. Terlepas dari pembatasan ini, penelitian akademis menunjukkan bahwa orang dalam - secara umum - cenderung mengungguli pasar di perusahaan mereka sendiri.
Rata-rata Profitabilitas Perdagangan
Profitabilitas perdagangan rata-rata adalah pengembalian rata-rata dari semua pembelian pasar terbuka yang dilakukan oleh orang dalam dalam tiga tahun terakhir. Untuk menghitung ini, kami memeriksa setiap pembelian pasar terbuka yang tidak direncanakan yang dilakukan oleh orang dalam, tidak termasuk semua perdagangan yang ditandai sebagai bagian dari rencana perdagangan 10b5-1. Kami kemudian menghitung kinerja rata-rata dari perdagangan tersebut selama 3, 6, dan 12 bulan, dengan merata-ratakan setiap durasi tersebut untuk menghasilkan metrik kinerja akhir untuk setiap perdagangan. Terakhir, kami merata-ratakan semua metrik kinerja untuk menghitung metrik kinerja untuk orang dalam. Daftar ini hanya mencakup orang dalam yang telah melakukan setidaknya tiga perdagangan dalam dua tahun terakhir.
Jika profitabilitas perdagangan orang dalam ini adalah "N/A", maka orang dalam tersebut belum melakukan pembelian di pasar terbuka dalam tiga tahun terakhir, atau perdagangan yang mereka lakukan terlalu baru untuk menghitung metrik kinerja yang andal.
Frekuensi Pembaruan: Setiap Hari
Lihat daftar pedagang dalam perusahaan yang paling menguntungkan.
Perusahaan dengan Posisi Orang Dalam yang Dilaporkan
Pengajuan SEC menunjukkan bahwa Perceptive Advisors Llc telah melaporkan kepemilikan atau perdagangan di perusahaan-perusahaan berikut:
Cara Membaca Grafik
Grafik berikut menunjukkan kinerja saham sekuritas setelah setiap perdagangan pasar terbuka yang tidak direncanakan yang dilakukan oleh Perceptive Advisors Llc. Perdagangan yang tidak direncanakan adalah perdagangan yang tidak dilakukan sebagai bagian dari rencana perdagangan 10b5-1. Kinerja saham digambarkan sebagai perubahan persentase kumulatif dalam harga saham. Misalnya, jika perdagangan orang dalam dilakukan pada 1 Januari 2019, grafik akan menunjukkan perubahan persentase harian sekuritas hingga saat ini. Jika harga saham naik dari $10 menjadi $15 selama periode ini, perubahan persentase kumulatif dalam harga saham akan menjadi 50%. Perubahan harga dari $10 menjadi $20 akan menjadi 100%, dan perubahan harga dari $10 menjadi $5 akan menjadi -50%.
Pada akhirnya, kita mencoba menentukan seberapa erat korelasi perdagangan orang dalam dengan pengembalian berlebih (positif atau negatif) pada harga saham untuk melihat apakah orang dalam tersebut mengatur waktu perdagangannya untuk mendapatkan keuntungan dari informasi orang dalam. Pertimbangkan situasi di mana orang dalam melakukan hal ini. Dalam situasi ini, kita akan mengharapkan (a) pengembalian positif setelah pembelian, atau (b) pengembalian negatif setelah penjualan. Dalam kasus (a), grafik PEMBELIAN akan menunjukkan serangkaian kurva yang miring ke atas, menunjukkan pengembalian positif setelah setiap transaksi pembelian. Dalam kasus (b), grafik PENJUALAN akan menunjukkan serangkaian kurva yang miring ke bawah, menunjukkan pengembalian negatif setelah setiap transaksi penjualan.
Namun, ini saja tidak cukup untuk menarik kesimpulan. Jika, misalnya, harga saham perusahaan berada dalam tren kenaikan non-siklikal selama bertahun-tahun, maka kita akan mengharapkan semua plot pasca-pembelian memiliki kemiringan ke atas. Demikian pula, penurunan non-siklikal selama bertahun-tahun akan menghasilkan plot pasca-perdagangan dengan kemiringan ke bawah. Tak satu pun dari grafik ini akan menunjukkan aktivitas perdagangan orang dalam.
Indikator terkuat adalah situasi di mana harga saham sangat siklikal, dan terdapat sinyal positif pada grafik PEMBELIAN dan plot negatif pada grafik PENJUALAN. Situasi ini akan sangat menunjukkan adanya orang dalam yang mengatur waktu perdagangan untuk keuntungan finansial mereka.
Pembelian Orang Dalam ACRV / Acrivon Therapeutics, Inc. - Analisis Keuntungan Jangka Pendek
Pada bagian ini, kami menganalisis profitabilitas setiap pembelian saham oleh orang dalam di pasar terbuka yang tidak direncanakan yang dilakukan di ACRV / Acrivon Therapeutics, Inc.. Analisis ini membantu memahami apakah orang dalam tersebut secara konsisten menghasilkan pengembalian abnormal, dan layak untuk diikuti. Analisis ini dilakukan selama satu tahun setelah setiap transaksi, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan pembelian pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Tanggal Perdagangan | Ticker | Orang Dalam | Dilaporkan Saham |
Dilaporkan Harga |
Disesuaikan Saham |
Disesuaikan Harga |
Dasar Biaya | Hari-hari menuju Maksimal |
Harga di Maksimal |
Maksimal Keuntungan ($) |
Maksimum Pengembalian (%) |
---|---|---|---|---|---|---|---|---|---|---|---|
2024-04-11 | ACRV | PERCEPTIVE ADVISORS LLC | 2,353,000 | 8.5000 | 2,353,000 | 8.5000 | 20,000,500 | 7 | 10.5400 | 4,800,120 | 24.00 |
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Penjualan Orang Dalam ACRV / Acrivon Therapeutics, Inc. - Analisis Kerugian Jangka Pendek
Pada bagian ini, kami menganalisis penghindaran kerugian jangka pendek dari setiap penjualan internal pasar terbuka yang tidak direncanakan yang dilakukan di ACRV / Acrivon Therapeutics, Inc.. Pola penghindaran kerugian yang konsisten dapat menunjukkan bahwa transaksi penjualan di masa mendatang dapat memprediksi penurunan harga. Analisis ini berlaku untuk satu tahun setelah setiap perdagangan, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan penjualan pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Pembelian Orang Dalam ADMA / ADMA Biologics, Inc. - Analisis Keuntungan Jangka Pendek
Pada bagian ini, kami menganalisis profitabilitas setiap pembelian saham oleh orang dalam di pasar terbuka yang tidak direncanakan yang dilakukan di ACRV / Acrivon Therapeutics, Inc.. Analisis ini membantu memahami apakah orang dalam tersebut secara konsisten menghasilkan pengembalian abnormal, dan layak untuk diikuti. Analisis ini dilakukan selama satu tahun setelah setiap transaksi, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan pembelian pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Penjualan Orang Dalam ADMA / ADMA Biologics, Inc. - Analisis Kerugian Jangka Pendek
Pada bagian ini, kami menganalisis penghindaran kerugian jangka pendek dari setiap penjualan internal pasar terbuka yang tidak direncanakan yang dilakukan di ACRV / Acrivon Therapeutics, Inc.. Pola penghindaran kerugian yang konsisten dapat menunjukkan bahwa transaksi penjualan di masa mendatang dapat memprediksi penurunan harga. Analisis ini berlaku untuk satu tahun setelah setiap perdagangan, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan penjualan pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Pembelian Orang Dalam AIS / Tidal Trust III - VistaShares Artificial Intelligence Supercycle ETF - Analisis Keuntungan Jangka Pendek
Pada bagian ini, kami menganalisis profitabilitas setiap pembelian saham oleh orang dalam di pasar terbuka yang tidak direncanakan yang dilakukan di ACRV / Acrivon Therapeutics, Inc.. Analisis ini membantu memahami apakah orang dalam tersebut secara konsisten menghasilkan pengembalian abnormal, dan layak untuk diikuti. Analisis ini dilakukan selama satu tahun setelah setiap transaksi, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan pembelian pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Tanggal Perdagangan | Ticker | Orang Dalam | Dilaporkan Saham |
Dilaporkan Harga |
Disesuaikan Saham |
Disesuaikan Harga |
Dasar Biaya | Hari-hari menuju Maksimal |
Harga di Maksimal |
Maksimal Keuntungan ($) |
Maksimum Pengembalian (%) |
---|---|---|---|---|---|---|---|
Tidak ada transaksi pasar terbuka tak terduga yang diketahui untuk kombinasi orang dalam dan sekuritas ini. |
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Penjualan Orang Dalam AIS / Tidal Trust III - VistaShares Artificial Intelligence Supercycle ETF - Analisis Kerugian Jangka Pendek
Pada bagian ini, kami menganalisis penghindaran kerugian jangka pendek dari setiap penjualan internal pasar terbuka yang tidak direncanakan yang dilakukan di ACRV / Acrivon Therapeutics, Inc.. Pola penghindaran kerugian yang konsisten dapat menunjukkan bahwa transaksi penjualan di masa mendatang dapat memprediksi penurunan harga. Analisis ini berlaku untuk satu tahun setelah setiap perdagangan, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan penjualan pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Tanggal Perdagangan | Ticker | Orang Dalam | Dilaporkan Saham |
Dilaporkan Harga |
Disesuaikan Saham |
Disesuaikan Harga |
Dasar Biaya | Hari-hari menuju Menit |
Harga di Menit |
Kerugian Maksimal Dihindari ($) |
Kerugian Maksimal Dihindari (%) |
---|---|---|---|---|---|---|---|
Tidak ada transaksi pasar terbuka tak terduga yang diketahui untuk kombinasi orang dalam dan sekuritas ini. |
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Pembelian Orang Dalam ALDX / Aldeyra Therapeutics, Inc. - Analisis Keuntungan Jangka Pendek
Pada bagian ini, kami menganalisis profitabilitas setiap pembelian saham oleh orang dalam di pasar terbuka yang tidak direncanakan yang dilakukan di ACRV / Acrivon Therapeutics, Inc.. Analisis ini membantu memahami apakah orang dalam tersebut secara konsisten menghasilkan pengembalian abnormal, dan layak untuk diikuti. Analisis ini dilakukan selama satu tahun setelah setiap transaksi, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan pembelian pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Penjualan Orang Dalam ALDX / Aldeyra Therapeutics, Inc. - Analisis Kerugian Jangka Pendek
Pada bagian ini, kami menganalisis penghindaran kerugian jangka pendek dari setiap penjualan internal pasar terbuka yang tidak direncanakan yang dilakukan di ACRV / Acrivon Therapeutics, Inc.. Pola penghindaran kerugian yang konsisten dapat menunjukkan bahwa transaksi penjualan di masa mendatang dapat memprediksi penurunan harga. Analisis ini berlaku untuk satu tahun setelah setiap perdagangan, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan penjualan pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Pembelian Orang Dalam ANIP / ANI Pharmaceuticals, Inc. - Analisis Keuntungan Jangka Pendek
Pada bagian ini, kami menganalisis profitabilitas setiap pembelian saham oleh orang dalam di pasar terbuka yang tidak direncanakan yang dilakukan di ACRV / Acrivon Therapeutics, Inc.. Analisis ini membantu memahami apakah orang dalam tersebut secara konsisten menghasilkan pengembalian abnormal, dan layak untuk diikuti. Analisis ini dilakukan selama satu tahun setelah setiap transaksi, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan pembelian pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Penjualan Orang Dalam ANIP / ANI Pharmaceuticals, Inc. - Analisis Kerugian Jangka Pendek
Pada bagian ini, kami menganalisis penghindaran kerugian jangka pendek dari setiap penjualan internal pasar terbuka yang tidak direncanakan yang dilakukan di ACRV / Acrivon Therapeutics, Inc.. Pola penghindaran kerugian yang konsisten dapat menunjukkan bahwa transaksi penjualan di masa mendatang dapat memprediksi penurunan harga. Analisis ini berlaku untuk satu tahun setelah setiap perdagangan, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan penjualan pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Pembelian Orang Dalam ATHA / Athira Pharma, Inc. - Analisis Keuntungan Jangka Pendek
Pada bagian ini, kami menganalisis profitabilitas setiap pembelian saham oleh orang dalam di pasar terbuka yang tidak direncanakan yang dilakukan di ACRV / Acrivon Therapeutics, Inc.. Analisis ini membantu memahami apakah orang dalam tersebut secara konsisten menghasilkan pengembalian abnormal, dan layak untuk diikuti. Analisis ini dilakukan selama satu tahun setelah setiap transaksi, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan pembelian pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Penjualan Orang Dalam ATHA / Athira Pharma, Inc. - Analisis Kerugian Jangka Pendek
Pada bagian ini, kami menganalisis penghindaran kerugian jangka pendek dari setiap penjualan internal pasar terbuka yang tidak direncanakan yang dilakukan di ACRV / Acrivon Therapeutics, Inc.. Pola penghindaran kerugian yang konsisten dapat menunjukkan bahwa transaksi penjualan di masa mendatang dapat memprediksi penurunan harga. Analisis ini berlaku untuk satu tahun setelah setiap perdagangan, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan penjualan pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Tanggal Perdagangan | Ticker | Orang Dalam | Dilaporkan Saham |
Dilaporkan Harga |
Disesuaikan Saham |
Disesuaikan Harga |
Dasar Biaya | Hari-hari menuju Menit |
Harga di Menit |
Kerugian Maksimal Dihindari ($) |
Kerugian Maksimal Dihindari (%) |
---|---|---|---|---|---|---|---|
Tidak ada transaksi pasar terbuka tak terduga yang diketahui untuk kombinasi orang dalam dan sekuritas ini. |
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Pembelian Orang Dalam ATXS / Astria Therapeutics, Inc. - Analisis Keuntungan Jangka Pendek
Pada bagian ini, kami menganalisis profitabilitas setiap pembelian saham oleh orang dalam di pasar terbuka yang tidak direncanakan yang dilakukan di ACRV / Acrivon Therapeutics, Inc.. Analisis ini membantu memahami apakah orang dalam tersebut secara konsisten menghasilkan pengembalian abnormal, dan layak untuk diikuti. Analisis ini dilakukan selama satu tahun setelah setiap transaksi, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan pembelian pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Penjualan Orang Dalam ATXS / Astria Therapeutics, Inc. - Analisis Kerugian Jangka Pendek
Pada bagian ini, kami menganalisis penghindaran kerugian jangka pendek dari setiap penjualan internal pasar terbuka yang tidak direncanakan yang dilakukan di ACRV / Acrivon Therapeutics, Inc.. Pola penghindaran kerugian yang konsisten dapat menunjukkan bahwa transaksi penjualan di masa mendatang dapat memprediksi penurunan harga. Analisis ini berlaku untuk satu tahun setelah setiap perdagangan, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan penjualan pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Tanggal Perdagangan | Ticker | Orang Dalam | Dilaporkan Saham |
Dilaporkan Harga |
Disesuaikan Saham |
Disesuaikan Harga |
Dasar Biaya | Hari-hari menuju Menit |
Harga di Menit |
Kerugian Maksimal Dihindari ($) |
Kerugian Maksimal Dihindari (%) |
---|---|---|---|---|---|---|---|
Tidak ada transaksi pasar terbuka tak terduga yang diketahui untuk kombinasi orang dalam dan sekuritas ini. |
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Pembelian Orang Dalam CRNX / Crinetics Pharmaceuticals, Inc. - Analisis Keuntungan Jangka Pendek
Pada bagian ini, kami menganalisis profitabilitas setiap pembelian saham oleh orang dalam di pasar terbuka yang tidak direncanakan yang dilakukan di ACRV / Acrivon Therapeutics, Inc.. Analisis ini membantu memahami apakah orang dalam tersebut secara konsisten menghasilkan pengembalian abnormal, dan layak untuk diikuti. Analisis ini dilakukan selama satu tahun setelah setiap transaksi, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan pembelian pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Penjualan Orang Dalam CRNX / Crinetics Pharmaceuticals, Inc. - Analisis Kerugian Jangka Pendek
Pada bagian ini, kami menganalisis penghindaran kerugian jangka pendek dari setiap penjualan internal pasar terbuka yang tidak direncanakan yang dilakukan di ACRV / Acrivon Therapeutics, Inc.. Pola penghindaran kerugian yang konsisten dapat menunjukkan bahwa transaksi penjualan di masa mendatang dapat memprediksi penurunan harga. Analisis ini berlaku untuk satu tahun setelah setiap perdagangan, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan penjualan pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Tanggal Perdagangan | Ticker | Orang Dalam | Dilaporkan Saham |
Dilaporkan Harga |
Disesuaikan Saham |
Disesuaikan Harga |
Dasar Biaya | Hari-hari menuju Menit |
Harga di Menit |
Kerugian Maksimal Dihindari ($) |
Kerugian Maksimal Dihindari (%) |
---|---|---|---|---|---|---|---|
Tidak ada transaksi pasar terbuka tak terduga yang diketahui untuk kombinasi orang dalam dan sekuritas ini. |
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Pembelian Orang Dalam FOLD / Amicus Therapeutics, Inc. - Analisis Keuntungan Jangka Pendek
Pada bagian ini, kami menganalisis profitabilitas setiap pembelian saham oleh orang dalam di pasar terbuka yang tidak direncanakan yang dilakukan di ACRV / Acrivon Therapeutics, Inc.. Analisis ini membantu memahami apakah orang dalam tersebut secara konsisten menghasilkan pengembalian abnormal, dan layak untuk diikuti. Analisis ini dilakukan selama satu tahun setelah setiap transaksi, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan pembelian pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Penjualan Orang Dalam FOLD / Amicus Therapeutics, Inc. - Analisis Kerugian Jangka Pendek
Pada bagian ini, kami menganalisis penghindaran kerugian jangka pendek dari setiap penjualan internal pasar terbuka yang tidak direncanakan yang dilakukan di ACRV / Acrivon Therapeutics, Inc.. Pola penghindaran kerugian yang konsisten dapat menunjukkan bahwa transaksi penjualan di masa mendatang dapat memprediksi penurunan harga. Analisis ini berlaku untuk satu tahun setelah setiap perdagangan, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan penjualan pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Tanggal Perdagangan | Ticker | Orang Dalam | Dilaporkan Saham |
Dilaporkan Harga |
Disesuaikan Saham |
Disesuaikan Harga |
Dasar Biaya | Hari-hari menuju Menit |
Harga di Menit |
Kerugian Maksimal Dihindari ($) |
Kerugian Maksimal Dihindari (%) |
---|---|---|---|---|---|---|---|---|---|---|---|
2016-08-25 | FOLD | PERCEPTIVE ADVISORS LLC | 1,100,000 | 6.8100 | 1,100,000 | 6.8100 | 7,491,000 | 119 | 4.53 | -2,508,000 | -33.48 |
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Pembelian Orang Dalam LPTX / Leap Therapeutics, Inc. - Analisis Keuntungan Jangka Pendek
Pada bagian ini, kami menganalisis profitabilitas setiap pembelian saham oleh orang dalam di pasar terbuka yang tidak direncanakan yang dilakukan di ACRV / Acrivon Therapeutics, Inc.. Analisis ini membantu memahami apakah orang dalam tersebut secara konsisten menghasilkan pengembalian abnormal, dan layak untuk diikuti. Analisis ini dilakukan selama satu tahun setelah setiap transaksi, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan pembelian pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Tanggal Perdagangan | Ticker | Orang Dalam | Dilaporkan Saham |
Dilaporkan Harga |
Disesuaikan Saham |
Disesuaikan Harga |
Dasar Biaya | Hari-hari menuju Maksimal |
Harga di Maksimal |
Maksimal Keuntungan ($) |
Maksimum Pengembalian (%) |
---|---|---|---|---|---|---|---|---|---|---|---|
2020-06-22 | LPTX | PERCEPTIVE ADVISORS LLC | 1,750,000 | 2.0000 | 175,000 | 20.0000 | 3,500,000 | 240 | 301 | 49,175,000 | 1,405.00 |
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Penjualan Orang Dalam LPTX / Leap Therapeutics, Inc. - Analisis Kerugian Jangka Pendek
Pada bagian ini, kami menganalisis penghindaran kerugian jangka pendek dari setiap penjualan internal pasar terbuka yang tidak direncanakan yang dilakukan di ACRV / Acrivon Therapeutics, Inc.. Pola penghindaran kerugian yang konsisten dapat menunjukkan bahwa transaksi penjualan di masa mendatang dapat memprediksi penurunan harga. Analisis ini berlaku untuk satu tahun setelah setiap perdagangan, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan penjualan pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Tanggal Perdagangan | Ticker | Orang Dalam | Dilaporkan Saham |
Dilaporkan Harga |
Disesuaikan Saham |
Disesuaikan Harga |
Dasar Biaya | Hari-hari menuju Menit |
Harga di Menit |
Kerugian Maksimal Dihindari ($) |
Kerugian Maksimal Dihindari (%) |
---|---|---|---|---|---|---|---|
Tidak ada transaksi pasar terbuka tak terduga yang diketahui untuk kombinasi orang dalam dan sekuritas ini. |
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Pembelian Orang Dalam LYRA / Lyra Therapeutics, Inc. - Analisis Keuntungan Jangka Pendek
Pada bagian ini, kami menganalisis profitabilitas setiap pembelian saham oleh orang dalam di pasar terbuka yang tidak direncanakan yang dilakukan di ACRV / Acrivon Therapeutics, Inc.. Analisis ini membantu memahami apakah orang dalam tersebut secara konsisten menghasilkan pengembalian abnormal, dan layak untuk diikuti. Analisis ini dilakukan selama satu tahun setelah setiap transaksi, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan pembelian pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Penjualan Orang Dalam LYRA / Lyra Therapeutics, Inc. - Analisis Kerugian Jangka Pendek
Pada bagian ini, kami menganalisis penghindaran kerugian jangka pendek dari setiap penjualan internal pasar terbuka yang tidak direncanakan yang dilakukan di ACRV / Acrivon Therapeutics, Inc.. Pola penghindaran kerugian yang konsisten dapat menunjukkan bahwa transaksi penjualan di masa mendatang dapat memprediksi penurunan harga. Analisis ini berlaku untuk satu tahun setelah setiap perdagangan, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan penjualan pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Tanggal Perdagangan | Ticker | Orang Dalam | Dilaporkan Saham |
Dilaporkan Harga |
Disesuaikan Saham |
Disesuaikan Harga |
Dasar Biaya | Hari-hari menuju Menit |
Harga di Menit |
Kerugian Maksimal Dihindari ($) |
Kerugian Maksimal Dihindari (%) |
---|---|---|---|---|---|---|---|
Tidak ada transaksi pasar terbuka tak terduga yang diketahui untuk kombinasi orang dalam dan sekuritas ini. |
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Pembelian Orang Dalam MGTX / MeiraGTx Holdings plc - Analisis Keuntungan Jangka Pendek
Pada bagian ini, kami menganalisis profitabilitas setiap pembelian saham oleh orang dalam di pasar terbuka yang tidak direncanakan yang dilakukan di ACRV / Acrivon Therapeutics, Inc.. Analisis ini membantu memahami apakah orang dalam tersebut secara konsisten menghasilkan pengembalian abnormal, dan layak untuk diikuti. Analisis ini dilakukan selama satu tahun setelah setiap transaksi, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan pembelian pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Penjualan Orang Dalam MGTX / MeiraGTx Holdings plc - Analisis Kerugian Jangka Pendek
Pada bagian ini, kami menganalisis penghindaran kerugian jangka pendek dari setiap penjualan internal pasar terbuka yang tidak direncanakan yang dilakukan di ACRV / Acrivon Therapeutics, Inc.. Pola penghindaran kerugian yang konsisten dapat menunjukkan bahwa transaksi penjualan di masa mendatang dapat memprediksi penurunan harga. Analisis ini berlaku untuk satu tahun setelah setiap perdagangan, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan penjualan pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Tanggal Perdagangan | Ticker | Orang Dalam | Dilaporkan Saham |
Dilaporkan Harga |
Disesuaikan Saham |
Disesuaikan Harga |
Dasar Biaya | Hari-hari menuju Menit |
Harga di Menit |
Kerugian Maksimal Dihindari ($) |
Kerugian Maksimal Dihindari (%) |
---|---|---|---|---|---|---|---|
Tidak ada transaksi pasar terbuka tak terduga yang diketahui untuk kombinasi orang dalam dan sekuritas ini. |
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Pembelian Orang Dalam NAUT / Nautilus Biotechnology, Inc. - Analisis Keuntungan Jangka Pendek
Pada bagian ini, kami menganalisis profitabilitas setiap pembelian saham oleh orang dalam di pasar terbuka yang tidak direncanakan yang dilakukan di ACRV / Acrivon Therapeutics, Inc.. Analisis ini membantu memahami apakah orang dalam tersebut secara konsisten menghasilkan pengembalian abnormal, dan layak untuk diikuti. Analisis ini dilakukan selama satu tahun setelah setiap transaksi, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan pembelian pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Penjualan Orang Dalam NAUT / Nautilus Biotechnology, Inc. - Analisis Kerugian Jangka Pendek
Pada bagian ini, kami menganalisis penghindaran kerugian jangka pendek dari setiap penjualan internal pasar terbuka yang tidak direncanakan yang dilakukan di ACRV / Acrivon Therapeutics, Inc.. Pola penghindaran kerugian yang konsisten dapat menunjukkan bahwa transaksi penjualan di masa mendatang dapat memprediksi penurunan harga. Analisis ini berlaku untuk satu tahun setelah setiap perdagangan, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan penjualan pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Tanggal Perdagangan | Ticker | Orang Dalam | Dilaporkan Saham |
Dilaporkan Harga |
Disesuaikan Saham |
Disesuaikan Harga |
Dasar Biaya | Hari-hari menuju Menit |
Harga di Menit |
Kerugian Maksimal Dihindari ($) |
Kerugian Maksimal Dihindari (%) |
---|---|---|---|---|---|---|---|
Tidak ada transaksi pasar terbuka tak terduga yang diketahui untuk kombinasi orang dalam dan sekuritas ini. |
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Pembelian Orang Dalam OBIO / Orchestra BioMed Holdings, Inc. - Analisis Keuntungan Jangka Pendek
Pada bagian ini, kami menganalisis profitabilitas setiap pembelian saham oleh orang dalam di pasar terbuka yang tidak direncanakan yang dilakukan di ACRV / Acrivon Therapeutics, Inc.. Analisis ini membantu memahami apakah orang dalam tersebut secara konsisten menghasilkan pengembalian abnormal, dan layak untuk diikuti. Analisis ini dilakukan selama satu tahun setelah setiap transaksi, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan pembelian pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Tanggal Perdagangan | Ticker | Orang Dalam | Dilaporkan Saham |
Dilaporkan Harga |
Disesuaikan Saham |
Disesuaikan Harga |
Dasar Biaya | Hari-hari menuju Maksimal |
Harga di Maksimal |
Maksimal Keuntungan ($) |
Maksimum Pengembalian (%) |
---|---|---|---|---|---|---|---|---|---|---|---|
2025-08-01 | OBIO | PERCEPTIVE ADVISORS LLC | 700,000 | 2.7500 | 700,000 | 2.7500 | 1,925,000 | 25 | 3.0000 | 175,000 | 9.09 |
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Penjualan Orang Dalam OBIO / Orchestra BioMed Holdings, Inc. - Analisis Kerugian Jangka Pendek
Pada bagian ini, kami menganalisis penghindaran kerugian jangka pendek dari setiap penjualan internal pasar terbuka yang tidak direncanakan yang dilakukan di ACRV / Acrivon Therapeutics, Inc.. Pola penghindaran kerugian yang konsisten dapat menunjukkan bahwa transaksi penjualan di masa mendatang dapat memprediksi penurunan harga. Analisis ini berlaku untuk satu tahun setelah setiap perdagangan, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan penjualan pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Tanggal Perdagangan | Ticker | Orang Dalam | Dilaporkan Saham |
Dilaporkan Harga |
Disesuaikan Saham |
Disesuaikan Harga |
Dasar Biaya | Hari-hari menuju Menit |
Harga di Menit |
Kerugian Maksimal Dihindari ($) |
Kerugian Maksimal Dihindari (%) |
---|---|---|---|---|---|---|---|
Tidak ada transaksi pasar terbuka tak terduga yang diketahui untuk kombinasi orang dalam dan sekuritas ini. |
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Pembelian Orang Dalam SCYX / SCYNEXIS, Inc. - Analisis Keuntungan Jangka Pendek
Pada bagian ini, kami menganalisis profitabilitas setiap pembelian saham oleh orang dalam di pasar terbuka yang tidak direncanakan yang dilakukan di ACRV / Acrivon Therapeutics, Inc.. Analisis ini membantu memahami apakah orang dalam tersebut secara konsisten menghasilkan pengembalian abnormal, dan layak untuk diikuti. Analisis ini dilakukan selama satu tahun setelah setiap transaksi, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan pembelian pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Tanggal Perdagangan | Ticker | Orang Dalam | Dilaporkan Saham |
Dilaporkan Harga |
Disesuaikan Saham |
Disesuaikan Harga |
Dasar Biaya | Hari-hari menuju Maksimal |
Harga di Maksimal |
Maksimal Keuntungan ($) |
Maksimum Pengembalian (%) |
---|---|---|---|---|---|---|---|
Tidak ada transaksi pasar terbuka tak terduga yang diketahui untuk kombinasi orang dalam dan sekuritas ini. |
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Penjualan Orang Dalam SCYX / SCYNEXIS, Inc. - Analisis Kerugian Jangka Pendek
Pada bagian ini, kami menganalisis penghindaran kerugian jangka pendek dari setiap penjualan internal pasar terbuka yang tidak direncanakan yang dilakukan di ACRV / Acrivon Therapeutics, Inc.. Pola penghindaran kerugian yang konsisten dapat menunjukkan bahwa transaksi penjualan di masa mendatang dapat memprediksi penurunan harga. Analisis ini berlaku untuk satu tahun setelah setiap perdagangan, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan penjualan pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Pembelian Orang Dalam SLDB / Solid Biosciences Inc. - Analisis Keuntungan Jangka Pendek
Pada bagian ini, kami menganalisis profitabilitas setiap pembelian saham oleh orang dalam di pasar terbuka yang tidak direncanakan yang dilakukan di ACRV / Acrivon Therapeutics, Inc.. Analisis ini membantu memahami apakah orang dalam tersebut secara konsisten menghasilkan pengembalian abnormal, dan layak untuk diikuti. Analisis ini dilakukan selama satu tahun setelah setiap transaksi, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan pembelian pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Penjualan Orang Dalam SLDB / Solid Biosciences Inc. - Analisis Kerugian Jangka Pendek
Pada bagian ini, kami menganalisis penghindaran kerugian jangka pendek dari setiap penjualan internal pasar terbuka yang tidak direncanakan yang dilakukan di ACRV / Acrivon Therapeutics, Inc.. Pola penghindaran kerugian yang konsisten dapat menunjukkan bahwa transaksi penjualan di masa mendatang dapat memprediksi penurunan harga. Analisis ini berlaku untuk satu tahun setelah setiap perdagangan, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan penjualan pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Tanggal Perdagangan | Ticker | Orang Dalam | Dilaporkan Saham |
Dilaporkan Harga |
Disesuaikan Saham |
Disesuaikan Harga |
Dasar Biaya | Hari-hari menuju Menit |
Harga di Menit |
Kerugian Maksimal Dihindari ($) |
Kerugian Maksimal Dihindari (%) |
---|---|---|---|---|---|---|---|
Tidak ada transaksi pasar terbuka tak terduga yang diketahui untuk kombinasi orang dalam dan sekuritas ini. |
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Pembelian Orang Dalam SLNO / Soleno Therapeutics, Inc. - Analisis Keuntungan Jangka Pendek
Pada bagian ini, kami menganalisis profitabilitas setiap pembelian saham oleh orang dalam di pasar terbuka yang tidak direncanakan yang dilakukan di ACRV / Acrivon Therapeutics, Inc.. Analisis ini membantu memahami apakah orang dalam tersebut secara konsisten menghasilkan pengembalian abnormal, dan layak untuk diikuti. Analisis ini dilakukan selama satu tahun setelah setiap transaksi, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan pembelian pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Penjualan Orang Dalam SLNO / Soleno Therapeutics, Inc. - Analisis Kerugian Jangka Pendek
Pada bagian ini, kami menganalisis penghindaran kerugian jangka pendek dari setiap penjualan internal pasar terbuka yang tidak direncanakan yang dilakukan di ACRV / Acrivon Therapeutics, Inc.. Pola penghindaran kerugian yang konsisten dapat menunjukkan bahwa transaksi penjualan di masa mendatang dapat memprediksi penurunan harga. Analisis ini berlaku untuk satu tahun setelah setiap perdagangan, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan penjualan pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Tanggal Perdagangan | Ticker | Orang Dalam | Dilaporkan Saham |
Dilaporkan Harga |
Disesuaikan Saham |
Disesuaikan Harga |
Dasar Biaya | Hari-hari menuju Menit |
Harga di Menit |
Kerugian Maksimal Dihindari ($) |
Kerugian Maksimal Dihindari (%) |
---|---|---|---|---|---|---|---|
Tidak ada transaksi pasar terbuka tak terduga yang diketahui untuk kombinasi orang dalam dan sekuritas ini. |
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Pembelian Orang Dalam TLPH / Talphera, Inc. - Analisis Keuntungan Jangka Pendek
Pada bagian ini, kami menganalisis profitabilitas setiap pembelian saham oleh orang dalam di pasar terbuka yang tidak direncanakan yang dilakukan di ACRV / Acrivon Therapeutics, Inc.. Analisis ini membantu memahami apakah orang dalam tersebut secara konsisten menghasilkan pengembalian abnormal, dan layak untuk diikuti. Analisis ini dilakukan selama satu tahun setelah setiap transaksi, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan pembelian pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Penjualan Orang Dalam TLPH / Talphera, Inc. - Analisis Kerugian Jangka Pendek
Pada bagian ini, kami menganalisis penghindaran kerugian jangka pendek dari setiap penjualan internal pasar terbuka yang tidak direncanakan yang dilakukan di ACRV / Acrivon Therapeutics, Inc.. Pola penghindaran kerugian yang konsisten dapat menunjukkan bahwa transaksi penjualan di masa mendatang dapat memprediksi penurunan harga. Analisis ini berlaku untuk satu tahun setelah setiap perdagangan, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan penjualan pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Pembelian Orang Dalam VRCA / Verrica Pharmaceuticals Inc. - Analisis Keuntungan Jangka Pendek
Pada bagian ini, kami menganalisis profitabilitas setiap pembelian saham oleh orang dalam di pasar terbuka yang tidak direncanakan yang dilakukan di ACRV / Acrivon Therapeutics, Inc.. Analisis ini membantu memahami apakah orang dalam tersebut secara konsisten menghasilkan pengembalian abnormal, dan layak untuk diikuti. Analisis ini dilakukan selama satu tahun setelah setiap transaksi, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan pembelian pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Penjualan Orang Dalam VRCA / Verrica Pharmaceuticals Inc. - Analisis Kerugian Jangka Pendek
Pada bagian ini, kami menganalisis penghindaran kerugian jangka pendek dari setiap penjualan internal pasar terbuka yang tidak direncanakan yang dilakukan di ACRV / Acrivon Therapeutics, Inc.. Pola penghindaran kerugian yang konsisten dapat menunjukkan bahwa transaksi penjualan di masa mendatang dapat memprediksi penurunan harga. Analisis ini berlaku untuk satu tahun setelah setiap perdagangan, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan penjualan pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Tanggal Perdagangan | Ticker | Orang Dalam | Dilaporkan Saham |
Dilaporkan Harga |
Disesuaikan Saham |
Disesuaikan Harga |
Dasar Biaya | Hari-hari menuju Menit |
Harga di Menit |
Kerugian Maksimal Dihindari ($) |
Kerugian Maksimal Dihindari (%) |
---|---|---|---|---|---|---|---|
Tidak ada transaksi pasar terbuka tak terduga yang diketahui untuk kombinasi orang dalam dan sekuritas ini. |
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Pembelian Orang Dalam VYNE / VYNE Therapeutics Inc. - Analisis Keuntungan Jangka Pendek
Pada bagian ini, kami menganalisis profitabilitas setiap pembelian saham oleh orang dalam di pasar terbuka yang tidak direncanakan yang dilakukan di ACRV / Acrivon Therapeutics, Inc.. Analisis ini membantu memahami apakah orang dalam tersebut secara konsisten menghasilkan pengembalian abnormal, dan layak untuk diikuti. Analisis ini dilakukan selama satu tahun setelah setiap transaksi, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan pembelian pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Penjualan Orang Dalam VYNE / VYNE Therapeutics Inc. - Analisis Kerugian Jangka Pendek
Pada bagian ini, kami menganalisis penghindaran kerugian jangka pendek dari setiap penjualan internal pasar terbuka yang tidak direncanakan yang dilakukan di ACRV / Acrivon Therapeutics, Inc.. Pola penghindaran kerugian yang konsisten dapat menunjukkan bahwa transaksi penjualan di masa mendatang dapat memprediksi penurunan harga. Analisis ini berlaku untuk satu tahun setelah setiap perdagangan, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan penjualan pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Sejarah Perdagangan Orang Dalam
Tabel ini menunjukkan daftar lengkap transaksi orang dalam yang dilakukan oleh Perceptive Advisors Llc sebagaimana diungkapkan kepada Komisi Bursa Efek (Securities Exchange Commission/SEC).
Tanggal File | Tanggal Transaksi | Formulir | Ticker | Keamanan | Kode | Saham | Sisa Saham | Persen Ubah |
Bagikan Harga |
Tran Nilai |
Sisa Nilai |
|
---|---|---|---|---|---|---|---|---|---|---|---|---|
2025-08-05 |
|
4 | OBIO |
Orchestra BioMed Holdings, Inc.
Common Stock |
P - Purchase | 700,000 | 5,292,556 | 15.24 | 2.75 | 1,925,000 | 14,554,529 | |
2025-05-01 |
|
4 | ACRV |
Acrivon Therapeutics, Inc.
Common Stock |
S - Sale | -298,886 | 3,104,139 | -8.78 | 1.34 | -400,507 | 4,159,546 | |
2025-05-01 |
|
4 | ACRV |
Acrivon Therapeutics, Inc.
Common Stock |
S - Sale | -437,881 | 3,403,025 | -11.40 | 1.41 | -617,412 | 4,798,265 | |
2025-04-29 |
|
4 | ACRV |
Acrivon Therapeutics, Inc.
Common Stock |
S - Sale | -250,000 | 3,840,906 | -6.11 | 1.41 | -352,500 | 5,415,677 | |
2025-04-29 |
|
4 | ACRV |
Acrivon Therapeutics, Inc.
Common Stock |
S - Sale | -215,283 | 4,090,906 | -5.00 | 1.56 | -335,841 | 6,381,813 | |
2025-04-29 |
|
4 | ACRV |
Acrivon Therapeutics, Inc.
Common Stock |
S - Sale | -1,054,669 | 4,306,189 | -19.67 | 1.95 | -2,056,605 | 8,397,069 | |
2025-04-07 |
|
4 | ALDX |
Aldeyra Therapeutics, Inc.
Common Stock |
S - Sale | -3,400,000 | 5,875,851 | -36.65 | 1.42 | -4,828,000 | 8,343,708 | |
2025-02-21 |
|
4 | SLDB |
Solid Biosciences Inc.
Common Stock |
P - Purchase | 5,000,000 | 11,833,539 | 73.17 | 4.03 | 20,150,000 | 47,689,162 | |
2025-02-14 |
|
4 | ADGM |
Adagio Medical Holdings, Inc.
Common Stock |
A - Award | 64,167 | 9,675,684 | 0.67 | ||||
2024-08-14 |
|
4 | MGTX |
MeiraGTx Holdings plc
Ordinary Shares |
P - Purchase | 1,250,000 | 12,531,103 | 11.08 | 4.00 | 5,000,000 | 50,124,412 | |
2024-08-01 | 3 | ADGM |
Adagio Medical Holdings, Inc.
Common stock |
7,160,397 | ||||||||
2024-07-17 | 3 | OBIO |
Orchestra BioMed Holdings, Inc.
Common Stock, $0.0001 par value per share |
4,592,556 | ||||||||
2024-04-15 |
|
4 | ACRV |
Acrivon Therapeutics, Inc.
Common Stock |
P - Purchase | 2,353,000 | 5,360,858 | 78.23 | 8.50 | 20,000,500 | 45,567,293 | |
2024-04-08 |
|
4 | ALDX |
Aldeyra Therapeutics, Inc.
Common Stock |
P - Purchase | 37,712 | 9,275,851 | 0.41 | 4.74 | 178,755 | 43,967,534 | |
2024-04-08 |
|
4 | ALDX |
Aldeyra Therapeutics, Inc.
Common Stock |
P - Purchase | 140,281 | 9,238,139 | 1.54 | 4.67 | 655,112 | 43,142,109 | |
2024-04-03 |
|
4 | ALDX |
Aldeyra Therapeutics, Inc.
Common Stock |
P - Purchase | 309,847 | 9,097,858 | 3.53 | 4.09 | 1,267,274 | 37,210,239 | |
2024-04-03 |
|
4 | ALDX |
Aldeyra Therapeutics, Inc.
Common Stock |
P - Purchase | 186,051 | 8,788,011 | 2.16 | 3.44 | 640,015 | 30,230,758 | |
2024-04-03 |
|
4 | ALDX |
Aldeyra Therapeutics, Inc.
Common Stock |
P - Purchase | 8,374 | 8,601,960 | 0.10 | 3.25 | 27,216 | 27,956,370 | |
2024-02-21 |
|
4 | CERE |
Cerevel Therapeutics Holdings, Inc.
Common Stock |
G - Gift | -170,317 | 0 | -100.00 | ||||
2024-02-20 |
|
4 | LIAN |
LianBio
Ordinary Shares |
F - Taxes | -19,218 | 17,082 | -52.94 | 4.76 | -91,478 | 81,310 | |
2024-02-20 |
|
4 | LIAN |
LianBio
Ordinary Shares |
F - Taxes | -19,218 | 17,082 | -52.94 | 4.76 | -91,478 | 81,310 | |
2024-02-20 |
|
4 | LIAN |
LianBio
Ordinary Shares |
M - Exercise | 36,300 | 36,300 | 2.52 | 91,476 | 91,476 | ||
2024-02-20 |
|
4 | LIAN |
LianBio
Ordinary Shares |
M - Exercise | 36,300 | 36,300 | 2.52 | 91,476 | 91,476 | ||
2024-02-05 |
|
4 | ATXS |
Astria Therapeutics, Inc.
Common Stock |
P - Purchase | 2,481,350 | 4,873,721 | 103.72 | 12.09 | 29,999,522 | 58,923,287 | |
2024-01-12 |
|
4 | SLDB |
Solid Biosciences Inc.
Common Stock |
P - Purchase | 3,410,713 | 6,833,539 | 99.65 | 5.53 | 18,861,243 | 37,789,471 | |
2023-12-29 |
|
4 | ATHA |
Athira Pharma, Inc.
Common Stock |
P - Purchase | 163,954 | 5,402,964 | 3.13 | 2.38 | 390,211 | 12,859,054 | |
2023-12-29 |
|
4 | ATHA |
Athira Pharma, Inc.
Common Stock |
P - Purchase | 409,598 | 5,239,010 | 8.48 | 2.44 | 999,419 | 12,783,184 | |
2023-12-29 |
|
4 | ATHA |
Athira Pharma, Inc.
Common Stock |
P - Purchase | 32,134 | 4,829,412 | 0.67 | 2.28 | 73,266 | 11,011,059 | |
2023-12-29 |
|
4 | VRCA |
Verrica Pharmaceuticals Inc.
Common Stock |
P - Purchase | 115,774 | 7,099,182 | 1.66 | 7.24 | 838,204 | 51,398,078 | |
2023-12-29 |
|
4 | VRCA |
Verrica Pharmaceuticals Inc.
Common Stock |
P - Purchase | 126,116 | 6,983,408 | 1.84 | 7.08 | 892,901 | 49,442,529 | |
2023-12-29 |
|
4 | VRCA |
Verrica Pharmaceuticals Inc.
Common Stock |
P - Purchase | 79,726 | 6,857,292 | 1.18 | 7.20 | 574,027 | 49,372,502 | |
2023-12-26 |
|
4 | VRCA |
Verrica Pharmaceuticals Inc.
Common Stock |
P - Purchase | 54,652 | 6,777,566 | 0.81 | 6.49 | 354,691 | 43,986,403 | |
2023-12-26 |
|
4 | VRCA |
Verrica Pharmaceuticals Inc.
Common Stock |
P - Purchase | 250,000 | 6,722,914 | 3.86 | 6.67 | 1,667,500 | 44,841,836 | |
2023-12-26 |
|
4 | VRCA |
Verrica Pharmaceuticals Inc.
Common Stock |
P - Purchase | 200,000 | 6,472,914 | 3.19 | 6.17 | 1,234,000 | 39,937,879 | |
2023-12-22 |
|
4 | ATXS |
Astria Therapeutics, Inc.
Common Stock |
P - Purchase | 740,000 | 2,392,371 | 44.78 | 6.20 | 4,588,000 | 14,832,700 | |
2023-12-19 |
|
4 | VRCA |
Verrica Pharmaceuticals Inc.
Common Stock |
P - Purchase | 277,008 | 6,272,914 | 4.62 | 5.36 | 1,484,763 | 33,622,819 | |
2023-12-19 |
|
4 | VRCA |
Verrica Pharmaceuticals Inc.
Common Stock |
P - Purchase | 456,923 | 5,995,906 | 8.25 | 5.41 | 2,471,953 | 32,437,851 | |
2023-12-19 |
|
4 | VRCA |
Verrica Pharmaceuticals Inc.
Common Stock |
P - Purchase | 500,000 | 5,538,983 | 9.92 | 5.97 | 2,985,000 | 33,067,729 | |
2023-11-14 |
|
4 | CRGX |
CARGO Therapeutics, Inc.
Common Stock |
P - Purchase | 333,333 | 333,333 | 15.00 | 4,999,995 | 4,999,995 | ||
2023-11-14 |
|
4 | CRGX |
CARGO Therapeutics, Inc.
Common Stock |
P - Purchase | 333,333 | 333,333 | 15.00 | 4,999,995 | 4,999,995 | ||
2023-11-14 |
|
4 | CRGX |
CARGO Therapeutics, Inc.
Common Stock |
C - Conversion | 2,579,502 | 2,579,502 | |||||
2023-10-18 |
|
4 | ATXS |
Astria Therapeutics, Inc.
Common Stock |
P - Purchase | 460,546 | 1,611,699 | 40.01 | 6.51 | 2,999,997 | 10,498,607 | |
2023-10-18 |
|
4 | ATXS |
Astria Therapeutics, Inc.
Common Stock |
P - Purchase | 614,062 | 1,652,371 | 59.14 | 6.51 | 4,000,000 | 10,763,545 | |
2023-10-18 |
|
4 | ALDX |
Aldeyra Therapeutics, Inc.
Common Stock |
S - Sale | -306,499 | 8,593,586 | -3.44 | 1.74 | -533,308 | 14,952,840 | |
2023-10-18 |
|
4 | ALDX |
Aldeyra Therapeutics, Inc.
Common Stock |
S - Sale | -2,450,000 | 8,900,085 | -21.59 | 1.60 | -3,920,000 | 14,240,136 | |
2023-10-17 |
|
4 | CERE |
Cerevel Therapeutics Holdings, Inc.
Common Stock |
P - Purchase | 876,808 | 10,794,876 | 8.84 | 22.81 | 19,999,990 | 246,231,122 | |
2023-09-28 |
|
4 | SLNO |
SOLENO THERAPEUTICS INC
Common Stock |
P - Purchase | 250,000 | 3,074,542 | 8.85 | 20.00 | 5,000,000 | 61,490,840 | |
2023-09-28 |
|
4 | SLNO |
SOLENO THERAPEUTICS INC
Common Stock |
P - Purchase | 36,939 | 2,824,542 | 1.33 | 21.00 | 775,719 | 59,315,382 | |
2023-09-28 |
|
4 | SLNO |
SOLENO THERAPEUTICS INC
Common Stock |
P - Purchase | 117,996 | 2,787,603 | 4.42 | 20.03 | 2,363,460 | 55,835,688 | |
2023-09-28 |
|
4 | SLNO |
SOLENO THERAPEUTICS INC
Common Stock |
P - Purchase | 88,685 | 2,669,607 | 3.44 | 19.11 | 1,694,770 | 51,016,190 | |
2023-09-28 |
|
4 | SLNO |
SOLENO THERAPEUTICS INC
Common Stock |
P - Purchase | 52,691 | 2,580,922 | 2.08 | 18.24 | 961,084 | 47,076,017 | |
2023-09-28 |
|
4 | SLNO |
SOLENO THERAPEUTICS INC
Common Stock |
P - Purchase | 75,477 | 2,528,231 | 3.08 | 17.28 | 1,304,243 | 43,687,832 | |
2023-09-28 |
|
4 | SLNO |
SOLENO THERAPEUTICS INC
Common Stock |
P - Purchase | 27,769 | 2,452,754 | 1.15 | 16.00 | 444,304 | 39,244,064 | |
2023-09-28 |
|
4 | SLNO |
SOLENO THERAPEUTICS INC
Common Stock |
P - Purchase | 3,326 | 2,424,985 | 0.14 | 14.61 | 48,593 | 35,429,031 | |
2023-09-28 |
|
4 | SLNO |
SOLENO THERAPEUTICS INC
Common Stock |
P - Purchase | 30,511 | 2,421,659 | 1.28 | 13.92 | 424,713 | 33,709,493 | |
2023-09-28 |
|
4 | SLNO |
SOLENO THERAPEUTICS INC
Common Stock |
P - Purchase | 42,838 | 2,391,148 | 1.82 | 12.84 | 550,040 | 30,702,340 | |
2023-09-28 |
|
4 | SLNO |
SOLENO THERAPEUTICS INC
Common Stock |
P - Purchase | 77,837 | 2,348,310 | 3.43 | 11.81 | 919,255 | 27,733,541 | |
2023-09-28 |
|
4 | SLNO |
SOLENO THERAPEUTICS INC
Common Stock |
P - Purchase | 37,911 | 2,270,473 | 1.70 | 11.05 | 418,917 | 25,088,727 | |
2023-09-28 |
|
4 | SLNO |
SOLENO THERAPEUTICS INC
Common Stock |
P - Purchase | 5,419 | 2,232,562 | 0.24 | 9.52 | 51,589 | 21,253,990 | |
2023-09-28 |
|
4 | SLNO |
SOLENO THERAPEUTICS INC
Common Stock |
P - Purchase | 13,687 | 2,227,143 | 0.62 | 8.30 | 113,602 | 18,485,287 | |
2023-09-28 |
|
4 | SLNO |
SOLENO THERAPEUTICS INC
Common Stock |
P - Purchase | 5,703 | 2,213,456 | 0.26 | 7.65 | 43,628 | 16,932,938 | |
2023-06-06 |
|
4 | SLNO |
SOLENO THERAPEUTICS INC
Common Stock |
P - Purchase | 200 | 2,207,753 | 0.01 | 5.93 | 1,186 | 13,091,975 | |
2023-06-06 |
|
4 | SLNO |
SOLENO THERAPEUTICS INC
Common Stock |
P - Purchase | 78,468 | 2,207,553 | 3.69 | 5.98 | 469,239 | 13,201,167 | |
2023-06-06 |
|
4 | SLNO |
SOLENO THERAPEUTICS INC
Common Stock |
P - Purchase | 64,630 | 2,129,085 | 3.13 | 5.93 | 383,256 | 12,625,474 | |
2023-06-02 |
|
4 | LYRA |
Lyra Therapeutics, Inc.
Common Stock |
P - Purchase | 3,610,832 | 11,469,117 | 45.95 | 2.49 | 8,999,999 | 28,586,774 | |
2023-06-01 |
|
4 | SLNO |
SOLENO THERAPEUTICS INC
Common Stock |
P - Purchase | 7,500 | 2,064,455 | 0.36 | 5.59 | 41,925 | 11,540,303 | |
2023-06-01 |
|
4 | SLNO |
SOLENO THERAPEUTICS INC
Common Stock |
P - Purchase | 10,000 | 2,056,955 | 0.49 | 5.28 | 52,800 | 10,860,722 | |
2023-06-01 |
|
4 | SLNO |
SOLENO THERAPEUTICS INC
Common Stock |
P - Purchase | 17,500 | 2,046,955 | 0.86 | 5.34 | 93,450 | 10,930,740 | |
2023-05-26 |
|
4 | SLNO |
SOLENO THERAPEUTICS INC
210859 |
P - Purchase | 22,500 | 2,029,455 | 1.12 | 5.27 | 118,575 | 10,695,228 | |
2023-05-26 |
|
4 | SLNO |
SOLENO THERAPEUTICS INC
210859 |
P - Purchase | 37,500 | 2,006,955 | 1.90 | 5.18 | 194,250 | 10,396,027 | |
2023-05-26 |
|
4 | SLNO |
SOLENO THERAPEUTICS INC
210859 |
P - Purchase | 25,000 | 1,969,455 | 1.29 | 5.48 | 137,000 | 10,792,613 | |
2023-05-23 |
|
4 | SLNO |
SOLENO THERAPEUTICS INC
Common Stock |
P - Purchase | 27,500 | 1,944,455 | 1.43 | 5.45 | 149,875 | 10,597,280 | |
2023-05-23 |
|
4 | SLNO |
SOLENO THERAPEUTICS INC
Common Stock |
P - Purchase | 27,300 | 1,916,955 | 1.44 | 5.12 | 139,776 | 9,814,810 | |
2023-05-23 |
|
4 | SLNO |
SOLENO THERAPEUTICS INC
Common Stock |
P - Purchase | 25,200 | 1,889,655 | 1.35 | 4.62 | 116,424 | 8,730,206 | |
2023-05-18 | 3 | SLNO |
SOLENO THERAPEUTICS INC
Common Stock |
1,864,455 | ||||||||
2023-05-15 |
|
4 | MGTX |
MeiraGTx Holdings plc
Ordinary Shares |
P - Purchase | 4,347,826 | 11,281,103 | 62.71 | 5.75 | 25,000,000 | 64,866,342 | |
2023-05-01 |
|
4 | CEMI |
CHEMBIO DIAGNOSTICS, INC.
Common Stock |
U - Other | -5,162,782 | 0 | -100.00 | 0.45 | -2,323,252 | ||
2023-04-25 |
|
4 | CEMI |
CHEMBIO DIAGNOSTICS, INC.
Common Stock |
P - Purchase | 133,742 | 5,162,782 | 2.66 | 0.45 | 60,184 | 2,323,252 | |
2023-04-25 |
|
4 | CEMI |
CHEMBIO DIAGNOSTICS, INC.
Common Stock |
P - Purchase | 39,506 | 5,029,040 | 0.79 | 0.45 | 17,778 | 2,263,068 | |
2023-04-25 |
|
4 | CEMI |
CHEMBIO DIAGNOSTICS, INC.
Common Stock |
P - Purchase | 70,200 | 4,989,534 | 1.43 | 0.45 | 31,450 | 2,235,311 | |
2023-04-20 |
|
4 | CEMI |
CHEMBIO DIAGNOSTICS, INC.
Common Stock |
P - Purchase | 56,000 | 4,919,334 | 1.15 | 0.45 | 25,200 | 2,213,700 | |
2023-04-20 |
|
4 | CEMI |
CHEMBIO DIAGNOSTICS, INC.
Common Stock |
P - Purchase | 137,000 | 4,863,334 | 2.90 | 0.45 | 61,376 | 2,178,774 | |
2023-04-20 |
|
4 | CEMI |
CHEMBIO DIAGNOSTICS, INC.
Common Stock |
P - Purchase | 15,800 | 4,726,334 | 0.34 | 0.45 | 7,078 | 2,117,398 | |
2023-04-17 |
|
4 | CEMI |
CHEMBIO DIAGNOSTICS, INC.
Common Stock |
P - Purchase | 4,800 | 4,710,534 | 0.10 | 0.45 | 2,160 | 2,119,740 | |
2023-04-17 |
|
4 | CEMI |
CHEMBIO DIAGNOSTICS, INC.
Common Stock |
P - Purchase | 11,500 | 4,705,734 | 0.24 | 0.45 | 5,175 | 2,117,580 | |
2023-04-17 |
|
4 | CEMI |
CHEMBIO DIAGNOSTICS, INC.
Common Stock |
P - Purchase | 140,134 | 4,694,234 | 3.08 | 0.45 | 63,060 | 2,112,405 | |
2023-04-13 |
|
4 | CEMI |
CHEMBIO DIAGNOSTICS, INC.
Common Stock |
P - Purchase | 129,000 | 4,554,100 | 2.92 | 0.44 | 56,760 | 2,003,804 | |
2023-04-06 |
|
4 | VBIV |
VBI Vaccines Inc/BC
Common Stock |
S - Sale | -4,251,563 | 41,440,729 | -9.30 | 0.11 | -467,672 | 4,558,480 | |
2023-04-06 |
|
4 | VBIV |
VBI Vaccines Inc/BC
Common Stock |
S - Sale | -1,832,563 | 45,691,816 | -3.86 | 0.13 | -238,233 | 5,939,936 | |
2023-04-06 |
|
4 | VBIV |
VBI Vaccines Inc/BC
Common Stock |
S - Sale | -4,810,623 | 47,524,379 | -9.19 | 0.16 | -769,700 | 7,603,901 | |
2023-04-06 | 3 | CEMI |
CHEMBIO DIAGNOSTICS, INC.
Common Stock |
3,672,662 | ||||||||
2023-04-06 |
|
4 | CEMI |
CHEMBIO DIAGNOSTICS, INC.
Common Stock |
P - Purchase | 339,000 | 4,425,100 | 8.30 | 0.44 | 149,160 | 1,947,044 | |
2023-04-06 |
|
4 | CEMI |
CHEMBIO DIAGNOSTICS, INC.
Common Stock |
P - Purchase | 217,500 | 4,086,100 | 5.62 | 0.45 | 97,875 | 1,838,745 | |
2023-04-06 |
|
4 | CEMI |
CHEMBIO DIAGNOSTICS, INC.
Common Stock |
P - Purchase | 195,938 | 3,868,600 | 5.34 | 0.44 | 86,213 | 1,702,184 | |
2022-12-21 |
|
4 | ATXS |
Astria Therapeutics, Inc.
Common Stock |
P - Purchase | 908,265 | 1,038,309 | 698.43 | 11.01 | 9,999,998 | 11,431,782 | |
2022-12-06 |
|
4 | SLDB |
Solid Biosciences Inc.
Common Stock |
A - Award | 73,107 | 73,107 | |||||
2022-12-06 |
|
4 | SLDB |
Solid Biosciences Inc.
Common Stock |
A - Award | 365,536 | 3,422,826 | 11.96 | ||||
2022-12-06 |
|
4 | SLDB |
Solid Biosciences Inc.
Common Stock |
A - Award | 2,163,120 | 3,057,290 | 241.91 | 7.05 | 15,249,996 | 21,553,894 | |
2022-11-18 | 3 | ACRV |
Acrivon Therapeutics, Inc.
Common Stock |
3,007,858 | ||||||||
2022-11-02 |
|
4 | QTNT |
Quotient Ltd
Ordinary Shares, nil par value |
S - Sale | -8,255,607 | 7,945,211 | -50.96 | 0.08 | -660,449 | 635,617 | |
2022-10-13 |
|
4 | ALBO |
ALBIREO PHARMA, INC.
Common Stock |
S - Sale | -406 | 1,939,723 | -0.02 | 22.79 | -9,253 | 44,206,287 | |
2022-10-13 |
|
4 | ALBO |
ALBIREO PHARMA, INC.
Common Stock |
S - Sale | -178,726 | 1,940,129 | -8.44 | 22.01 | -3,933,759 | 42,702,239 | |
2022-10-13 |
|
4 | ALBO |
ALBIREO PHARMA, INC.
Common Stock |
S - Sale | -7,240 | 2,118,855 | -0.34 | 23.23 | -168,185 | 49,221,002 | |
2022-10-13 |
|
4 | ALBO |
ALBIREO PHARMA, INC.
Common Stock |
S - Sale | -89,979 | 2,126,095 | -4.06 | 22.26 | -2,002,933 | 47,326,875 | |
2022-10-13 |
|
4 | ALBO |
ALBIREO PHARMA, INC.
Common Stock |
S - Sale | -5,415 | 2,216,074 | -0.24 | 24.78 | -134,184 | 54,914,314 | |
2022-10-13 |
|
4 | ALBO |
ALBIREO PHARMA, INC.
Common Stock |
S - Sale | -38,310 | 2,221,489 | -1.70 | 24.18 | -926,336 | 53,715,604 | |
2022-10-13 |
|
4 | ALBO |
ALBIREO PHARMA, INC.
Common Stock |
S - Sale | -100,340 | 2,259,799 | -4.25 | 23.23 | -2,330,898 | 52,495,131 | |
2022-08-22 |
|
4 | LIAN |
LianBio
American Depositary Shares |
P - Purchase | 998,240 | 3,728,491 | 36.56 | 2.40 | 2,395,776 | 8,948,378 | |
2022-08-18 |
|
4 | CERE |
Cerevel Therapeutics Holdings, Inc.
Common Stock |
P - Purchase | 1,425,000 | 6,511,727 | 28.01 | 35.00 | 49,875,000 | 227,910,445 | |
2022-08-11 |
|
4 | ALDX |
Aldeyra Therapeutics, Inc.
Common Stock |
P - Purchase | 15,000 | 11,350,085 | 0.13 | 7.85 | 117,750 | 89,098,167 | |
2022-08-11 |
|
4 | ALDX |
Aldeyra Therapeutics, Inc.
Common Stock |
P - Purchase | 100,000 | 11,335,085 | 0.89 | 7.50 | 750,000 | 85,013,138 | |
2022-08-10 |
|
4 | ALDX |
Aldeyra Therapeutics, Inc.
Common Stock |
P - Purchase | 97,000 | 11,235,085 | 0.87 | 7.24 | 702,280 | 81,342,015 | |
2022-08-09 |
|
4 | ALDX |
Aldeyra Therapeutics, Inc.
Common Stock |
P - Purchase | 141,000 | 11,138,085 | 1.28 | 6.95 | 979,950 | 77,409,691 | |
2022-08-08 |
|
4 | ALDX |
Aldeyra Therapeutics, Inc.
Common Stock |
P - Purchase | 95,100 | 10,997,085 | 0.87 | 6.17 | 586,767 | 67,852,014 | |
2022-08-05 |
|
4 | ALDX |
Aldeyra Therapeutics, Inc.
Common Stock |
P - Purchase | 100,000 | 10,901,985 | 0.93 | 5.84 | 584,000 | 63,667,592 | |
2022-08-04 |
|
4 | ALDX |
Aldeyra Therapeutics, Inc.
Common Stock |
P - Purchase | 412,406 | 10,801,985 | 3.97 | 5.59 | 2,305,350 | 60,383,096 | |
2022-08-03 |
|
4 | ALDX |
Aldeyra Therapeutics, Inc.
Common Stock |
P - Purchase | 144,185 | 10,389,579 | 1.41 | 5.05 | 728,134 | 52,467,374 | |
2022-08-02 |
|
4 | ALDX |
Aldeyra Therapeutics, Inc.
Common Stock |
P - Purchase | 222,123 | 10,245,394 | 2.22 | 5.03 | 1,117,279 | 51,534,332 | |
2022-08-01 |
|
4 | ALDX |
Aldeyra Therapeutics, Inc.
Common Stock |
P - Purchase | 119,392 | 10,023,271 | 1.21 | 5.00 | 596,960 | 50,116,355 | |
2022-07-05 |
|
4 | VRCA |
Verrica Pharmaceuticals Inc.
Common Stock |
P - Purchase | 1,428,571 | 5,038,983 | 39.57 | 2.10 | 2,999,999 | 10,581,864 | |
2022-07-01 |
|
4 | ATHA |
Athira Pharma, Inc.
Common Stock |
P - Purchase | 1,101,362 | 4,797,278 | 29.80 | 2.99 | 3,293,072 | 14,343,861 | |
2022-07-01 |
|
4 | ATHA |
Athira Pharma, Inc.
Common Stock |
P - Purchase | 270,000 | 3,695,916 | 7.88 | 2.99 | 807,300 | 11,050,789 | |
2022-05-27 |
|
4 | LIAN |
LianBio
American Depositary Shares |
P - Purchase | 69,000 | 2,730,251 | 2.59 | 3.13 | 215,970 | 8,545,686 | |
2022-05-27 |
|
4 | ATHA |
Athira Pharma, Inc.
Stock Option (Right to Buy) |
A - Award | 13,871 | 13,871 | |||||
2022-05-25 |
|
4 | LIAN |
LianBio
American Depositary Shares |
P - Purchase | 120,000 | 2,661,251 | 4.72 | 2.63 | 315,600 | 6,999,090 | |
2022-05-25 |
|
4 | LIAN |
LianBio
American Depositary Shares |
P - Purchase | 42,551 | 2,541,251 | 1.70 | 2.47 | 105,101 | 6,276,890 | |
2022-05-25 |
|
4 | LIAN |
LianBio
American Depositary Shares |
P - Purchase | 8,700 | 2,498,700 | 0.35 | 2.49 | 21,663 | 6,221,763 | |
2022-04-18 |
|
4 | CRNX |
Crinetics Pharmaceuticals, Inc.
Common Stock |
P - Purchase | 157,515 | 5,321,032 | 3.05 | 22.22 | 3,499,983 | 118,233,331 | |
2022-04-14 |
|
4 | LYRA |
Lyra Therapeutics, Inc.
Common Stock |
P - Purchase | 5,924,170 | 7,858,285 | 306.30 | 4.22 | 24,999,997 | 33,161,963 | |
2021-12-10 |
|
4 | NAUT |
Nautilus Biotechnology, Inc.
Common Stock |
P - Purchase | 200,000 | 9,111,151 | 2.24 | 5.36 | 1,072,000 | 48,835,769 | |
2021-12-03 |
|
4 | VBIV |
VBI Vaccines Inc/BC
Common Stock |
S - Sale | -2,707,463 | 52,334,993 | -4.92 | 3.31 | -8,961,703 | 173,228,827 | |
2021-11-05 |
|
4 | LIAN |
LianBio
Ordinary Shares |
P - Purchase | 20,000 | 27,858,895 | 0.07 | 13.51 | 270,200 | 376,373,671 | |
2021-11-05 |
|
4 | LIAN |
LianBio
Ordinary Shares |
P - Purchase | 2,250,000 | 27,838,895 | 8.79 | 16.00 | 36,000,000 | 445,422,320 | |
2021-11-03 |
|
4 | LIAN |
LianBio
Series A Preferred Shares |
C - Conversion | -423,579 | 0 | -100.00 | ||||
2021-11-03 |
|
4 | LIAN |
LianBio
Series Seed Preferred Shares |
C - Conversion | -500,000 | 0 | -100.00 | ||||
2021-11-03 |
|
4 | LIAN |
LianBio
Series Seed Preferred Shares |
C - Conversion | -2,500,000 | 0 | -100.00 | ||||
2021-11-03 |
|
4 | LIAN |
LianBio
Series Seed Preferred Shares |
C - Conversion | -2,500,000 | 0 | -100.00 | ||||
2021-11-03 |
|
4 | LIAN |
LianBio
Series A Preferred Shares |
C - Conversion | -635,369 | 0 | -100.00 | ||||
2021-11-03 |
|
4 | LIAN |
LianBio
Ordinary Shares |
C - Conversion | 2,477,005 | 2,477,005 | |||||
2021-11-03 |
|
4 | LIAN |
LianBio
Ordinary Shares |
C - Conversion | 2,923,000 | 4,330,675 | 207.65 | ||||
2021-11-03 |
|
4 | LIAN |
LianBio
Ordinary Shares |
C - Conversion | 14,619,500 | 21,653,385 | 207.84 | ||||
2021-11-03 |
|
4 | LIAN |
LianBio
Ordinary Shares |
C - Conversion | 14,619,500 | 21,653,385 | 207.84 | ||||
2021-11-03 |
|
4 | LIAN |
LianBio
Ordinary Shares |
C - Conversion | 3,715,510 | 10,969,395 | 51.22 | ||||
2021-11-03 |
|
4 | LIAN |
LianBio
Ordinary Shares |
P - Purchase | 100,000 | 7,253,885 | 1.40 | 13.50 | 1,350,000 | 97,927,448 | |
2021-11-03 |
|
4 | LIAN |
LianBio
Ordinary Shares |
P - Purchase | 120,000 | 7,153,885 | 1.71 | 15.50 | 1,860,000 | 110,885,218 | |
2021-10-29 | 3 | LIAN |
LianBio
Ordinary Shares |
7,033,885 | ||||||||
2021-10-29 | 3 | LIAN |
LianBio
Ordinary Shares |
7,033,885 | ||||||||
2021-10-29 | 3 | LIAN |
LianBio
Ordinary Shares |
1,406,775 | ||||||||
2021-10-25 |
|
4 | CRNX |
Crinetics Pharmaceuticals, Inc.
Common Stock |
P - Purchase | 1,200,000 | 5,163,517 | 30.28 | 19.80 | 23,760,000 | 102,237,637 | |
2021-10-15 |
|
4 | AGRX |
AGILE THERAPEUTICS INC
Warrants (right to buy) |
P - Purchase | 2,687,280 | 2,687,280 | |||||
2021-10-15 |
|
4 | AGRX |
AGILE THERAPEUTICS INC
Common Stock |
P - Purchase | 5,734,560 | 21,654,485 | 36.02 | 0.85 | 4,874,376 | 18,406,312 | |
2021-10-14 |
|
4 | ISO |
IsoPlexis Corp
Series D Redeemable Convertible Preferred Stock |
C - Conversion | -24,629 | 0 | -100.00 | ||||
2021-10-14 |
|
4 | ISO |
IsoPlexis Corp
Series D Redeemable Convertible Preferred Stock |
C - Conversion | -40,373 | 0 | -100.00 | ||||
2021-10-14 |
|
4 | ISO |
IsoPlexis Corp
Series D Redeemable Convertible Preferred Stock |
C - Conversion | -325,014 | 0 | -100.00 | ||||
2021-10-14 |
|
4 | ISO |
IsoPlexis Corp
Common Stock |
P - Purchase | 850,000 | 3,554,587 | 31.43 | 15.00 | 12,750,000 | 53,318,805 | |
2021-10-14 |
|
4 | ISO |
IsoPlexis Corp
Common Stock |
C - Conversion | 204,949 | 204,949 | |||||
2021-10-14 |
|
4 | ISO |
IsoPlexis Corp
Common Stock |
C - Conversion | 335,962 | 335,962 | |||||
2021-10-14 |
|
4 | ISO |
IsoPlexis Corp
Common Stock |
C - Conversion | 2,704,587 | 2,704,587 | |||||
2021-10-13 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock |
S - Sale | -7,306 | 2,487,019 | -0.29 | 13.40 | -97,900 | 33,326,055 | |
2021-10-13 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock |
S - Sale | -9,351 | 2,494,325 | -0.37 | 13.15 | -122,966 | 32,800,374 | |
2021-10-13 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock |
S - Sale | -12,475 | 2,503,676 | -0.50 | 12.03 | -150,074 | 30,119,222 | |
2021-10-13 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock |
S - Sale | -2,462 | 2,516,151 | -0.10 | 13.66 | -33,631 | 34,370,623 | |
2021-10-13 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock |
S - Sale | -5,038 | 2,518,613 | -0.20 | 12.90 | -64,990 | 32,490,108 | |
2021-10-13 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock |
S - Sale | -286 | 2,523,651 | -0.01 | 15.05 | -4,304 | 37,980,948 | |
2021-10-13 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock |
S - Sale | -13,082 | 2,523,937 | -0.52 | 14.80 | -193,614 | 37,354,268 | |
2021-09-30 |
|
4 | ADMA |
ADMA BIOLOGICS, INC.
Common Stock |
S - Sale | -137,495 | 13,262,375 | -1.03 | 1.12 | -153,994 | 14,853,860 | |
2021-09-30 |
|
4 | ADMA |
ADMA BIOLOGICS, INC.
Common Stock |
S - Sale | -82,505 | 13,399,870 | -0.61 | 1.16 | -95,706 | 15,543,849 | |
2021-09-30 |
|
4 | ADMA |
ADMA BIOLOGICS, INC.
Common Stock |
S - Sale | -40,603 | 13,482,375 | -0.30 | 1.22 | -49,536 | 16,448,498 | |
2021-09-29 |
|
4 | ADMA |
ADMA BIOLOGICS, INC.
Common Stock |
S - Sale | -250,000 | 13,522,978 | -1.82 | 1.23 | -307,500 | 16,633,263 | |
2021-09-29 |
|
4 | ADMA |
ADMA BIOLOGICS, INC.
Common Stock |
S - Sale | -250,000 | 13,772,978 | -1.78 | 1.26 | -315,000 | 17,353,952 | |
2021-09-28 |
|
4 | LPTX |
LEAP THERAPEUTICS, INC.
Warrants (right to buy) |
P - Purchase | 3,508,771 | 3,508,771 | 2.85 | 9,996,489 | 9,996,489 | ||
2021-09-28 |
|
4 | ADMA |
ADMA BIOLOGICS, INC.
Common Stock |
S - Sale | -780,000 | 14,022,978 | -5.27 | 1.27 | -990,600 | 17,809,182 | |
2021-08-31 |
|
4 | CERE |
Cerevel Therapeutics Holdings, Inc.
Common Stock |
P - Purchase | 68,047 | 5,086,727 | 1.36 | 30.23 | 2,057,061 | 153,771,757 | |
2021-08-31 |
|
4 | LABP |
Landos Biopharma, Inc.
Stock Option (Right to Buy) |
A - Award | 25,291 | 25,291 | |||||
2021-08-25 |
|
4 | CERE |
Cerevel Therapeutics Holdings, Inc.
Common Stock |
P - Purchase | 61,387 | 5,018,680 | 1.24 | 28.57 | 1,753,827 | 143,383,688 | |
2021-08-25 |
|
4 | CERE |
Cerevel Therapeutics Holdings, Inc.
Common Stock |
P - Purchase | 69,761 | 4,957,293 | 1.43 | 27.73 | 1,934,473 | 137,465,735 | |
2021-08-25 |
|
4 | CERE |
Cerevel Therapeutics Holdings, Inc.
Common Stock |
P - Purchase | 44,437 | 4,887,532 | 0.92 | 25.78 | 1,145,586 | 126,000,575 | |
2021-08-19 |
|
4 | ADMA |
ADMA BIOLOGICS, INC.
Common Stock |
S - Sale | -350,352 | 14,802,978 | -2.31 | 1.24 | -434,436 | 18,355,693 | |
2021-08-19 |
|
4 | ADMA |
ADMA BIOLOGICS, INC.
Common Stock |
S - Sale | -552,380 | 15,153,330 | -3.52 | 1.29 | -712,570 | 19,547,796 | |
2021-08-19 |
|
4 | ADMA |
ADMA BIOLOGICS, INC.
Common Stock |
S - Sale | -879,092 | 15,705,710 | -5.30 | 1.35 | -1,186,774 | 21,202,708 | |
2021-08-18 |
|
4 | VYNE |
VYNE Therapeutics Inc.
Common Stock |
S - Sale | -250,000 | 4,935,057 | -4.82 | 1.74 | -435,000 | 8,586,999 | |
2021-08-17 |
|
4 | VYNE |
VYNE Therapeutics Inc.
Common Stock |
S - Sale | -250,000 | 5,185,057 | -4.60 | 1.84 | -460,000 | 9,540,505 | |
2021-08-16 |
|
4 | VYNE |
VYNE Therapeutics Inc.
Common Stock |
S - Sale | -338,897 | 5,435,057 | -5.87 | 2.23 | -755,740 | 12,120,177 | |
2021-07-09 |
|
4 | CERE |
Cerevel Therapeutics Holdings, Inc.
Common Stock |
P - Purchase | 200,000 | 4,843,095 | 4.31 | 25.00 | 5,000,000 | 121,077,375 | |
2021-06-30 |
|
4 | VBIV |
VBI Vaccines Inc/BC
Common Stock |
S - Sale | -145,548 | 0 | -100.00 | 3.80 | -553,082 | ||
2021-06-30 |
|
4 | VBIV |
VBI Vaccines Inc/BC
Common Stock |
S - Sale | -500,709 | 0 | -100.00 | 3.80 | -1,902,694 | ||
2021-06-14 |
|
4 | MGTX |
MeiraGTx Holdings plc
Stock Option (right to buy) |
A - Award | 15,000 | 15,000 | |||||
2021-06-14 |
|
4 | MGTX |
MeiraGTx Holdings plc
Restricted Share Units |
A - Award | 15,000 | 15,000 | |||||
2021-06-11 |
|
4 | NAUT |
Nautilus Biotechnology, Inc.
Common Stock |
J - Other | 2,914,113 | 8,911,151 | 48.59 | ||||
2021-06-11 |
|
4 | NAUT |
Nautilus Biotechnology, Inc.
Common Stock |
P - Purchase | 5,500,000 | 5,997,038 | 1,106.56 | 10.00 | 55,000,000 | 59,970,380 | |
2021-06-11 |
|
4 | NAUT |
Nautilus Biotechnology, Inc.
Common Stock |
P - Purchase | 7,063 | 497,038 | 1.44 | 10.05 | 70,983 | 4,995,232 | |
2021-06-11 |
|
4 | VBIV |
VBI Vaccines Inc/BC
Warrant (right to buy) |
X - Other | -465,936 | 0 | -100.00 | ||||
2021-06-11 |
|
4 | VBIV |
VBI Vaccines Inc/BC
Warrant (right to buy) |
X - Other | -1,602,888 | 0 | -100.00 | ||||
2021-06-11 |
|
4 | VBIV |
VBI Vaccines Inc/BC
Common Stock |
S - Sale | -320,388 | 145,548 | -68.76 | 4.00 | -1,281,552 | 582,192 | |
2021-06-11 |
|
4 | VBIV |
VBI Vaccines Inc/BC
Common Stock |
S - Sale | -1,102,179 | 500,709 | -68.76 | 4.00 | -4,408,716 | 2,002,836 | |
2021-06-11 |
|
4 | VBIV |
VBI Vaccines Inc/BC
Common Stock |
X - Other | 465,936 | 465,936 | 2.75 | 1,281,324 | 1,281,324 | ||
2021-06-11 |
|
4 | VBIV |
VBI Vaccines Inc/BC
Common Stock |
X - Other | 1,602,888 | 1,602,888 | 2.75 | 4,407,942 | 4,407,942 | ||
2021-06-03 |
|
4 | ARYA |
ARYA Sciences Acquisition Corp III
Class A Ordinary Shares |
P - Purchase | 330,050 | 489,975 | 206.38 | 10.05 | 3,317,002 | 4,924,249 | |
2021-06-01 |
|
4 | ATHA |
Athira Pharma, Inc.
Stock Option (Right to Buy) |
A - Award | 13,871 | 13,871 | |||||
2021-05-24 |
|
4 | ARYA |
ARYA Sciences Acquisition Corp III
Class A Ordinary Shares |
P - Purchase | 159,925 | 159,925 | 10.05 | 1,607,246 | 1,607,246 | ||
2021-05-07 |
|
4 | VYNE |
VYNE Therapeutics Inc.
Common Stock |
S - Sale | -1,000,000 | 5,773,954 | -14.76 | 3.67 | -3,670,000 | 21,190,411 | |
2021-05-04 |
|
4 | ALDX |
Aldeyra Therapeutics, Inc.
Common Stock |
P - Purchase | 1,200,000 | 9,903,879 | 13.79 | 12.50 | 15,000,000 | 123,798,488 | |
2021-04-27 |
|
4 | RAIN |
Rain Therapeutics Inc.
Series B Convertible Preferred Stock |
C - Conversion | -1,195,792 | 0 | -100.00 | ||||
2021-04-27 |
|
4 | RAIN |
Rain Therapeutics Inc.
Series A Convertible Preferred Stock |
C - Conversion | -949,992 | 0 | -100.00 | ||||
2021-04-27 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock |
P - Purchase | 550,000 | 2,537,019 | 27.68 | 17.00 | 9,350,000 | 43,129,323 | |
2021-04-27 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock |
C - Conversion | 1,107,316 | 1,987,019 | 125.87 | ||||
2021-04-27 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock |
C - Conversion | 879,703 | 879,703 | |||||
2021-04-09 |
|
4 | CRNX |
Crinetics Pharmaceuticals, Inc.
Common Stock |
P - Purchase | 304,136 | 3,963,517 | 8.31 | 16.44 | 4,999,996 | 65,160,219 | |
2021-04-06 |
|
4 | AGRX |
AGILE THERAPEUTICS INC
Warrants (right to buy) |
J - Other | 450,000 | 450,000 | |||||
2021-03-23 |
|
4 | SLDB |
Solid Biosciences Inc.
Common Stock |
P - Purchase | 2,608,695 | 13,412,552 | 24.15 | 5.75 | 14,999,996 | 77,122,174 | |
2021-03-16 |
|
4 | RXDX |
Prometheus Biosciences, Inc.
Series D-2 Convertible Preferred Stock |
C - Conversion | -14,462,623 | 0 | -100.00 | ||||
2021-03-16 |
|
4 | RXDX |
Prometheus Biosciences, Inc.
Series D-1 Convertible Preferred Stock |
C - Conversion | -10,177,703 | 0 | -100.00 | ||||
2021-03-16 |
|
4 | RXDX |
Prometheus Biosciences, Inc.
Common Stock |
P - Purchase | 850,000 | 3,314,032 | 34.50 | 19.00 | 16,150,000 | 62,966,608 | |
2021-03-16 |
|
4 | RXDX |
Prometheus Biosciences, Inc.
Common Stock |
C - Conversion | 1,446,262 | 2,464,032 | 142.10 | ||||
2021-03-16 |
|
4 | RXDX |
Prometheus Biosciences, Inc.
Common Stock |
C - Conversion | 1,017,770 | 1,017,770 | |||||
2021-02-09 |
|
4 | LABP |
Landos Biopharma, Inc.
Common Stock |
P - Purchase | 34,951 | 7,299,751 | 0.48 | 14.60 | 510,285 | 106,576,365 | |
2021-02-09 |
|
4 | LABP |
Landos Biopharma, Inc.
Common Stock |
P - Purchase | 64,730 | 7,264,800 | 0.90 | 13.80 | 893,274 | 100,254,240 | |
2021-02-09 |
|
4 | LABP |
Landos Biopharma, Inc.
Common Stock |
P - Purchase | 1,771 | 7,200,070 | 0.02 | 13.10 | 23,200 | 94,320,917 | |
2021-02-09 |
|
4 | LABP |
Landos Biopharma, Inc.
Common Stock |
P - Purchase | 86,671 | 7,198,299 | 1.22 | 12.53 | 1,085,988 | 90,194,686 | |
2021-02-09 |
|
4 | LABP |
Landos Biopharma, Inc.
Common Stock |
P - Purchase | 34,611 | 7,111,628 | 0.49 | 11.38 | 393,873 | 80,930,327 | |
2021-02-09 |
|
4 | LABP |
Landos Biopharma, Inc.
Common Stock |
P - Purchase | 27,453 | 7,077,017 | 0.39 | 11.14 | 305,826 | 78,837,969 | |
2021-02-08 |
|
4 | LABP |
Landos Biopharma, Inc.
Series B Preferred Stock |
C - Conversion | -1,770,600 | 0 | -100.00 | ||||
2021-02-08 |
|
4 | LABP |
Landos Biopharma, Inc.
Series B Preferred Stock |
C - Conversion | -2,857,795 | 0 | -100.00 | ||||
2021-02-08 |
|
4 | LABP |
Landos Biopharma, Inc.
Series B Preferred Stock |
C - Conversion | -2,857,795 | 0 | -100.00 | ||||
2021-02-08 |
|
4 | LABP |
Landos Biopharma, Inc.
Series A Preferred Stock |
C - Conversion | -2,941,769 | 0 | -100.00 | ||||
2021-02-08 |
|
4 | LABP |
Landos Biopharma, Inc.
Series A Preferred Stock |
C - Conversion | -2,941,769 | 0 | -100.00 | ||||
2021-02-08 |
|
4 | LABP |
Landos Biopharma, Inc.
Common Stock |
P - Purchase | 1,250,000 | 7,049,564 | 21.55 | 16.00 | 20,000,000 | 112,793,024 | |
2021-02-08 |
|
4 | LABP |
Landos Biopharma, Inc.
Common Stock |
C - Conversion | 1,770,600 | 1,770,600 | |||||
2021-02-08 |
|
4 | LABP |
Landos Biopharma, Inc.
Common Stock |
C - Conversion | 2,857,795 | 5,799,564 | 97.15 | ||||
2021-02-08 |
|
4 | LABP |
Landos Biopharma, Inc.
Common Stock |
C - Conversion | 2,857,795 | 5,799,564 | 97.15 | ||||
2021-02-08 |
|
4 | LABP |
Landos Biopharma, Inc.
Common Stock |
C - Conversion | 2,941,769 | 2,941,769 | |||||
2021-02-08 |
|
4 | LABP |
Landos Biopharma, Inc.
Common Stock |
C - Conversion | 2,941,769 | 2,941,769 | |||||
2021-02-03 | 3 | LABP |
Landos Biopharma, Inc.
Common Stock |
3,090,924 | ||||||||
2021-02-03 | 3 | CATB |
CATABASIS PHARMACEUTICALS INC
Common Stock |
543,373 | ||||||||
2021-02-03 | 3 | CATB |
CATABASIS PHARMACEUTICALS INC
Common Stock |
1,933,551 | ||||||||
2021-02-03 |
|
4 | CATB |
CATABASIS PHARMACEUTICALS INC
Series X Convertible Preferred Stock |
A - Award | 1,617 | 30,920 | 5.52 | 3,009.53 | 4,866,410 | 93,054,668 | |
2021-02-03 |
|
4 | CATB |
CATABASIS PHARMACEUTICALS INC
Series X Convertible Preferred Stock |
A - Award | 4,851 | 4,851 | 3,009.53 | 14,599,230 | 14,599,230 | ||
2021-02-01 |
|
4 | VYNE |
VYNE Therapeutics Inc.
Common Stock |
P - Purchase | 4,219,409 | 27,095,819 | 18.44 | 2.37 | 9,999,999 | 64,217,091 | |
2021-01-27 |
|
4 | ATHA |
Athira Pharma, Inc.
Common Stock |
P - Purchase | 311,111 | 3,425,916 | 9.99 | 22.50 | 6,999,998 | 77,083,110 | |
2021-01-26 | 3 | SCYX |
SCYNEXIS INC
Common Stock |
2,400,000 | ||||||||
2021-01-26 |
|
4 | SCYX |
SCYNEXIS INC
Common Stock |
S - Sale | -33,849 | 1,800,000 | -1.85 | 8.95 | -302,949 | 16,110,000 | |
2021-01-26 |
|
4 | SCYX |
SCYNEXIS INC
Common Stock |
S - Sale | -285,151 | 1,833,849 | -13.46 | 8.16 | -2,326,832 | 14,964,208 | |
2021-01-26 |
|
4 | SCYX |
SCYNEXIS INC
Common Stock |
S - Sale | -95,000 | 2,120,000 | -4.29 | 7.38 | -701,100 | 15,645,600 | |
2021-01-26 |
|
4 | SCYX |
SCYNEXIS INC
Common Stock |
S - Sale | -185,000 | 2,215,000 | -7.71 | 7.43 | -1,374,550 | 16,457,450 | |
2021-01-22 |
|
4 | MOTS |
Motus GI Holdings, Inc.
Common Stock |
S - Sale | -550,000 | 2,660,542 | -17.13 | 1.48 | -814,000 | 3,937,602 | |
2021-01-22 |
|
4 | MOTS |
Motus GI Holdings, Inc.
Common Stock |
S - Sale | -674,352 | 3,210,542 | -17.36 | 1.68 | -1,132,911 | 5,393,711 | |
2021-01-22 |
|
4 | MOTS |
Motus GI Holdings, Inc.
Common Stock |
S - Sale | -325,648 | 3,884,894 | -7.73 | 1.80 | -586,166 | 6,992,809 | |
2021-01-21 |
|
4 | ALDX |
Aldeyra Therapeutics, Inc.
Common Stock |
P - Purchase | 1,368,421 | 8,703,879 | 18.65 | 9.50 | 13,000,000 | 82,686,850 | |
2021-01-11 |
|
4 | ALDX |
Aldeyra Therapeutics, Inc.
Common Stock |
P - Purchase | 50,000 | 7,335,458 | 0.69 | 7.60 | 380,000 | 55,749,481 | |
2021-01-11 |
|
4 | ALDX |
Aldeyra Therapeutics, Inc.
Common Stock |
P - Purchase | 152,668 | 7,285,458 | 2.14 | 10.21 | 1,558,740 | 74,384,526 | |
2021-01-11 |
|
4 | ALDX |
Aldeyra Therapeutics, Inc.
Common Stock |
P - Purchase | 347,332 | 7,132,790 | 5.12 | 9.21 | 3,198,928 | 65,692,996 | |
2021-01-11 |
|
4 | ALDX |
Aldeyra Therapeutics, Inc.
Common Stock |
P - Purchase | 500,000 | 6,785,458 | 7.95 | 8.13 | 4,065,000 | 55,165,774 | |
2020-12-15 |
|
4 | SLDB |
Solid Biosciences Inc.
Common Stock |
A - Award | 4,054,054 | 10,803,857 | 60.06 | 3.70 | 15,000,000 | 39,974,271 | |
2020-11-24 |
|
4 | MGTX |
MeiraGTx Holdings plc
Ordinary Shares |
P - Purchase | 500,000 | 6,933,277 | 7.77 | 12.85 | 6,425,000 | 89,092,609 | |
2020-10-29 |
|
4 | CERE |
Cerevel Therapeutics Holdings, Inc.
Common stock |
P - Purchase | 3,000,000 | 3,157,295 | 1,907.24 | 10.00 | 30,000,000 | 31,572,950 | |
2020-10-22 |
|
4 | ARYB |
ARYA Sciences Acquisition Corp II
Class A ordinary shares |
P - Purchase | 43,195 | 157,295 | 37.86 | 10.09 | 435,838 | 1,587,107 | |
2020-10-22 |
|
4 | ARYB |
ARYA Sciences Acquisition Corp II
Class A ordinary shares |
P - Purchase | 114,100 | 114,100 | 10.00 | 1,141,000 | 1,141,000 | ||
2020-09-22 |
|
4 | ATHA |
Athira Pharma, Inc.
Series B Preferred Stock |
C - Conversion | -1,644,785 | 0 | -100.00 | ||||
2020-09-22 |
|
4 | ATHA |
Athira Pharma, Inc.
Common Stock |
P - Purchase | 1,058,824 | 3,114,805 | 51.50 | 17.00 | 18,000,008 | 52,951,685 | |
2020-09-22 |
|
4 | ATHA |
Athira Pharma, Inc.
Common Stock |
C - Conversion | 1,644,785 | 2,055,981 | 400.00 | ||||
2020-09-17 | 3 | ATHA |
Athira Pharma, Inc.
Common Stock |
411,196 | ||||||||
2020-09-16 |
|
4 | QTNT |
Quotient Ltd
Ordinary Shares |
P - Purchase | 2,911,764 | 16,200,818 | 21.91 | 4.25 | 12,374,997 | 68,853,476 | |
2020-09-15 |
|
4 | ALBO |
ALBIREO PHARMA, INC.
Common Stock |
P - Purchase | 400,000 | 2,360,139 | 20.41 | 40.00 | 16,000,000 | 94,405,560 | |
2020-09-14 |
|
4 | ATNX |
Athenex, Inc.
Common Stock |
P - Purchase | 1,800,000 | 13,532,467 | 15.34 | 11.00 | 19,800,000 | 148,857,137 | |
2020-09-14 |
|
4 | ATNX |
Athenex, Inc.
Common Stock |
P - Purchase | 200,000 | 11,732,467 | 1.73 | 11.24 | 2,248,000 | 131,872,929 | |
2020-07-13 |
|
4 | ALDX |
Aldeyra Therapeutics, Inc.
Common Stock |
P - Purchase | 3,200,000 | 6,285,458 | 103.71 | 4.25 | 13,600,000 | 26,713,196 | |
2020-06-24 |
|
4 | LPTX |
LEAP THERAPEUTICS, INC.
Common Stock |
P - Purchase | 1,750,000 | 8,476,496 | 26.02 | 2.00 | 3,500,000 | 16,952,992 | |
2020-06-18 |
|
4 | SLDB |
Solid Biosciences Inc.
Stock Option (Right to Buy) |
A - Award | 30,000 | 30,000 | |||||
2020-06-11 | 3 | MNLO |
Menlo Therapeutics Inc.
Common Stock |
40,347,416 | ||||||||
2020-06-11 | 3 | MNLO |
Menlo Therapeutics Inc.
Common Stock |
40,347,416 | ||||||||
2020-06-11 | 3 | MNLO |
Menlo Therapeutics Inc.
Common Stock |
40,347,416 | ||||||||
2020-06-11 | 3 | MNLO |
Menlo Therapeutics Inc.
Common Stock |
40,347,416 | ||||||||
2020-06-11 | 3 | MNLO |
Menlo Therapeutics Inc.
Common Stock |
40,347,416 | ||||||||
2020-06-11 |
|
4 | MNLO |
Menlo Therapeutics Inc.
Common Stock |
P - Purchase | 2,702,702 | 22,876,410 | 13.40 | 1.85 | 4,999,999 | 42,321,358 | |
2020-06-04 |
|
4 | MGTX |
MeiraGTx Holdings plc
Stock Option (right to buy) |
A - Award | 25,000 | 25,000 | |||||
2020-05-29 |
|
4 | LYRA |
Lyra Therapeutics, Inc.
Common Stock |
P - Purchase | 625,000 | 1,934,115 | 47.74 | 16.00 | 10,000,000 | 30,945,840 | |
2020-05-06 |
|
4 | LYRA |
Lyra Therapeutics, Inc.
Common Warrants |
X - Other | -339,604 | 0 | -100.00 | ||||
2020-05-06 |
|
4 | LYRA |
Lyra Therapeutics, Inc.
Common Warrants |
X - Other | -141,221 | 0 | -100.00 | ||||
2020-05-06 |
|
4 | LYRA |
Lyra Therapeutics, Inc.
Series C Convertible Preferred Stock |
C - Conversion | -16,232,511 | 0 | -100.00 | ||||
2020-05-06 |
|
4 | LYRA |
Lyra Therapeutics, Inc.
Series C Convertible Preferred Stock |
C - Conversion | -39,035,325 | 0 | -100.00 | ||||
2020-05-06 |
|
4 | LYRA |
Lyra Therapeutics, Inc.
Series B Convertible Preferred Stock |
C - Conversion | -26,666,666 | 0 | -100.00 | ||||
2020-05-06 |
|
4 | LYRA |
Lyra Therapeutics, Inc.
Common Stock |
F - Taxes | -183,174 | 1,288,446 | -12.45 | 16.00 | -2,930,784 | 20,615,136 | |
2020-05-06 |
|
4 | LYRA |
Lyra Therapeutics, Inc.
Common Stock |
X - Other | 339,604 | 1,471,620 | 30.00 | 8.63 | 2,930,783 | 12,700,081 | |
2020-05-06 |
|
4 | LYRA |
Lyra Therapeutics, Inc.
Common Stock |
F - Taxes | -76,172 | 1,309,115 | -5.50 | 16.00 | -1,218,752 | 20,945,840 | |
2020-05-06 |
|
4 | LYRA |
Lyra Therapeutics, Inc.
Common Stock |
X - Other | 141,221 | 1,385,287 | 11.35 | 8.63 | 1,218,737 | 11,955,027 | |
2020-05-06 |
|
4 | LYRA |
Lyra Therapeutics, Inc.
Common Stock |
C - Conversion | 470,739 | 1,244,066 | 60.87 | ||||
2020-05-06 |
|
4 | LYRA |
Lyra Therapeutics, Inc.
Common Stock |
C - Conversion | 1,132,016 | 1,132,016 | |||||
2020-05-06 |
|
4 | LYRA |
Lyra Therapeutics, Inc.
Common Stock |
C - Conversion | 773,327 | 773,327 | |||||
2020-05-01 |
|
4 | LYRA |
Lyra Therapeutics, Inc.
Stock Option |
A - Award | 14,500 | 14,500 | |||||
2020-05-01 |
|
4 | LYRA |
Lyra Therapeutics, Inc.
Stock Option |
A - Award | 14,500 | 14,500 | |||||
2020-04-28 |
|
4 | VBIV |
VBI Vaccines Inc/BC
Common Stock |
P - Purchase | 9,090,909 | 55,042,456 | 19.78 | 1.10 | 10,000,000 | 60,546,702 | |
2020-04-20 | 3 | LPTX |
LEAP THERAPEUTICS, INC.
Common Stock |
13,452,992 | ||||||||
2020-04-20 | 3 | LPTX |
LEAP THERAPEUTICS, INC.
Common Stock |
13,452,992 | ||||||||
2020-04-20 | 3 | LPTX |
LEAP THERAPEUTICS, INC.
Common Stock |
13,452,992 | ||||||||
2020-04-20 | 3 | LPTX |
LEAP THERAPEUTICS, INC.
Common Stock |
13,452,992 | ||||||||
2020-04-20 | 3 | LPTX |
LEAP THERAPEUTICS, INC.
Common Stock |
13,452,992 | ||||||||
2020-04-20 |
|
4 | CRNX |
Crinetics Pharmaceuticals, Inc.
Common Stock |
P - Purchase | 1,071,428 | 3,659,381 | 41.40 | 14.00 | 14,999,992 | 51,231,334 | |
2020-03-23 |
|
4 | ADMA |
ADMA BIOLOGICS, INC.
Common Stock |
P - Purchase | 500,000 | 16,584,802 | 3.11 | 2.10 | 1,050,000 | 34,828,084 | |
2020-03-17 |
|
4 | AGRX |
AGILE THERAPEUTICS INC
Common Stock |
P - Purchase | 1,000,000 | 15,919,925 | 6.70 | 1.75 | 1,750,000 | 27,859,869 | |
2020-02-25 |
|
4 | AGRX |
AGILE THERAPEUTICS INC
Common Stock |
P - Purchase | 3,000,000 | 14,919,925 | 25.17 | 3.00 | 9,000,000 | 44,759,775 | |
2020-02-25 |
|
4 | AGRX |
AGILE THERAPEUTICS INC
Warrants (right to buy) |
J - Other | 700,000 | 700,000 | |||||
2020-02-25 |
|
4 | AGRX |
AGILE THERAPEUTICS INC
Warrants (right to buy) |
J - Other | 700,000 | 700,000 | |||||
2020-02-11 |
|
4 | ADMA |
ADMA BIOLOGICS, INC.
Common Stock |
P - Purchase | 4,563,700 | 16,084,802 | 39.61 | 3.50 | 15,972,950 | 56,296,807 | |
2020-02-04 |
|
4 | ALBO |
ALBIREO PHARMA, INC.
Common Stock |
P - Purchase | 255,809 | 1,960,139 | 15.01 | 21.00 | 5,371,989 | 41,162,919 | |
2019-12-27 |
|
4 | ATNX |
Athenex, Inc.
Common Stock |
P - Purchase | 73,698 | 11,532,467 | 0.64 | 14.39 | 1,060,514 | 165,952,200 | |
2019-12-26 |
|
4 | ATNX |
Athenex, Inc.
Common Stock |
P - Purchase | 153,237 | 11,458,769 | 1.36 | 14.30 | 2,191,289 | 163,860,397 | |
2019-12-26 |
|
4 | ATNX |
Athenex, Inc.
Common Stock |
P - Purchase | 189,322 | 11,305,532 | 1.70 | 14.14 | 2,677,013 | 159,860,222 | |
2019-12-26 |
|
4 | ATNX |
Athenex, Inc.
Common Stock |
P - Purchase | 120,931 | 11,116,210 | 1.10 | 13.86 | 1,676,104 | 154,070,671 | |
2019-12-26 |
|
4 | ATNX |
Athenex, Inc.
Common Stock |
P - Purchase | 142,812 | 10,995,279 | 1.32 | 13.72 | 1,959,381 | 150,855,228 | |
2019-11-18 |
|
4 | KDMN |
Kadmon Holdings, Inc.
Common Stock |
P - Purchase | 1,470,588 | 14,636,334 | 11.17 | 3.40 | 4,999,999 | 49,763,536 | |
2019-11-18 |
|
4 | AGRX |
AGILE THERAPEUTICS INC
Common Stock |
P - Purchase | 333,800 | 11,919,925 | 2.88 | 1.74 | 580,812 | 20,740,670 | |
2019-11-18 |
|
4 | AGRX |
AGILE THERAPEUTICS INC
Common Stock |
P - Purchase | 2,000,000 | 11,586,125 | 20.86 | 1.60 | 3,200,000 | 18,537,800 | |
2019-11-18 |
|
4 | AGRX |
AGILE THERAPEUTICS INC
Common Stock |
P - Purchase | 3,000,000 | 9,586,125 | 45.55 | 1.72 | 5,160,000 | 16,488,135 | |
2019-11-18 |
|
4 | AGRX |
AGILE THERAPEUTICS INC
Common Stock |
P - Purchase | 435,015 | 6,586,125 | 7.07 | 1.69 | 735,175 | 11,130,551 | |
2019-11-15 |
|
4 | DOVA |
Dova Pharmaceuticals Inc.
Common Stock |
J - Other | -3,125,851 | 0 | -100.00 | ||||
2019-11-12 |
|
4 | QTNT |
Quotient Ltd
Ordinary Shares |
P - Purchase | 2,500,000 | 13,289,054 | 23.17 | 7.00 | 17,500,000 | 93,023,378 | |
2019-10-31 |
|
4 | AGRX |
AGILE THERAPEUTICS INC
Common Stock |
S - Sale | -760,291 | 6,151,110 | -11.00 | 0.44 | -334,528 | 2,706,488 | |
2019-10-30 |
|
4 | AGRX |
AGILE THERAPEUTICS INC
Common Stock |
S - Sale | -3,815,349 | 6,911,401 | -35.57 | 0.51 | -1,945,828 | 3,524,815 | |
2019-10-30 |
|
4 | AGRX |
AGILE THERAPEUTICS INC
Common Stock |
P - Purchase | 2,300,000 | 10,726,750 | 27.29 | 0.95 | 2,185,000 | 10,190,412 | |
2019-10-21 |
|
4 | ATNX |
Athenex, Inc.
Common Stock |
P - Purchase | 50,000 | 10,852,467 | 0.46 | 10.93 | 546,500 | 118,617,464 | |
2019-10-18 |
|
4 | ATNX |
Athenex, Inc.
Common Stock |
P - Purchase | 67,222 | 10,802,467 | 0.63 | 10.29 | 691,714 | 111,157,385 | |
2019-09-24 |
|
4 | VBIV |
VBI Vaccines Inc/BC
Common Stock |
P - Purchase | 20,000,000 | 45,951,556 | 77.07 | 0.50 | 10,000,000 | 22,975,778 | |
2019-09-18 |
|
4 | ATNX |
Athenex, Inc.
Common Stock |
P - Purchase | 30,000 | 10,735,245 | 0.28 | 13.58 | 407,400 | 145,784,627 | |
2019-09-16 |
|
4 | ATNX |
Athenex, Inc.
Common Stock |
P - Purchase | 56,416 | 10,705,245 | 0.53 | 14.27 | 805,056 | 152,763,846 | |
2019-09-16 |
|
4 | ATNX |
Athenex, Inc.
Common Stock |
P - Purchase | 13,584 | 10,648,829 | 0.13 | 14.05 | 190,855 | 149,616,047 | |
2019-08-20 |
|
4 | MGTX |
MeiraGTx Holdings plc
Ordinary Shares |
P - Purchase | 425,531 | 6,433,277 | 7.08 | 23.50 | 9,999,978 | 151,182,010 | |
2019-08-16 |
|
4 | ATNX |
Athenex, Inc.
Common Stock |
P - Purchase | 20,000 | 10,635,245 | 0.19 | 14.96 | 299,200 | 159,103,265 | |
2019-08-16 |
|
4 | ATNX |
Athenex, Inc.
Common Stock |
P - Purchase | 30,000 | 10,615,245 | 0.28 | 15.00 | 450,000 | 159,228,675 | |
2019-08-09 |
|
4 | ATNX |
Athenex, Inc.
Common Stock |
P - Purchase | 30,000 | 10,585,245 | 0.28 | 15.76 | 472,800 | 166,823,461 | |
2019-08-09 |
|
4 | ATNX |
Athenex, Inc.
Common Stock |
P - Purchase | 37,764 | 10,555,245 | 0.36 | 15.79 | 596,294 | 166,667,319 | |
2019-08-09 |
|
4 | ATNX |
Athenex, Inc.
Common Stock |
P - Purchase | 248,752 | 10,517,481 | 2.42 | 15.04 | 3,741,230 | 158,182,914 | |
2019-08-09 |
|
4 | ATNX |
Athenex, Inc.
Common Stock |
P - Purchase | 371,756 | 10,268,729 | 3.76 | 14.14 | 5,256,630 | 145,199,828 | |
2019-08-09 |
|
4 | ATNX |
Athenex, Inc.
Common Stock |
P - Purchase | 74,855 | 9,896,973 | 0.76 | 13.12 | 982,098 | 129,848,286 | |
2019-08-09 |
|
4 | ATNX |
Athenex, Inc.
Common Stock |
P - Purchase | 1,495 | 9,822,118 | 0.02 | 17.89 | 26,746 | 175,717,691 | |
2019-08-09 |
|
4 | ATNX |
Athenex, Inc.
Common Stock |
P - Purchase | 20,786 | 9,820,623 | 0.21 | 17.90 | 372,069 | 175,789,152 | |
2019-08-09 |
|
4 | ATNX |
Athenex, Inc.
Common Stock |
P - Purchase | 23,073 | 9,799,837 | 0.24 | 17.85 | 411,853 | 174,927,090 | |
2019-08-06 | 3 | FOMX |
Foamix Pharmaceuticals Ltd.
Common Stock |
22,407,762 | ||||||||
2019-08-06 | 3 | FOMX |
Foamix Pharmaceuticals Ltd.
Common Stock |
22,407,762 | ||||||||
2019-08-06 | 3 | FOMX |
Foamix Pharmaceuticals Ltd.
Common Stock |
22,407,762 | ||||||||
2019-08-06 | 3 | FOMX |
Foamix Pharmaceuticals Ltd.
Common Stock |
22,407,762 | ||||||||
2019-08-06 | 3 | FOMX |
Foamix Pharmaceuticals Ltd.
Common Stock |
22,407,762 | ||||||||
2019-07-29 |
|
4 | SLDB |
Solid Biosciences Inc.
Common Stock |
P - Purchase | 2,822,581 | 6,749,803 | 71.87 | 4.65 | 13,125,002 | 31,386,584 | |
2019-07-11 |
|
4 | DOVA |
Dova Pharmaceuticals Inc.
Common Stock |
P - Purchase | 42,916 | 3,708,705 | 1.17 | 16.67 | 715,410 | 61,824,112 | |
2019-07-11 |
|
4 | DOVA |
Dova Pharmaceuticals Inc.
Common Stock |
P - Purchase | 12,354 | 3,665,789 | 0.34 | 16.89 | 208,659 | 61,915,176 | |
2019-07-11 |
|
4 | DOVA |
Dova Pharmaceuticals Inc.
Common Stock |
P - Purchase | 29,834 | 3,653,435 | 0.82 | 16.61 | 495,543 | 60,683,555 | |
2019-07-09 |
|
4 | DOVA |
Dova Pharmaceuticals Inc.
Common Stock |
P - Purchase | 50,000 | 3,632,601 | 1.40 | 16.46 | 823,000 | 59,792,612 | |
2019-07-03 |
|
4 | DOVA |
Dova Pharmaceuticals Inc.
Common Stock |
P - Purchase | 1,705 | 3,573,601 | 0.05 | 16.67 | 28,422 | 59,571,929 | |
2019-07-03 |
|
4 | DOVA |
Dova Pharmaceuticals Inc.
Common Stock |
P - Purchase | 715 | 3,571,896 | 0.02 | 16.14 | 11,540 | 57,650,401 | |
2019-07-03 |
|
4 | DOVA |
Dova Pharmaceuticals Inc.
Common Stock |
P - Purchase | 18,121 | 3,571,181 | 0.51 | 14.24 | 258,043 | 50,853,617 | |
2019-07-01 |
|
4 | DOVA |
Dova Pharmaceuticals Inc.
Common Stock |
P - Purchase | 39,383 | 3,553,060 | 1.12 | 14.48 | 570,266 | 51,448,309 | |
2019-07-01 |
|
4 | DOVA |
Dova Pharmaceuticals Inc.
Common Stock |
P - Purchase | 60,617 | 3,513,560 | 1.76 | 13.97 | 846,819 | 49,084,433 | |
2019-07-01 |
|
4 | DOVA |
Dova Pharmaceuticals Inc.
Common Stock |
P - Purchase | 186,696 | 3,453,060 | 5.72 | 13.58 | 2,535,332 | 46,892,555 | |
2019-07-01 |
|
4 | DOVA |
Dova Pharmaceuticals Inc.
Common Stock |
P - Purchase | 140,513 | 3,266,364 | 4.50 | 12.46 | 1,750,792 | 40,698,895 | |
2019-07-01 |
|
4 | MOTS |
Motus GI Holdings, Inc.
Common Stock |
P - Purchase | 1,000,000 | 4,210,542 | 31.15 | 3.00 | 3,000,000 | 12,631,626 | |
2019-06-21 |
|
4 | MGTX |
MeiraGTx Holdings plc
Stock Option (right to buy) |
A - Award | 25,000 | 25,000 | |||||
2019-06-20 |
|
4 | VBIV |
VBI Vaccines Inc/BC
Common Stock |
P - Purchase | 1,000,000 | 25,951,556 | 4.01 | 0.65 | 650,000 | 16,868,511 | |
2019-06-20 |
|
4 | ATNX |
Athenex, Inc.
Common Stock |
P - Purchase | 50,742 | 9,776,764 | 0.52 | 17.73 | 899,656 | 173,342,026 | |
2019-06-19 |
|
4 | ATNX |
Athenex, Inc.
Common Stock |
P - Purchase | 130,000 | 9,726,022 | 1.35 | 17.94 | 2,332,200 | 174,484,835 | |
2019-06-18 |
|
4 | VBIV |
VBI Vaccines Inc/BC
Common Stock |
P - Purchase | 1,000,000 | 24,951,556 | 4.18 | 0.62 | 618,000 | 15,420,062 | |
2019-06-18 |
|
4 | ATNX |
Athenex, Inc.
Common Stock |
P - Purchase | 324,290 | 9,596,022 | 3.50 | 17.69 | 5,736,690 | 169,753,629 | |
2019-06-17 |
|
4 | SLDB |
Solid Biosciences Inc.
Stock Option (Right to Buy) |
A - Award | 10,000 | 10,000 | |||||
2019-06-17 |
|
4 | ATNX |
Athenex, Inc.
Common Stock |
P - Purchase | 75,710 | 9,271,732 | 0.82 | 17.05 | 1,290,856 | 158,083,031 | |
2019-05-23 |
|
4 | ADMA |
ADMA BIOLOGICS, INC.
Common Stock |
P - Purchase | 4,000,000 | 11,521,102 | 53.18 | 4.00 | 16,000,000 | 46,084,408 | |
2019-05-23 |
|
4 | ADMA |
ADMA BIOLOGICS, INC.
Warrants (right to buy) |
P - Purchase | 250,000 | 250,000 | |||||
2019-05-23 |
|
4 | ADMA |
ADMA BIOLOGICS, INC.
Warrants (right to buy) |
P - Purchase | 1,360,000 | 1,360,000 | |||||
2019-05-08 | 3 | ATNX |
Athenex, Inc.
Common Stock |
18,192,044 | ||||||||
2019-05-08 | 3 | ATNX |
Athenex, Inc.
Common Stock |
18,192,044 | ||||||||
2019-05-08 | 3 | ATNX |
Athenex, Inc.
Common Stock |
18,192,044 | ||||||||
2019-05-08 | 3 | ATNX |
Athenex, Inc.
Common Stock |
18,192,044 | ||||||||
2019-05-08 | 3 | ATNX |
Athenex, Inc.
Common Stock |
18,192,044 | ||||||||
2019-05-08 |
|
4 | ATNX |
Athenex, Inc.
Common Stock |
P - Purchase | 77,010 | 9,196,022 | 0.84 | 12.90 | 993,429 | 118,628,684 | |
2019-05-08 |
|
4 | ATNX |
Athenex, Inc.
Common Stock |
P - Purchase | 22,990 | 9,119,012 | 0.25 | 12.08 | 277,719 | 110,157,665 | |
2019-03-06 | 3 | AGRX |
AGILE THERAPEUTICS INC
Common Stock |
16,853,500 | ||||||||
2019-03-06 | 3 | AGRX |
AGILE THERAPEUTICS INC
Common Stock |
16,853,500 | ||||||||
2019-03-06 | 3 | AGRX |
AGILE THERAPEUTICS INC
Common Stock |
16,853,500 | ||||||||
2019-03-06 | 3 | AGRX |
AGILE THERAPEUTICS INC
Common Stock |
16,853,500 | ||||||||
2019-03-06 | 3 | AGRX |
AGILE THERAPEUTICS INC
Common Stock |
16,853,500 | ||||||||
2019-03-05 |
|
4 | MGTX |
MeiraGTx Holdings plc
Ordinary Shares |
P - Purchase | 1,304,348 | 6,007,746 | 27.73 | 13.80 | 18,000,002 | 82,906,895 | |
2019-01-17 |
|
4 | MOTS |
Motus GI Holdings, Inc.
Common Stock |
P - Purchase | 400,000 | 3,210,541 | 14.23 | 2.70 | 1,080,000 | 8,668,461 | |
2019-01-17 |
|
4 | MOTS |
Motus GI Holdings, Inc.
Common Stock |
P - Purchase | 10,000 | 2,810,541 | 0.36 | 5.00 | 50,000 | 14,052,705 | |
2019-01-09 |
|
4 | LJPC |
LA JOLLA PHARMACEUTICAL CO
Common Stock |
S - Sale | -450,235 | 2,253,376 | -16.65 | 5.26 | -2,368,236 | 11,852,758 | |
2019-01-09 |
|
4 | LJPC |
LA JOLLA PHARMACEUTICAL CO
Common Stock |
S - Sale | -800,000 | 2,703,611 | -22.83 | 5.25 | -4,200,000 | 14,193,958 | |
2019-01-09 |
|
4 | LJPC |
LA JOLLA PHARMACEUTICAL CO
Common Stock |
S - Sale | -25,800 | 3,503,611 | -0.73 | 6.46 | -166,668 | 22,633,327 | |
2019-01-09 |
|
4 | LJPC |
LA JOLLA PHARMACEUTICAL CO
Common Stock |
S - Sale | -25,800 | 3,503,611 | -0.73 | 6.46 | -166,668 | 22,633,327 | |
2019-01-09 |
|
4 | LJPC |
LA JOLLA PHARMACEUTICAL CO
Common Stock |
S - Sale | -4,200 | 3,529,411 | -0.12 | 5.26 | -22,092 | 18,564,702 | |
2019-01-09 |
|
4 | LJPC |
LA JOLLA PHARMACEUTICAL CO
Common Stock |
S - Sale | -4,200 | 3,529,411 | -0.12 | 5.26 | -22,092 | 18,564,702 | |
2019-01-09 |
|
4 | LJPC |
LA JOLLA PHARMACEUTICAL CO
Common Stock |
S - Sale | -4,592 | 3,563,611 | -0.13 | 9.52 | -43,716 | 33,925,577 | |
2019-01-09 |
|
4 | LJPC |
LA JOLLA PHARMACEUTICAL CO
Common Stock |
S - Sale | -34,401 | 3,568,203 | -0.95 | 9.05 | -311,329 | 32,292,237 | |
2019-01-09 |
|
4 | LJPC |
LA JOLLA PHARMACEUTICAL CO
Common Stock |
S - Sale | -131,866 | 3,602,604 | -3.53 | 7.56 | -996,907 | 27,235,686 | |
2019-01-09 |
|
4 | LJPC |
LA JOLLA PHARMACEUTICAL CO
Common Stock |
S - Sale | -147,497 | 3,734,470 | -3.80 | 6.67 | -983,805 | 24,908,915 | |
2019-01-09 |
|
4 | LJPC |
LA JOLLA PHARMACEUTICAL CO
Common Stock |
S - Sale | -431,644 | 3,881,967 | -10.01 | 5.64 | -2,434,472 | 21,894,294 | |
2018-12-17 |
|
4 | VBIV |
VBI Vaccines Inc/BC
Common Stock |
P - Purchase | 14,285,714 | 23,631,439 | 152.86 | 1.40 | 20,000,000 | 33,084,015 | |
2018-12-10 |
|
4 | QTNT |
Quotient Ltd
Ordinary Shares |
P - Purchase | 2,000,000 | 10,789,054 | 22.76 | 6.50 | 13,000,000 | 70,128,851 | |
2018-10-15 |
|
4 | CORI |
Corium International, Inc.
Common Stock |
S - Sale | -2,350,000 | 2,724,686 | -46.31 | 12.52 | -29,422,000 | 34,113,069 | |
2018-10-15 |
|
4 | CORI |
Corium International, Inc.
Common Stock |
S - Sale | -500,000 | 5,074,686 | -8.97 | 12.51 | -6,255,000 | 63,484,322 | |
2018-10-15 |
|
4 | CORI |
Corium International, Inc.
Common Stock |
S - Sale | -500,000 | 5,574,686 | -8.23 | 12.50 | -6,250,000 | 69,683,575 | |
2018-10-15 |
|
4 | CORI |
Corium International, Inc.
Common Stock |
S - Sale | -282,447 | 6,074,686 | -4.44 | 12.51 | -3,533,412 | 75,994,322 | |
2018-10-05 |
|
4 | FOLD |
AMICUS THERAPEUTICS INC
Common Stock |
P - Purchase | 30,000 | 20,724,424 | 0.14 | 12.69 | 380,700 | 262,992,941 | |
2018-10-05 |
|
4 | FOLD |
AMICUS THERAPEUTICS INC
Common Stock |
P - Purchase | 20,000 | 20,694,424 | 0.10 | 12.45 | 249,000 | 257,645,579 | |
2018-09-25 |
|
4 | FOLD |
AMICUS THERAPEUTICS INC
Common Stock |
P - Purchase | 50,000 | 20,674,424 | 0.24 | 12.53 | 626,500 | 259,050,533 | |
2018-09-17 |
|
4 | FOLD |
AMICUS THERAPEUTICS INC
Common Stock |
P - Purchase | 100,000 | 20,624,424 | 0.49 | 11.74 | 1,174,000 | 242,130,738 | |
2018-09-14 |
|
4 | FOLD |
AMICUS THERAPEUTICS INC
Common Stock |
P - Purchase | 500,000 | 20,524,424 | 2.50 | 12.00 | 6,001,500 | 246,354,661 | |
2018-08-27 |
|
4/A | CRNX |
Crinetics Pharmaceuticals, Inc.
Series B Preferred Stock |
C - Conversion | -6,186,205 | 0 | -100.00 | ||||
2018-08-27 |
|
4/A | CRNX |
Crinetics Pharmaceuticals, Inc.
Common Stock |
P - Purchase | 400,000 | 2,587,953 | 18.28 | 17.00 | 6,800,000 | 43,995,201 | |
2018-08-27 |
|
4/A | CRNX |
Crinetics Pharmaceuticals, Inc.
Common Stock |
C - Conversion | 1,880,305 | 2,187,953 | 611.19 | ||||
2018-08-27 |
|
4/A | CRNX |
Crinetics Pharmaceuticals, Inc.
Common Stock |
P - Purchase | 307,648 | 307,648 | 21.30 | 6,552,902 | 6,552,902 | ||
2018-08-14 |
|
4 | ZGNX |
ZOGENIX, INC.
Common Stock |
P - Purchase | 100,000 | 4,070,357 | 2.52 | 52.00 | 5,200,000 | 211,658,564 | |
2018-08-01 |
|
4 | VRCA |
Verrica Pharmaceuticals Inc.
Series C Preferred Stock |
C - Conversion | -2,193,463 | 0 | -100.00 | ||||
2018-08-01 |
|
4 | VRCA |
Verrica Pharmaceuticals Inc.
Series B Preferred Stock |
C - Conversion | -1,937,984 | 0 | -100.00 | ||||
2018-08-01 |
|
4 | VRCA |
Verrica Pharmaceuticals Inc.
Common Stock |
P - Purchase | 1,000,000 | 3,410,412 | 41.49 | 15.00 | 15,000,000 | 51,156,180 | |
2018-08-01 |
|
4 | VRCA |
Verrica Pharmaceuticals Inc.
Common Stock |
C - Conversion | 1,279,733 | 2,410,412 | 113.18 | ||||
2018-08-01 |
|
4 | VRCA |
Verrica Pharmaceuticals Inc.
Common Stock |
C - Conversion | 1,130,679 | 1,130,679 | |||||
2018-07-27 |
|
4 | SLDB |
Solid Biosciences Inc.
Stock Option (Right to Buy) |
A - Award | 1,835 | 1,835 | |||||
2018-07-26 |
|
4 | AGRX |
AGILE THERAPEUTICS INC
Common Stock |
S - Sale | -298,628 | 3,231,372 | -8.46 | 0.30 | -89,439 | 967,796 | |
2018-07-20 |
|
4 | QTNT |
Quotient Ltd
Warrants (right to buy) |
X - Other | -2,306,034 | 0 | -100.00 | ||||
2018-07-20 |
|
4 | QTNT |
Quotient Ltd
Ordinary Shares |
X - Other | 2,306,034 | 8,789,054 | 35.57 | 5.80 | 13,374,997 | 50,976,513 | |
2018-07-20 |
|
4 | CRNX |
Crinetics Pharmaceuticals, Inc.
Series B Preferred Stock |
C - Conversion | -6,186,205 | 0 | -100.00 | ||||
2018-07-20 |
|
4 | CRNX |
Crinetics Pharmaceuticals, Inc.
Common Stock |
P - Purchase | 400,000 | 2,280,305 | 21.27 | 17.00 | 6,800,000 | 38,765,185 | |
2018-07-20 |
|
4 | CRNX |
Crinetics Pharmaceuticals, Inc.
Common Stock |
C - Conversion | 1,880,305 | 1,880,305 | |||||
2018-06-22 | 3 | KDMN |
Kadmon Holdings, Inc.
Common Stock |
26,331,492 | ||||||||
2018-06-22 | 3 | KDMN |
Kadmon Holdings, Inc.
Common Stock |
26,331,492 | ||||||||
2018-06-22 | 3 | KDMN |
Kadmon Holdings, Inc.
Common Stock |
26,331,492 | ||||||||
2018-06-22 | 3 | KDMN |
Kadmon Holdings, Inc.
Common Stock |
26,331,492 | ||||||||
2018-06-22 | 3 | KDMN |
Kadmon Holdings, Inc.
Common Stock |
26,331,492 | ||||||||
2018-06-13 |
|
4 | DOVA |
Dova Pharmaceuticals, Inc.
Common Stock |
P - Purchase | 5,591 | 3,125,851 | 0.18 | 29.82 | 166,724 | 93,212,877 | |
2018-06-13 |
|
4 | DOVA |
Dova Pharmaceuticals, Inc.
Common Stock |
P - Purchase | 14,109 | 3,120,260 | 0.45 | 29.18 | 411,701 | 91,049,187 | |
2018-06-12 |
|
4 | DOVA |
Dova Pharmaceuticals, Inc.
Common Stock |
P - Purchase | 2,000 | 3,106,151 | 0.06 | 28.97 | 57,940 | 89,985,194 | |
2018-06-12 |
|
4 | DOVA |
Dova Pharmaceuticals, Inc.
Common Stock |
P - Purchase | 23,000 | 3,104,151 | 0.75 | 28.62 | 658,260 | 88,840,802 | |
2018-06-12 |
|
4 | MGTX |
MeiraGTx Holdings plc
Ordinary Shares |
P - Purchase | 1,333,333 | 4,703,398 | 39.56 | 15.00 | 19,999,995 | 70,550,970 | |
2018-06-12 |
|
4 | MGTX |
MeiraGTx Holdings plc
Ordinary Shares |
P - Purchase | 50,000 | 3,370,065 | 1.51 | 15.22 | 761,000 | 51,292,389 | |
2018-06-11 |
|
4 | DOVA |
Dova Pharmaceuticals, Inc.
Common Stock |
P - Purchase | 8,400 | 3,081,151 | 0.27 | 29.16 | 244,944 | 89,846,363 | |
2018-06-11 |
|
4 | DOVA |
Dova Pharmaceuticals, Inc.
Common Stock |
P - Purchase | 19,223 | 3,072,751 | 0.63 | 28.40 | 545,933 | 87,266,128 | |
2018-06-11 |
|
4 | DOVA |
Dova Pharmaceuticals, Inc.
Common Stock |
P - Purchase | 22,377 | 3,053,528 | 0.74 | 27.63 | 618,277 | 84,368,979 | |
2018-06-08 |
|
4 | DOVA |
Dova Pharmaceuticals, Inc.
Common Stock |
P - Purchase | 51,763 | 3,031,151 | 1.74 | 28.99 | 1,500,609 | 87,873,067 | |
2018-06-08 |
|
4 | DOVA |
Dova Pharmaceuticals, Inc.
Common Stock |
P - Purchase | 48,237 | 2,979,388 | 1.65 | 28.30 | 1,365,107 | 84,316,680 | |
2018-06-08 | 3 | MGTX |
MeiraGTx Holdings plc
Ordinary shares |
6,640,130 | ||||||||
2018-06-08 | 3 | MGTX |
MeiraGTx Holdings plc
Ordinary shares |
6,640,130 | ||||||||
2018-06-08 | 3 | MGTX |
MeiraGTx Holdings plc
Ordinary shares |
6,640,130 | ||||||||
2018-06-08 | 3 | MGTX |
MeiraGTx Holdings plc
Ordinary shares |
6,640,130 | ||||||||
2018-06-08 | 3 | MGTX |
MeiraGTx Holdings plc
Ordinary shares |
6,640,130 | ||||||||
2018-06-07 |
|
4 | DOVA |
Dova Pharmaceuticals, Inc.
Common Stock |
P - Purchase | 3,168 | 2,931,151 | 0.11 | 27.13 | 85,948 | 79,522,127 | |
2018-06-07 |
|
4 | DOVA |
Dova Pharmaceuticals, Inc.
Common Stock |
P - Purchase | 56,162 | 2,927,983 | 1.96 | 26.31 | 1,477,622 | 77,035,233 | |
2018-06-07 |
|
4 | DOVA |
Dova Pharmaceuticals, Inc.
Common Stock |
P - Purchase | 40,670 | 2,871,821 | 1.44 | 25.45 | 1,035,052 | 73,087,844 | |
2018-06-06 |
|
4 | DOVA |
Dova Pharmaceuticals, Inc.
Common Stock |
P - Purchase | 10,000 | 2,831,151 | 0.35 | 25.07 | 250,700 | 70,976,956 | |
2018-06-06 | 3 | DOVA |
Dova Pharmaceuticals, Inc.
Common Stock |
5,642,302 | ||||||||
2018-06-06 | 3 | DOVA |
Dova Pharmaceuticals, Inc.
Common Stock |
5,642,302 | ||||||||
2018-06-06 | 3 | DOVA |
Dova Pharmaceuticals, Inc.
Common Stock |
5,642,302 | ||||||||
2018-06-06 | 3 | DOVA |
Dova Pharmaceuticals, Inc.
Common Stock |
5,642,302 | ||||||||
2018-06-06 | 3 | DOVA |
Dova Pharmaceuticals, Inc.
Common Stock |
5,642,302 | ||||||||
2018-05-24 |
|
4 | QTNT |
Quotient Ltd
Ordinary Shares |
P - Purchase | 231,992 | 6,483,020 | 3.71 | 6.65 | 1,542,747 | 43,112,083 | |
2018-05-24 |
|
4 | QTNT |
Quotient Ltd
Ordinary Shares |
P - Purchase | 218,008 | 6,251,028 | 3.61 | 6.24 | 1,360,370 | 39,006,415 | |
2018-03-28 | 3 | AGRX |
AGILE THERAPEUTICS INC
Common Stock |
7,060,000 | ||||||||
2018-03-28 | 3 | AGRX |
AGILE THERAPEUTICS INC
Common Stock |
7,060,000 | ||||||||
2018-03-28 | 3 | AGRX |
AGILE THERAPEUTICS INC
Common Stock |
7,060,000 | ||||||||
2018-03-28 | 3 | AGRX |
AGILE THERAPEUTICS INC
Common Stock |
7,060,000 | ||||||||
2018-03-28 | 3 | AGRX |
AGILE THERAPEUTICS INC
Common Stock |
7,060,000 | ||||||||
2018-03-26 |
|
4 | LJPC |
LA JOLLA PHARMACEUTICAL CO
Common Stock |
P - Purchase | 700,000 | 4,313,611 | 19.37 | 29.50 | 20,650,000 | 127,251,524 | |
2018-03-07 |
|
4 | FOLD |
AMICUS THERAPEUTICS INC
Common Stock |
P - Purchase | 335,827 | 18,424,424 | 1.86 | 13.56 | 4,553,814 | 249,835,189 | |
2018-03-06 |
|
4 | FOLD |
AMICUS THERAPEUTICS INC
Common Stock |
P - Purchase | 100,000 | 18,088,597 | 0.56 | 13.90 | 1,389,500 | 251,341,055 | |
2018-03-05 |
|
4 | FOLD |
AMICUS THERAPEUTICS INC
Common Stock |
P - Purchase | 100,000 | 17,988,597 | 0.56 | 13.69 | 1,369,000 | 246,263,893 | |
2018-02-21 |
|
4 | MOTS |
Motus GI Holdings, Inc.
Series A Convertible Preferred Stock |
C - Conversion | -256,386 | 0 | -100.00 | ||||
2018-02-21 |
|
4 | MOTS |
Motus GI Holdings, Inc.
Common Stock |
P - Purchase | 1,000,000 | 2,800,541 | 55.54 | 5.00 | 5,000,000 | 14,002,705 | |
2018-02-21 |
|
4 | MOTS |
Motus GI Holdings, Inc.
Common Stock |
C - Conversion | 256,386 | 1,800,541 | 16.60 | ||||
2018-02-21 |
|
4 | MOTS |
Motus GI Holdings, Inc.
Warrant (right to buy) |
J - Other | 180,055 | 180,055 | |||||
2018-02-20 |
|
4 | LJPC |
LA JOLLA PHARMACEUTICAL CO
Common Stock |
P - Purchase | 50,000 | 3,613,611 | 1.40 | 32.42 | 1,621,000 | 117,153,269 | |
2018-02-15 |
|
4 | LJPC |
LA JOLLA PHARMACEUTICAL CO
Common Stock |
P - Purchase | 100,000 | 3,563,611 | 2.89 | 32.69 | 3,269,000 | 116,494,444 | |
2018-02-15 |
|
4 | LJPC |
LA JOLLA PHARMACEUTICAL CO
Common Stock |
P - Purchase | 75,000 | 3,463,611 | 2.21 | 32.75 | 2,456,250 | 113,433,260 | |
2018-02-13 | 3 | MOTS |
Motus GI Holdings, Inc.
Common Stock |
3,088,310 | ||||||||
2018-02-13 | 3 | MOTS |
Motus GI Holdings, Inc.
Common Stock |
3,088,310 | ||||||||
2018-02-13 | 3 | MOTS |
Motus GI Holdings, Inc.
Common Stock |
3,088,310 | ||||||||
2018-02-13 | 3 | MOTS |
Motus GI Holdings, Inc.
Common Stock |
3,088,310 | ||||||||
2018-01-30 |
|
4 | SLDB |
Solid Biosciences Inc.
Common Stock |
P - Purchase | 20,000 | 3,927,222 | 0.51 | 27.33 | 546,520 | 107,315,268 | |
2018-01-30 |
|
4 | SLDB |
Solid Biosciences Inc.
Common Stock |
P - Purchase | 1,000,000 | 3,907,222 | 34.40 | 16.00 | 16,000,000 | 62,515,552 | |
2018-01-25 |
|
4 | ALBO |
ALBIREO PHARMA, INC.
Common Stock |
P - Purchase | 275,000 | 1,595,000 | 20.83 | 33.00 | 9,075,000 | 52,635,000 | |
2018-01-25 | 3 | SLDB |
Solid Biosciences, LLC
Common Stock |
5,814,444 | ||||||||
2018-01-25 | 3 | SLDB |
Solid Biosciences, LLC
Common Stock |
5,814,444 | ||||||||
2018-01-25 | 3 | SLDB |
Solid Biosciences, LLC
Common Stock |
5,814,444 | ||||||||
2018-01-25 | 3 | SLDB |
Solid Biosciences, LLC
Common Stock |
5,814,444 | ||||||||
2018-01-18 |
|
4 | CORI |
Corium International, Inc.
Common Stock |
P - Purchase | 310,000 | 6,357,133 | 5.13 | 12.80 | 3,968,000 | 81,371,302 | |
2018-01-18 |
|
4 | CORI |
Corium International, Inc.
Common Stock |
P - Purchase | 149,650 | 6,047,133 | 2.54 | 12.24 | 1,831,716 | 74,016,908 | |
2018-01-18 |
|
4 | CORI |
Corium International, Inc.
Common Stock |
P - Purchase | 50,350 | 5,897,483 | 0.86 | 11.83 | 595,640 | 69,767,224 | |
2017-12-19 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Common Stock |
P - Purchase | 175,000 | 4,889,066 | 3.71 | 38.00 | 6,650,000 | 185,784,508 | |
2017-12-18 | 3 | LJPC |
LA JOLLA PHARMACEUTICAL CO
Common Stock |
6,777,222 | ||||||||
2017-12-18 | 3 | LJPC |
LA JOLLA PHARMACEUTICAL CO
Common Stock |
6,777,222 | ||||||||
2017-12-18 | 3 | LJPC |
LA JOLLA PHARMACEUTICAL CO
Common Stock |
6,777,222 | ||||||||
2017-12-18 | 3 | LJPC |
LA JOLLA PHARMACEUTICAL CO
Common Stock |
6,777,222 | ||||||||
2017-12-15 | 3 | GBT |
Global Blood Therapeutics, Inc.
Common Stock |
9,428,132 | ||||||||
2017-12-15 | 3 | GBT |
Global Blood Therapeutics, Inc.
Common Stock |
9,428,132 | ||||||||
2017-12-15 | 3 | GBT |
Global Blood Therapeutics, Inc.
Common Stock |
9,428,132 | ||||||||
2017-12-15 | 3 | GBT |
Global Blood Therapeutics, Inc.
Common Stock |
9,428,132 | ||||||||
2017-12-04 | 3 | ALBO |
ALBIREO PHARMA, INC.
Common stock |
2,640,000 | ||||||||
2017-12-04 | 3 | ALBO |
ALBIREO PHARMA, INC.
Common stock |
2,640,000 | ||||||||
2017-12-04 | 3 | ALBO |
ALBIREO PHARMA, INC.
Common stock |
2,640,000 | ||||||||
2017-12-04 | 3 | ALBO |
ALBIREO PHARMA, INC.
Common stock |
2,640,000 | ||||||||
2017-11-15 | 3 | ADMA |
ADMA BIOLOGICS, INC.
Common stock, par value $0.0001 per share |
7,642,204 | ||||||||
2017-11-15 | 3 | ADMA |
ADMA BIOLOGICS, INC.
Common stock, par value $0.0001 per share |
7,642,204 | ||||||||
2017-11-15 | 3 | ADMA |
ADMA BIOLOGICS, INC.
Common stock, par value $0.0001 per share |
7,642,204 | ||||||||
2017-11-15 | 3 | ADMA |
ADMA BIOLOGICS, INC.
Common stock, par value $0.0001 per share |
7,642,204 | ||||||||
2017-11-01 | 3/A | QTNT |
Quotient Ltd
Ordinary Shares |
6,033,020 | ||||||||
2017-10-30 |
|
4 | VBIV |
VBI Vaccines Inc/BC
Common Stock |
P - Purchase | 3,100,000 | 9,345,725 | 49.63 | 3.05 | 9,455,000 | 28,504,461 | |
2017-10-26 | 3 | QTNT |
Quotient Ltd
Ordinary Shares |
12,086,040 | ||||||||
2017-10-26 | 3 | QTNT |
Quotient Ltd
Ordinary Shares |
12,086,040 | ||||||||
2017-10-26 | 3 | QTNT |
Quotient Ltd
Ordinary Shares |
12,086,040 | ||||||||
2017-10-26 | 3 | QTNT |
Quotient Ltd
Ordinary Shares |
12,086,040 | ||||||||
2017-10-03 |
|
4 | ZGNX |
ZOGENIX, INC.
Common Stock |
P - Purchase | 22,055 | 3,670,357 | 0.60 | 27.67 | 610,341 | 101,571,991 | |
2017-10-03 |
|
4 | ZGNX |
ZOGENIX, INC.
Common Stock |
P - Purchase | 8,920 | 3,648,302 | 0.25 | 40.14 | 358,081 | 146,455,976 | |
2017-10-03 |
|
4 | ZGNX |
ZOGENIX, INC.
Common Stock |
P - Purchase | 12,586 | 3,639,382 | 0.35 | 39.22 | 493,600 | 142,730,011 | |
2017-10-03 |
|
4 | ZGNX |
ZOGENIX, INC.
Common Stock |
P - Purchase | 8,112 | 3,626,796 | 0.22 | 38.56 | 312,791 | 139,845,990 | |
2017-10-03 |
|
4 | ZGNX |
ZOGENIX, INC.
Common Stock |
P - Purchase | 6,153 | 3,618,684 | 0.17 | 37.14 | 228,530 | 134,402,266 | |
2017-10-03 |
|
4 | ZGNX |
ZOGENIX, INC.
Common Stock |
P - Purchase | 3,800 | 3,612,531 | 0.11 | 36.26 | 137,805 | 131,006,630 | |
2017-10-03 |
|
4 | ZGNX |
ZOGENIX, INC.
Common Stock |
P - Purchase | 6,000 | 3,608,731 | 0.17 | 34.91 | 209,475 | 125,989,821 | |
2017-10-03 |
|
4 | ZGNX |
ZOGENIX, INC.
Common Stock |
P - Purchase | 8,260 | 3,602,731 | 0.23 | 33.86 | 279,665 | 121,980,185 | |
2017-10-03 |
|
4 | ZGNX |
ZOGENIX, INC.
Common Stock |
P - Purchase | 15,937 | 3,594,471 | 0.45 | 32.96 | 525,311 | 118,479,875 | |
2017-10-03 |
|
4 | ZGNX |
ZOGENIX, INC.
Common Stock |
P - Purchase | 102,199 | 3,578,534 | 2.94 | 31.90 | 3,260,240 | 114,158,455 | |
2017-10-03 |
|
4 | ZGNX |
ZOGENIX, INC.
Common Stock |
P - Purchase | 28,033 | 3,476,335 | 0.81 | 31.19 | 874,220 | 108,410,898 | |
2017-10-03 |
|
4 | ZGNX |
ZOGENIX, INC.
Common Stock |
P - Purchase | 300,000 | 3,970,357 | 8.17 | 37.50 | 11,250,000 | 148,888,388 | |
2017-09-25 |
|
4 | VSAR |
Versartis, Inc.
Common Stock |
S - Sale | -350,000 | 2,099,563 | -14.29 | 3.35 | -1,172,500 | 7,033,536 | |
2017-09-25 |
|
4 | VSAR |
Versartis, Inc.
Common Stock |
S - Sale | -500,000 | 2,449,563 | -16.95 | 3.27 | -1,633,250 | 8,001,498 | |
2017-09-25 |
|
4 | VSAR |
Versartis, Inc.
Common Stock |
S - Sale | -250,000 | 2,949,563 | -7.81 | 3.17 | -792,500 | 9,350,115 | |
2017-09-25 |
|
4 | VSAR |
Versartis, Inc.
Common Stock |
S - Sale | -250,000 | 3,199,563 | -7.25 | 3.03 | -757,250 | 9,691,476 | |
2017-09-25 |
|
4 | VSAR |
Versartis, Inc.
Common Stock |
S - Sale | -300,000 | 3,449,563 | -8.00 | 3.09 | -926,250 | 10,650,526 | |
2017-09-25 |
|
4 | VSAR |
Versartis, Inc.
Common Stock |
S - Sale | -353,421 | 3,749,563 | -8.61 | 3.56 | -1,258,143 | 13,348,069 | |
2017-09-25 |
|
4 | VSAR |
Versartis, Inc.
Common Stock |
S - Sale | -126,579 | 4,102,984 | -2.99 | 3.74 | -473,659 | 15,353,366 | |
2017-09-21 |
|
4 | ALDX |
Aldeyra Therapeutics, Inc.
Common Stock |
P - Purchase | 200,000 | 3,085,458 | 6.93 | 7.25 | 1,450,000 | 22,369,570 | |
2017-07-14 |
|
4 | FOLD |
AMICUS THERAPEUTICS INC
Common Stock |
P - Purchase | 1,500,000 | 17,888,597 | 9.15 | 12.25 | 18,375,000 | 219,135,313 | |
2017-07-05 |
|
4 | CORI |
Corium International, Inc.
Common Stock |
P - Purchase | 301,004 | 5,847,133 | 5.43 | 7.70 | 2,319,236 | 45,052,160 | |
2017-07-05 |
|
4 | ALDX |
Aldeyra Therapeutics, Inc.
Common Stock |
P - Purchase | 296,007 | 2,885,458 | 11.43 | 4.60 | 1,361,632 | 13,273,107 | |
2017-07-05 |
|
4 | ZGNX |
ZOGENIX, INC.
Common Stock |
P - Purchase | 175,653 | 3,448,302 | 5.37 | 14.45 | 2,538,186 | 49,827,964 | |
2017-06-21 |
|
4 | ACRX |
ACELRX PHARMACEUTICALS INC
Common Stock |
S - Sale | -875,000 | 4,533,728 | -16.18 | 2.40 | -2,100,000 | 10,880,947 | |
2017-05-25 |
|
4 | CORI |
Corium International, Inc.
Common Stock |
P - Purchase | 1,902,400 | 5,546,129 | 52.21 | 6.25 | 11,890,000 | 34,663,306 | |
2017-05-25 | 3 | CORI |
Corium International, Inc.
Common Stock |
7,287,458 | ||||||||
2017-05-25 | 3 | CORI |
Corium International, Inc.
Common Stock |
7,287,458 | ||||||||
2017-05-25 | 3 | CORI |
Corium International, Inc.
Common Stock |
7,287,458 | ||||||||
2017-05-25 | 3 | CORI |
Corium International, Inc.
Common Stock |
7,287,458 | ||||||||
2017-05-18 | 3 | ZGNX |
ZOGENIX, INC.
Common Stock |
6,545,298 | ||||||||
2017-05-18 | 3 | ZGNX |
ZOGENIX, INC.
Common Stock |
6,545,298 | ||||||||
2017-05-18 | 3 | ZGNX |
ZOGENIX, INC.
Common Stock |
6,545,298 | ||||||||
2017-05-18 | 3 | ZGNX |
ZOGENIX, INC.
Common Stock |
6,545,298 | ||||||||
2017-03-14 |
|
4/A | VSAR |
Versartis, Inc.
Common Stock |
P - Purchase | 59,133 | 4,229,563 | 1.42 | 15.51 | 917,425 | 65,619,978 | |
2017-03-14 |
|
4/A | VSAR |
Versartis, Inc.
Common Stock |
P - Purchase | 34,883 | 4,170,430 | 0.84 | 14.94 | 521,281 | 62,321,655 | |
2017-02-15 |
|
4 | ALDX |
Aldeyra Therapeutics, Inc.
Common Stock |
P - Purchase | 893,025 | 2,589,451 | 52.64 | 4.50 | 4,018,612 | 11,652,530 | |
2017-02-14 |
|
4 | VSAR |
Versartis, Inc.
Common Stock |
P - Purchase | 59,133 | 4,228,563 | 1.42 | 15.51 | 917,425 | 65,604,464 | |
2017-02-14 |
|
4 | VSAR |
Versartis, Inc.
Common Stock |
P - Purchase | 34,883 | 4,169,430 | 0.84 | 14.94 | 521,281 | 62,306,711 | |
2017-02-10 |
|
4 | VSAR |
Versartis, Inc.
Common Stock |
P - Purchase | 41,211 | 4,134,547 | 1.01 | 14.27 | 587,928 | 58,984,688 | |
2017-02-10 |
|
4 | VSAR |
Versartis, Inc.
Common Stock |
P - Purchase | 104,612 | 4,093,336 | 2.62 | 13.51 | 1,413,319 | 55,301,379 | |
2017-01-04 |
|
4 | VSAR |
Versartis, Inc.
Common Stock |
P - Purchase | 94,750 | 4,013,411 | 2.42 | 14.66 | 1,388,846 | 58,828,578 | |
2017-01-04 |
|
4 | FOLD |
AMICUS THERAPEUTICS INC
Common Stock |
P - Purchase | 94,750 | 16,293,847 | 0.58 | 4.96 | 470,055 | 80,833,775 | |
2017-01-04 |
|
4/A | VSAR |
Versartis, Inc.
Common Stock |
P - Purchase | 71,063 | 3,989,724 | 1.81 | 14.66 | 1,041,641 | 58,481,374 | |
2016-12-30 |
|
4 | VSAR |
Versartis, Inc.
Common Stock |
P - Purchase | 47,375 | 3,918,661 | 1.22 | 14.37 | 680,589 | 56,295,484 | |
2016-12-30 |
|
4 | FOLD |
AMICUS THERAPEUTICS INC
Common Stock |
P - Purchase | 94,750 | 16,293,847 | 0.58 | 4.85 | 459,916 | 79,090,333 | |
2016-12-30 |
|
4 | FOLD |
AMICUS THERAPEUTICS INC
Common Stock |
P - Purchase | 47,375 | 16,199,097 | 0.29 | 4.91 | 232,706 | 79,569,964 | |
2016-12-27 |
|
4 | FOLD |
AMICUS THERAPEUTICS INC
Common Stock |
P - Purchase | 37,900 | 16,151,722 | 0.24 | 4.92 | 186,582 | 79,514,927 | |
2016-12-27 |
|
4 | FOLD |
AMICUS THERAPEUTICS INC
Common Stock |
P - Purchase | 47,375 | 16,113,822 | 0.29 | 4.72 | 223,468 | 76,008,898 | |
2016-12-23 |
|
4 | FOLD |
AMICUS THERAPEUTICS INC
Common Stock |
P - Purchase | 189,500 | 16,066,447 | 1.19 | 4.51 | 854,834 | 72,475,742 | |
2016-12-08 |
|
4 | VBIV |
VBI VACCINES INC.
Warrant |
P - Purchase | 1,341,282 | 2,068,824 | 184.36 | 3.36 | 4,500,001 | 6,940,905 | |
2016-12-08 |
|
4 | VBIV |
VBI VACCINES INC.
Warrant |
P - Purchase | 363,771 | 727,542 | 100.00 | 4.13 | 1,502,374 | 3,004,748 | |
2016-12-08 |
|
4 | VBIV |
VBI VACCINES INC.
Common Stock |
P - Purchase | 3,383,955 | 6,213,314 | 119.60 | 3.05 | 10,321,063 | 18,950,608 | |
2016-12-02 | 3 | FOLD |
AMICUS THERAPEUTICS INC
Common Stock |
26,447,894 | ||||||||
2016-12-02 | 3 | FOLD |
AMICUS THERAPEUTICS INC
Common Stock |
26,447,894 | ||||||||
2016-12-02 | 3 | FOLD |
AMICUS THERAPEUTICS INC
Common Stock |
26,447,894 | ||||||||
2016-12-02 | 3 | FOLD |
AMICUS THERAPEUTICS INC
Common Stock |
26,447,894 | ||||||||
2016-12-02 | 3/A | FOLD |
AMICUS THERAPEUTICS INC
Common Stock |
15,876,947 | ||||||||
2016-10-05 | 3/A | VSAR |
Versartis, Inc.
Common Stock |
3,871,286 | ||||||||
2016-09-30 |
|
4 | ACRX |
ACELRX PHARMACEUTICALS INC
Common Stock |
S - Sale | -97,200 | 5,386,410 | -1.77 | 3.88 | -377,117 | 20,898,194 | |
2016-09-30 |
|
4 | ACRX |
ACELRX PHARMACEUTICALS INC
Common Stock |
S - Sale | -119,300 | 5,483,610 | -2.13 | 3.96 | -472,380 | 21,712,902 | |
2016-09-28 | 3 | VSAR |
Versartis, Inc.
Common Stock |
7,594,838 | ||||||||
2016-09-28 | 3 | VSAR |
Versartis, Inc.
Common Stock |
7,594,838 | ||||||||
2016-09-28 | 3 | VSAR |
Versartis, Inc.
Common Stock |
7,594,838 | ||||||||
2016-09-28 | 3 | VSAR |
Versartis, Inc.
Common Stock |
7,594,838 | ||||||||
2016-09-16 |
|
4 | ACRX |
ACELRX PHARMACEUTICALS INC
Common Stock |
S - Sale | -115,923 | 5,602,910 | -2.03 | 3.63 | -420,511 | 20,324,556 | |
2016-09-16 |
|
4 | ACRX |
ACELRX PHARMACEUTICALS INC
Common Stock |
S - Sale | -276,927 | 5,718,833 | -4.62 | 3.73 | -1,032,301 | 21,318,094 | |
2016-08-26 |
|
4 | FOLD |
AMICUS THERAPEUTICS INC
Common Stock |
S - Sale | -1,100,000 | 14,139,444 | -7.22 | 6.81 | -7,491,000 | 96,289,614 | |
2016-05-26 |
|
4 | ALDX |
Aldeyra Therapeutics, Inc.
Common Stock |
P - Purchase | 700,000 | 1,940,458 | 56.43 | 5.00 | 3,500,000 | 9,702,290 | |
2015-11-19 |
|
4 | ACRX |
ACELRX PHARMACEUTICALS INC
Common Stock |
S - Sale | -42,300 | 5,995,760 | -0.70 | 5.35 | -226,132 | 32,052,733 | |
2015-11-19 |
|
4 | ACRX |
ACELRX PHARMACEUTICALS INC
Common Stock |
S - Sale | -133,900 | 6,038,060 | -2.17 | 5.36 | -717,409 | 32,350,718 | |
2015-11-09 |
|
4 | ACRX |
ACELRX PHARMACEUTICALS INC
Common Stock |
S - Sale | -17,100 | 6,171,960 | -0.28 | 4.47 | -76,365 | 27,562,739 | |
2015-11-09 |
|
4 | ACRX |
ACELRX PHARMACEUTICALS INC
Common Stock |
S - Sale | -75,000 | 6,189,060 | -1.20 | 4.62 | -346,260 | 28,573,652 | |
2015-11-05 |
|
4 | ALDX |
Aldeyra Therapeutics, Inc.
Common Stock |
P - Purchase | 45,100 | 1,240,458 | 3.77 | 6.50 | 293,150 | 8,062,977 | |
2015-10-28 |
|
4 | ALDX |
Aldeyra Therapeutics, Inc.
Common Stock |
P - Purchase | 50,000 | 1,195,358 | 4.37 | 6.46 | 323,150 | 7,725,599 | |
2015-10-26 |
|
4 | ALDX |
Aldeyra Therapeutics, Inc.
Common Stock |
P - Purchase | 18,020 | 1,145,358 | 1.60 | 6.47 | 116,661 | 7,415,048 | |
2015-10-22 |
|
4 | ALDX |
Aldeyra Therapeutics, Inc.
Common Stock |
P - Purchase | 22,797 | 1,127,338 | 2.06 | 6.44 | 146,858 | 7,262,311 | |
2015-10-22 |
|
4 | ALDX |
Aldeyra Therapeutics, Inc.
Common Stock |
P - Purchase | 14,348 | 1,104,541 | 1.32 | 6.30 | 90,335 | 6,954,190 | |
2015-10-22 | 3 | ALDX |
Aldeyra Therapeutics, Inc.
Common Stock |
2,180,386 | ||||||||
2015-10-22 | 3 | ALDX |
Aldeyra Therapeutics, Inc.
Common Stock |
2,180,386 | ||||||||
2015-10-22 | 3 | ALDX |
Aldeyra Therapeutics, Inc.
Common Stock |
2,180,386 | ||||||||
2015-10-22 | 3 | ALDX |
Aldeyra Therapeutics, Inc.
Common Stock |
2,180,386 | ||||||||
2015-10-08 |
|
4 | FOLD |
AMICUS THERAPEUTICS INC
Common Stock |
P - Purchase | 50,000 | 15,239,444 | 0.33 | 6.27 | 313,500 | 95,551,314 | |
2015-10-07 |
|
4 | FOLD |
AMICUS THERAPEUTICS INC
Common Stock |
P - Purchase | 7,000 | 15,189,444 | 0.05 | 6.34 | 44,380 | 96,301,075 | |
2015-10-07 |
|
4 | FOLD |
AMICUS THERAPEUTICS INC
Common Stock |
P - Purchase | 14,000 | 15,182,444 | 0.09 | 6.47 | 90,580 | 98,230,413 | |
2015-10-07 |
|
4 | FOLD |
AMICUS THERAPEUTICS INC
Common Stock |
P - Purchase | 14,000 | 15,168,444 | 0.09 | 6.65 | 93,100 | 100,870,153 | |
2015-10-07 |
|
4 | FOLD |
AMICUS THERAPEUTICS INC
Common Stock |
P - Purchase | 43,000 | 15,154,444 | 0.28 | 6.34 | 272,620 | 96,079,175 | |
2015-10-07 |
|
4 | FOLD |
AMICUS THERAPEUTICS INC
Common Stock |
P - Purchase | 86,000 | 15,111 | -121.32 | 6.47 | 556,420 | 97,771 | |
2015-10-07 |
|
4 | FOLD |
AMICUS THERAPEUTICS INC
Common Stock |
P - Purchase | 86,000 | 15,025,444 | 0.58 | 6.65 | 571,900 | 99,919,203 | |
2015-10-07 |
|
4 | FOLD |
AMICUS THERAPEUTICS INC
Common Stock |
P - Purchase | 35,000 | 14,939,444 | 0.23 | 6.76 | 236,600 | 100,990,641 | |
2015-10-07 |
|
4 | FOLD |
AMICUS THERAPEUTICS INC
Common Stock |
P - Purchase | 35,000 | 14,904,444 | 0.24 | 6.85 | 239,750 | 102,095,441 | |
2015-10-07 |
|
4 | FOLD |
AMICUS THERAPEUTICS INC
Common Stock |
P - Purchase | 215,000 | 14,869,444 | 1.47 | 6.76 | 1,453,400 | 100,517,441 | |
2015-10-07 |
|
4 | FOLD |
AMICUS THERAPEUTICS INC
Common Stock |
P - Purchase | 215,000 | 14,654,444 | 1.49 | 6.85 | 1,472,750 | 100,382,941 | |
2015-09-11 |
|
4 | ACRX |
ACELRX PHARMACEUTICALS INC
Common Stock |
S - Sale | -310,000 | 6,264,060 | -4.72 | 4.18 | -1,294,777 | 26,163,099 | |
2015-08-18 |
|
4 | VBIV |
VBI VACCINES INC.
Common Stock |
P - Purchase | 650,000 | 3,260,356 | 24.90 | 2.08 | 1,352,000 | 6,781,540 | |
2014-11-19 |
|
4 | FOLD |
AMICUS THERAPEUTICS INC
Common Stock |
P - Purchase | 2,100,000 | 14,439,444 | 17.02 | 6.50 | 13,650,000 | 93,856,386 | |
2014-07-01 |
|
4 | FOLD |
AMICUS THERAPEUTICS INC
Common Stock |
P - Purchase | 530,000 | 12,339,444 | 4.49 | 3.50 | 1,855,000 | 43,188,054 | |
2014-07-01 |
|
4 | FOLD |
AMICUS THERAPEUTICS INC
Common Stock |
P - Purchase | 3,470,000 | 11,809,444 | 41.61 | 3.50 | 12,145,000 | 41,333,054 | |
2014-05-30 | 3 | FOLD |
AMICUS THERAPEUTICS INC
Common Stock |
16,678,888 | ||||||||
2014-05-30 | 3 | FOLD |
AMICUS THERAPEUTICS INC
Common Stock |
16,678,888 | ||||||||
2014-05-30 | 3 | FOLD |
AMICUS THERAPEUTICS INC
Common Stock |
16,678,888 | ||||||||
2014-05-30 | 3 | FOLD |
AMICUS THERAPEUTICS INC
Common Stock |
16,678,888 | ||||||||
2013-11-12 |
|
4 | ACRX |
ACELRX PHARMACEUTICALS INC
Common Stock |
P - Purchase | 6,500 | 6,574,060 | 0.10 | 6.50 | 42,238 | 42,718,899 | |
2013-11-12 |
|
4 | ACRX |
ACELRX PHARMACEUTICALS INC
Common Stock |
P - Purchase | 93,500 | 6,567,560 | 1.44 | 6.50 | 607,572 | 42,676,662 | |
2013-11-12 |
|
4 | ACRX |
ACELRX PHARMACEUTICALS INC
Common Stock |
P - Purchase | 6,500 | 6,474,060 | 0.10 | 6.52 | 42,358 | 42,188,859 | |
2013-11-12 |
|
4 | ACRX |
ACELRX PHARMACEUTICALS INC
Common Stock |
P - Purchase | 93,500 | 6,467,560 | 1.47 | 6.52 | 609,302 | 42,146,501 | |
2013-11-06 |
|
4 | ACRX |
ACELRX PHARMACEUTICALS INC
Common Stock |
P - Purchase | 3,250 | 6,374,060 | 0.05 | 6.84 | 22,220 | 43,579,448 | |
2013-11-06 |
|
4 | ACRX |
ACELRX PHARMACEUTICALS INC
Common Stock |
P - Purchase | 46,750 | 6,370,810 | 0.74 | 6.84 | 319,630 | 43,557,228 | |
2013-11-06 |
|
4 | ACRX |
ACELRX PHARMACEUTICALS INC
Common Stock |
P - Purchase | 6,825 | 6,324,060 | 0.11 | 6.88 | 46,959 | 43,512,062 | |
2013-11-06 |
|
4 | ACRX |
ACELRX PHARMACEUTICALS INC
Common Stock |
P - Purchase | 98,175 | 6,317,235 | 1.58 | 6.88 | 675,483 | 43,465,104 | |
2013-11-04 |
|
4 | ACRX |
ACELRX PHARMACEUTICALS INC
Common Stock |
P - Purchase | 150,218 | 6,219,060 | 2.48 | 7.17 | 1,077,033 | 44,589,416 | |
2013-11-04 |
|
4 | ACRX |
ACELRX PHARMACEUTICALS INC
Common Stock |
P - Purchase | 10,442 | 6,068,842 | 0.17 | 7.17 | 74,867 | 43,512,383 | |
2013-11-04 |
|
4 | ACRX |
ACELRX PHARMACEUTICALS INC
Common Stock |
P - Purchase | 8,000 | 6,058,400 | 0.13 | 6.69 | 53,546 | 40,550,083 | |
2013-11-04 |
|
4 | ACRX |
ACELRX PHARMACEUTICALS INC
Common Stock |
P - Purchase | 192,000 | 6,050,400 | 3.28 | 6.69 | 1,285,094 | 40,496,537 | |
2013-09-09 |
|
4 | AEGR |
Aegerion Pharmaceuticals, Inc.
Common Stock |
S - Sale | -50,000 | 2,823,426 | -1.74 | 89.20 | -4,460,000 | 251,849,599 | |
2013-09-09 |
|
4 | AEGR |
Aegerion Pharmaceuticals, Inc.
Common Stock |
S - Sale | -700,000 | 2,873,426 | -19.59 | 89.20 | -62,440,000 | 256,309,599 | |
2013-09-09 |
|
4 | AEGR |
Aegerion Pharmaceuticals, Inc.
Call option (right to buy) |
X - Other | -1,000 | 0 | -100.00 | ||||
2013-09-09 |
|
4 | AEGR |
Aegerion Pharmaceuticals, Inc.
Call option (right to buy) |
X - Other | -1,000 | 0 | -100.00 | ||||
2013-09-09 |
|
4 | AEGR |
Aegerion Pharmaceuticals, Inc.
Common Stock |
X - Other | 100,000 | 3,573,426 | 2.88 | 25.00 | 2,500,000 | 89,335,650 | |
2013-09-09 |
|
4 | AEGR |
Aegerion Pharmaceuticals, Inc.
Common Stock |
X - Other | 100,000 | 3,473,426 | 2.96 | 25.00 | 2,500,000 | 86,835,650 | |
2013-07-24 |
|
4 | ACRX |
ACELRX PHARMACEUTICALS INC
Common Stock |
P - Purchase | 850,000 | 5,858,400 | 16.97 | 11.65 | 9,902,500 | 68,250,360 | |
2013-03-20 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Call option (right to sell) |
E - Other | 500 | 22,000 | 2.33 | ||||
2013-03-20 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Call option (right to sell) |
E - Other | 500 | 22,000 | 2.33 | ||||
2013-03-20 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Call option (right to sell) |
E - Other | 500 | 22,500 | 2.27 | ||||
2013-03-20 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Call option (right to sell) |
E - Other | 500 | 23,000 | 2.22 | ||||
2013-03-20 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Call option (right to sell) |
E - Other | 500 | 23,500 | 2.17 | ||||
2013-03-20 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Call option (right to sell) |
E - Other | 1,000 | 24,000 | 4.35 | ||||
2013-03-20 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Call option (right to sell) |
E - Other | 1,000 | 24,000 | 4.35 | ||||
2013-03-20 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Call option (right to sell) |
E - Other | 1,000 | 25,000 | 4.17 | ||||
2013-03-20 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Call option (right to sell) |
E - Other | 1,500 | 26,000 | 6.12 | ||||
2013-03-20 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Call option (right to sell) |
E - Other | 2,000 | 27,500 | 7.84 | ||||
2013-03-20 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Call option (right to sell) |
E - Other | 2,000 | 27,500 | 7.84 | ||||
2013-03-20 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Call option (right to sell) |
E - Other | 6,000 | 29,500 | 25.53 | ||||
2013-03-20 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Call option (right to sell) |
E - Other | 1,000 | 36,000 | 2.86 | ||||
2013-03-20 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Call option (right to sell) |
E - Other | 4,000 | 40,000 | 11.11 | ||||
2013-03-20 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Put option (right to sell) |
X - Other | 500 | 44,000 | 1.15 | ||||
2013-03-20 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Put option (right to sell) |
X - Other | 500 | 44,000 | 1.15 | ||||
2013-03-20 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Put option (right to sell) |
X - Other | 500 | 44,500 | 1.14 | ||||
2013-03-20 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Put option (right to sell) |
X - Other | 500 | 45,000 | 1.12 | ||||
2013-03-20 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Put option (right to sell) |
X - Other | 1,000 | 45,500 | 2.25 | ||||
2013-03-20 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Put option (right to sell) |
X - Other | 1,000 | 45,500 | 2.25 | ||||
2013-03-20 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Put option (right to sell) |
X - Other | 500 | ||||||
2013-03-20 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Put option (right to sell) |
X - Other | 1,000 | 47,500 | 2.15 | ||||
2013-03-20 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Put option (right to sell) |
X - Other | 1,000 | 48,500 | 2.11 | ||||
2013-03-20 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Put option (right to sell) |
X - Other | 1,500 | 49,500 | 3.12 | ||||
2013-03-20 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Put option (right to sell) |
X - Other | 1,500 | 49,500 | 3.12 | ||||
2013-03-20 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Put option (right to sell) |
X - Other | 4,000 | 51,000 | 8.51 | ||||
2013-03-20 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Put option (right to sell) |
X - Other | 4,000 | 51,000 | 8.51 | ||||
2013-03-20 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Put option (right to sell) |
X - Other | 1,000 | 55,000 | 1.85 | ||||
2013-03-20 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Put option (right to sell) |
X - Other | 2,000 | 56,000 | 3.70 | ||||
2013-03-20 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Common Stock |
X - Other | -50,000 | 812,560 | -5.80 | 10.00 | -500,000 | 8,125,600 | |
2013-03-20 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Common Stock |
X - Other | -50,000 | 812,560 | -5.80 | 10.00 | -500,000 | 8,125,600 | |
2013-03-20 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Common Stock |
X - Other | -50,000 | 862,560 | -5.48 | 12.50 | -625,000 | 10,782,000 | |
2013-03-20 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Common Stock |
X - Other | -50,000 | 862,560 | -5.48 | 12.50 | -625,000 | 10,782,000 | |
2013-03-20 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Common Stock |
X - Other | -50,000 | 862,560 | -5.48 | 12.50 | -625,000 | 10,782,000 | |
2013-03-20 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Common Stock |
X - Other | -100,000 | 962,560 | -9.41 | 12.50 | -1,250,000 | 12,032,000 | |
2013-03-20 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Common Stock |
X - Other | -100,000 | 962,560 | -9.41 | 12.50 | -1,250,000 | 12,032,000 | |
2013-03-20 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Common Stock |
X - Other | -100,000 | 962,560 | -9.41 | 12.50 | -1,250,000 | 12,032,000 | |
2013-03-20 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Common Stock |
X - Other | -100,000 | 1,162,560 | -7.92 | 10.00 | -1,000,000 | 11,625,600 | |
2013-03-20 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Common Stock |
X - Other | -150,000 | 1,362,560 | -9.92 | 12.50 | -1,875,000 | 17,032,000 | |
2013-03-20 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Common Stock |
X - Other | -400,000 | 1,512,560 | -20.91 | 12.50 | -5,000,000 | 18,907,000 | |
2013-03-20 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Common Stock |
X - Other | -400,000 | 1,512,560 | -20.91 | 12.50 | -5,000,000 | 18,907,000 | |
2013-03-20 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Common Stock |
X - Other | -200,000 | 2,012,560 | -9.04 | 12.50 | -2,500,000 | 25,157,000 | |
2013-03-20 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Common Stock |
X - Other | -150,000 | 2,612,560 | -5.43 | 15.00 | -2,250,000 | 39,188,400 | |
2013-03-20 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Common Stock |
X - Other | -100,000 | 2,762,560 | -3.49 | 10.00 | -1,000,000 | 27,625,600 | |
2013-03-06 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Put option (right to sell) |
P - Purchase | 500 | 64,500 | 0.78 | 2.76 | 1,380 | 178,020 | |
2013-03-06 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Put option (right to sell) |
P - Purchase | 1,000 | 64,000 | 1.59 | 1.94 | 1,945 | 124,480 | |
2013-03-06 |
|
4 | AEGR |
Aegerion Pharmaceuticals, Inc.
Call option (right to buy) |
P - Purchase | 1,000 | 2,000 | 100.00 | 8.26 | 8,260 | 16,520 | |
2013-03-06 |
|
4 | AEGR |
Aegerion Pharmaceuticals, Inc.
Call option (right to buy) |
P - Purchase | 1,000 | 2,000 | 100.00 | 8.26 | 8,260 | 16,520 | |
2013-02-27 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Put option (right to sell) |
P - Purchase | 500 | 63,000 | 0.80 | 0.90 | 450 | 56,700 | |
2013-02-27 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Call option (obligation to sell) |
S - Sale | -500 | 62,500 | -0.79 | 1.05 | -525 | 65,625 | |
2013-02-21 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Put option (right to sell) |
P - Purchase | 500 | 62,000 | 0.81 | 0.78 | 390 | 48,360 | |
2013-02-21 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Call option (obligation to sell) |
S - Sale | -500 | 61,500 | -0.81 | 1.04 | -520 | 63,960 | |
2013-02-21 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Put option (right to sell) |
P - Purchase | 1,000 | 61,000 | 1.67 | 0.79 | 790 | 48,190 | |
2013-02-21 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Call option (obligation to sell) |
S - Sale | -1,000 | 60,000 | -1.64 | 0.89 | -890 | 53,400 | |
2013-02-13 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Put option (right to sell) |
P - Purchase | 1,000 | 59,000 | 1.72 | 2.08 | 2,080 | 122,720 | |
2013-02-13 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Call option (obligation to sell) |
S - Sale | -1,000 | 58,000 | -1.69 | 0.38 | -380 | 22,040 | |
2013-02-08 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Put option (right to sell) |
P - Purchase | 1,500 | 57,000 | 2.70 | 2.33 | 3,495 | 132,810 | |
2013-02-08 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Call option (obligation to sell) |
S - Sale | -1,500 | 55,500 | -2.63 | 0.27 | -405 | 14,985 | |
2013-02-08 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Put option (right to sell) |
P - Purchase | 4,000 | 54,000 | 8.00 | 1.65 | 6,600 | 89,100 | |
2013-02-08 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Call option (obligation to sell) |
S - Sale | -2,000 | 50,000 | -3.85 | 0.55 | -1,100 | 27,500 | |
2013-02-06 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Call option (obligation to sell) |
S - Sale | -6,000 | 48,000 | -11.11 | 0.69 | -4,140 | 33,120 | |
2013-02-06 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Call option (obligation to sell) |
S - Sale | -500 | 42,000 | -1.18 | 2.05 | -1,025 | 86,100 | |
2013-02-05 |
|
4 | AEGR |
Aegerion Pharmaceuticals, Inc.
Common Stock |
P - Purchase | 50,000 | 3,373,426 | 1.50 | 27.79 | 1,389,400 | 93,740,762 | |
2013-02-04 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Call option (obligation to sell) |
S - Sale | -1,000 | 41,500 | -2.35 | 0.80 | -800 | 33,200 | |
2013-02-01 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Put option (right to sell) |
P - Purchase | 1,000 | 40,500 | 2.53 | 1.45 | 1,450 | 58,725 | |
2013-02-01 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Call option (obligation to sell) |
S - Sale | -1,000 | 39,500 | -2.47 | 0.88 | -875 | 34,562 | |
2013-02-01 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Put option (right to sell) |
P - Purchase | 2,000 | 38,500 | 5.48 | 1.32 | 2,650 | 51,012 | |
2013-02-01 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Call option (obligation to sell) |
S - Sale | -2,000 | 36,500 | -5.19 | 1.05 | -2,100 | 38,325 | |
2013-01-30 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Put option (right to sell) |
P - Purchase | 4,000 | 34,500 | 13.11 | 1.71 | 6,840 | 58,995 | |
2013-01-30 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Call option (right to buy) |
P - Purchase | 500 | 30,500 | 1.67 | 0.05 | 25 | 1,525 | |
2013-01-30 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Call option (right to buy) |
P - Purchase | 500 | 30,000 | 1.69 | 0.10 | 50 | 3,000 | |
2013-01-30 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Call option (obligation to sell) |
S - Sale | -4,000 | 29,500 | -11.94 | 0.80 | -3,200 | 23,600 | |
2013-01-30 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Put option (right to sell) |
P - Purchase | 2,000 | 25,500 | 8.51 | 1.50 | 3,000 | 38,250 | |
2013-01-30 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Put option (right to sell) |
P - Purchase | 2,000 | 23,500 | 9.30 | 1.85 | 3,700 | 43,475 | |
2013-01-30 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Put option (right to sell) |
P - Purchase | 2,000 | 21,500 | 10.26 | 0.65 | 1,300 | 13,979 | |
2013-01-30 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Put option (right to sell) |
P - Purchase | 1,500 | 19,500 | 8.33 | 2.87 | 4,300 | 55,901 | |
2013-01-30 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Put option (right to sell) |
P - Purchase | 1,000 | 18,000 | 5.88 | 0.80 | 800 | 14,400 | |
2013-01-30 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Call option (obligation to sell) |
S - Sale | -1,000 | 17,000 | -5.56 | 1.19 | -1,190 | 20,230 | |
2013-01-30 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Call option (obligation to sell) |
S - Sale | -1,000 | 16,000 | -5.88 | 2.43 | -2,428 | 38,846 | |
2013-01-30 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Call option (obligation to sell) |
S - Sale | -1,000 | 15,000 | -6.25 | 0.80 | -800 | 12,000 | |
2013-01-30 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Call option (obligation to sell) |
S - Sale | -2,000 | 14,000 | -12.50 | 1.47 | -2,935 | 20,545 | |
2013-01-30 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Call option (obligation to sell) |
S - Sale | -2,000 | 12,000 | -14.29 | 1.00 | -2,001 | 12,004 | |
2013-01-30 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Call option (obligation to sell) |
S - Sale | -2,000 | 10,000 | -16.67 | 0.88 | -1,757 | 8,787 | |
2013-01-23 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Call option (obligation to sell) |
S - Sale | -500 | 8,000 | -5.88 | 0.80 | -400 | 6,400 | |
2013-01-23 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Call option (obligation to sell) |
S - Sale | -500 | 7,500 | -6.25 | 1.40 | -702 | 10,531 | |
2013-01-22 |
|
4 | AEGR |
Aegerion Pharmaceuticals, Inc.
Common Stock |
P - Purchase | 50,000 | 3,323,426 | 1.53 | 27.62 | 1,381,000 | 91,793,026 | |
2013-01-18 |
|
4 | AEGR |
Aegerion Pharmaceuticals, Inc.
Common Stock |
P - Purchase | 25,000 | 3,273,426 | 0.77 | 26.73 | 668,142 | 87,484,601 | |
2013-01-18 |
|
4 | AEGR |
Aegerion Pharmaceuticals, Inc.
Common Stock |
P - Purchase | 25,000 | 3,273,426 | 0.77 | 26.73 | 668,142 | 87,484,601 | |
2013-01-15 |
|
4 | AEGR |
Aegerion Pharmaceuticals, Inc.
Common Stock |
P - Purchase | 150,000 | 3,223,426 | 4.88 | 26.64 | 3,996,000 | 85,872,069 | |
2013-01-15 |
|
4 | AEGR |
Aegerion Pharmaceuticals, Inc.
Common Stock |
P - Purchase | 200,000 | 3,073,426 | 6.96 | 27.66 | 5,531,220 | 84,998,977 | |
2013-01-15 |
|
4 | AEGR |
Aegerion Pharmaceuticals, Inc.
Common Stock |
P - Purchase | 125,000 | 2,873,426 | 4.55 | 26.64 | 3,330,000 | 76,548,069 | |
2013-01-11 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Call option (obligation to sell) |
S - Sale | -2,000 | 7,000 | -22.22 | 1.89 | -3,780 | 13,230 | |
2013-01-04 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Call option (obligation to sell) |
S - Sale | -1,000 | 5,000 | -16.67 | 1.20 | -1,200 | 6,000 | |
2013-01-04 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Call option (obligation to sell) |
S - Sale | -1,000 | 4,000 | -20.00 | 1.91 | -1,910 | 7,640 | |
2013-01-04 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Call option (obligation to sell) |
S - Sale | -2,000 | 3,000 | -40.00 | 1.35 | -2,700 | 4,050 | |
2013-01-04 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Call option (obligation to sell) |
S - Sale | -1,000 | 1,000 | -50.00 | 2.01 | -2,010 | 2,010 | |
2012-12-13 | 3 | ACRX |
ACELRX PHARMACEUTICALS INC
Common Stock |
5,008,400 | ||||||||
2012-12-05 |
|
4 | AEGR |
Aegerion Pharmaceuticals, Inc.
Common Stock |
P - Purchase | 20,000 | 2,615,293 | 0.77 | 21.27 | 425,400 | 55,627,282 | |
2012-12-03 |
|
4 | AEGR |
Aegerion Pharmaceuticals, Inc.
COMMON STOCK |
P - Purchase | 70,000 | 2,565,293 | 2.81 | 21.76 | 1,523,200 | 55,820,776 | |
2012-12-03 |
|
4 | AEGR |
Aegerion Pharmaceuticals, Inc.
COMMON STOCK |
P - Purchase | 20,000 | 2,495,293 | 0.81 | 20.75 | 415,000 | 51,777,330 | |
2012-12-03 |
|
4 | AEGR |
Aegerion Pharmaceuticals, Inc.
COMMON STOCK |
P - Purchase | 20,000 | 2,475,293 | 0.81 | 21.01 | 420,200 | 52,005,906 | |
2012-12-03 |
|
4 | AEGR |
Aegerion Pharmaceuticals, Inc.
COMMON STOCK |
P - Purchase | 10,000 | 2,455,293 | 0.41 | 19.50 | 195,000 | 47,878,214 | |
2012-12-03 |
|
4 | AEGR |
Aegerion Pharmaceuticals, Inc.
COMMON STOCK |
P - Purchase | 30,000 | 2,445,293 | 1.24 | 21.12 | 633,600 | 51,644,588 | |
2012-12-03 |
|
4 | AEGR |
Aegerion Pharmaceuticals, Inc.
COMMON STOCK |
P - Purchase | 30,000 | 2,595,293 | 1.17 | 22.71 | 681,300 | 58,939,104 | |
2012-12-03 |
|
4 | AEGR |
Aegerion Pharmaceuticals, Inc.
CALL OPTION (OBLIGATION TO SELL) |
X - Other | -2,475 | 0 | -100.00 | ||||
2012-12-03 |
|
4 | AEGR |
Aegerion Pharmaceuticals, Inc.
COMMON STOCK |
X - Other | -247,500 | 2,347,233 | -9.54 | 17.50 | -4,331,250 | 41,076,578 | |
2012-12-03 | 3 | AEGR |
Aegerion Pharmaceuticals, Inc.
COMMON STOCK |
2,415,293 | ||||||||
2012-12-03 | 3 | AEGR |
Aegerion Pharmaceuticals, Inc.
COMMON STOCK |
133,133 | ||||||||
2012-12-03 | 3 | AEGR |
Aegerion Pharmaceuticals, Inc.
COMMON STOCK |
2,594,733 | ||||||||
2012-12-03 | 3 | AEGR |
Aegerion Pharmaceuticals, Inc.
COMMON STOCK |
133,133 | ||||||||
2012-05-15 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Common Stock |
P - Purchase | 59,500 | 2,862,560 | 2.12 | 7.38 | 439,283 | 21,133,994 | |
2012-05-14 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Common Stock |
P - Purchase | 25,000 | 2,803,060 | 0.90 | 6.35 | 158,800 | 17,805,037 | |
2012-05-14 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Common Stock |
P - Purchase | 145,000 | 2,778,060 | 5.51 | 6.35 | 921,040 | 17,646,237 | |
2012-05-11 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Common Stock |
P - Purchase | 15,000 | 2,633,060 | 0.57 | 4.82 | 72,300 | 12,691,349 | |
2012-05-11 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Common Stock |
P - Purchase | 310,000 | 2,618,060 | 13.43 | 4.82 | 1,493,797 | 12,615,646 | |
2008-12-03 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
S - Sale | -9,600,000 | 20,580,260 | -31.81 | 0.15 | -1,466,880 | 3,144,664 | |
2008-12-03 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
S - Sale | -299,570 | 0 | -100.00 | 0.15 | -45,774 | ||
2008-12-03 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
S - Sale | -400,000 | 299,570 | -57.18 | 0.15 | -61,120 | 45,774 | |
2008-12-03 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
S - Sale | -1,943,250 | 699,570 | -73.53 | 0.14 | -273,804 | 98,569 | |
2008-12-03 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
S - Sale | -400,000 | 2,642,820 | -13.15 | 0.16 | -64,560 | 426,551 | |
2008-12-03 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
S - Sale | -29,740 | 3,042,820 | -0.97 | 0.16 | -4,729 | 483,808 | |
2008-12-03 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
S - Sale | -2,696,450 | 30,180,260 | -8.20 | 0.15 | -412,018 | 4,611,544 | |
2008-12-03 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
S - Sale | -24,681,360 | 32,876,710 | -42.88 | 0.14 | -3,477,604 | 4,632,328 | |
2008-06-19 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 2,040 | 3,072,560 | 0.07 | 3.23 | 6,589 | 9,924,369 | |
2008-06-19 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 48,960 | 57,558,070 | 0.09 | 3.23 | 158,141 | 185,912,566 | |
2008-06-11 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 1,340 | 3,070,520 | 0.04 | 3.36 | 4,502 | 10,316,947 | |
2008-06-11 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 32,260 | 57,509,110 | 0.06 | 3.36 | 108,394 | 193,230,610 | |
2008-06-11 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 4,000 | 3,069,180 | 0.13 | 3.43 | 13,720 | 10,527,287 | |
2008-06-11 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 96,000 | 57,476,850 | 0.17 | 3.43 | 329,280 | 197,145,596 | |
2008-06-11 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 8,000 | 3,065,180 | 0.26 | 3.15 | 25,200 | 9,655,317 | |
2008-06-11 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 4,000 | 3,057,180 | 0.13 | 3.37 | 13,480 | 10,302,697 | |
2008-06-11 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 192,000 | 57,380,850 | 0.34 | 3.15 | 604,800 | 180,749,678 | |
2008-06-11 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinarry Shares |
P - Purchase | 96,000 | 57,188,850 | 0.17 | 3.37 | 323,520 | 192,726,424 | |
2008-05-06 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 2,000 | 3,036,140 | 0.07 | 3.88 | 7,760 | 11,780,223 | |
2008-05-06 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 48,000 | 56,683,890 | 0.08 | 3.88 | 186,240 | 219,933,493 | |
2008-05-06 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 4,200 | 3,034,140 | 0.14 | 3.75 | 15,750 | 11,378,025 | |
2008-05-06 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 100,800 | 56,635,890 | 0.18 | 3.75 | 378,000 | 212,384,588 | |
2008-04-16 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 10,000 | 3,015,650 | 0.33 | 3.56 | 35,579 | 10,729,381 | |
2008-04-16 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 90,000 | 56,191,770 | 0.16 | 3.58 | 322,011 | 201,048,534 | |
2008-03-20 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 6,650 | 2,984,350 | 0.22 | 3.12 | 20,749 | 9,311,769 | |
2008-03-20 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 156,350 | 55,797,070 | 0.28 | 3.12 | 487,843 | 174,098,018 | |
2008-03-20 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 12,000 | 2,977,700 | 0.40 | 3.32 | 39,856 | 9,889,835 | |
2008-03-20 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 15,780 | 2,965,700 | 0.53 | 3.33 | 52,566 | 9,879,340 | |
2008-03-20 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary shares |
P - Purchase | 188,000 | 55,640,720 | 0.34 | 3.32 | 624,404 | 184,799,523 | |
2008-03-20 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary shares |
P - Purchase | 247,220 | 55,452,720 | 0.45 | 3.33 | 823,539 | 184,724,101 | |
2008-03-20 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 6,000 | 2,949,920 | 0.20 | 3.37 | 20,240 | 9,950,965 | |
2008-03-20 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 8,820 | 2,943,920 | 0.30 | 3.38 | 29,814 | 9,951,333 | |
2008-03-20 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 9,000 | 2,935,100 | 0.31 | 3.37 | 30,295 | 9,879,840 | |
2008-03-20 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary shares |
P - Purchase | 17,400 | 2,926,100 | 0.60 | 3.35 | 58,292 | 9,802,728 | |
2008-03-19 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 94,000 | 55,205,500 | 0.17 | 3.37 | 317,090 | 186,224,713 | |
2008-03-19 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 138,180 | 55,111,500 | 0.25 | 3.38 | 467,090 | 186,293,403 | |
2008-03-19 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 272,600 | 54,973,320 | 0.50 | 3.35 | 913,237 | 184,166,119 | |
2008-03-19 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 141,000 | 54,700,720 | 0.26 | 3.37 | 474,620 | 184,128,094 | |
2008-03-19 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 11,900 | 2,908,700 | 0.41 | 3.30 | 39,327 | 9,612,672 | |
2008-03-19 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 30,000 | 2,896,800 | 1.05 | 3.31 | 99,351 | 9,593,333 | |
2008-03-19 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 107,100 | 54,559,720 | 0.20 | 3.30 | 353,944 | 180,308,963 | |
2008-03-19 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 470,000 | 54,452,620 | 0.87 | 3.31 | 1,556,499 | 180,330,742 | |
2008-03-19 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 25,200 | 2,866,800 | 0.89 | 3.28 | 82,568 | 9,393,070 | |
2008-03-19 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 30,000 | 2,841,600 | 1.07 | 3.15 | 94,500 | 8,951,040 | |
2008-03-19 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 30,000 | 2,811,600 | 1.08 | 3.25 | 97,368 | 9,125,329 | |
2008-03-19 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 394,800 | 5,398,260 | 7.89 | 3.28 | 1,293,562 | 17,687,399 | |
2008-03-19 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 470,000 | 53,587,820 | 0.88 | 3.15 | 1,480,500 | 168,801,633 | |
2008-03-19 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 470,000 | 53,117,820 | 0.89 | 3.25 | 1,525,432 | 172,399,197 | |
2008-03-19 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 60,000 | 2,781,600 | 2.20 | 3.74 | 224,268 | 10,397,064 | |
2008-03-19 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 9,020 | 2,721,600 | 0.33 | 3.65 | 32,893 | 9,924,859 | |
2008-03-19 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 141,440 | 52,647,820 | 0.27 | 3.65 | 515,789 | 191,990,805 | |
2008-03-19 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 940,000 | 52,506,380 | 1.82 | 3.74 | 3,513,532 | 196,258,347 | |
2008-03-19 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 39,300 | 2,712,580 | 1.47 | 3.86 | 151,824 | 10,479,239 | |
2008-03-19 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 15,600 | 2,673,280 | 0.59 | 3.73 | 58,146 | 9,964,117 | |
2008-03-19 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 244,400 | 51,566,380 | 0.48 | 3.73 | 910,952 | 192,203,368 | |
2008-03-19 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 615,700 | 51,321,980 | 1.21 | 3.86 | 2,378,572 | 198,267,073 | |
2008-03-10 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 34,200 | 2,657,680 | 1.30 | 3.94 | 134,700 | 10,467,538 | |
2008-03-10 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 535,800 | 50,706,280 | 1.07 | 3.94 | 2,110,302 | 199,711,754 | |
2008-03-10 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 6,640 | 2,623,480 | 0.25 | 3.99 | 26,490 | 10,466,111 | |
2008-03-10 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 18,000 | 2,616,840 | 0.69 | 3.98 | 71,656 | 10,417,378 | |
2008-03-10 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 282,000 | 50,170,480 | 0.57 | 3.98 | 1,122,614 | 199,723,664 | |
2008-03-10 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 104,060 | 49,888,480 | 0.21 | 3.99 | 415,137 | 199,025,102 | |
2008-02-29 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 6,600 | 2,598,840 | 0.25 | 4.01 | 26,484 | 10,428,365 | |
2008-02-29 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 103,400 | 49,784,420 | 0.21 | 4.01 | 414,913 | 199,769,942 | |
2008-02-28 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 3,790 | 2,592,240 | 0.15 | 3.95 | 14,970 | 10,239,348 | |
2008-02-28 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 24,000 | 2,588,450 | 0.94 | 3.91 | 93,742 | 10,110,227 | |
2008-02-28 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 59,390 | 49,681,020 | 0.12 | 3.95 | 234,590 | 196,240,029 | |
2008-02-28 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 376,000 | 49,621,630 | 0.76 | 3.91 | 1,468,618 | 193,817,125 | |
2008-02-28 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 46,500 | 2,564,450 | 1.85 | 3.87 | 179,871 | 9,919,805 | |
2008-02-28 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 6,000 | 2,517,950 | 0.24 | 3.86 | 23,159 | 9,718,783 | |
2008-02-28 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 94,000 | 49,245,630 | 0.19 | 3.86 | 362,821 | 190,078,283 | |
2008-02-28 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 728,500 | 49,151,630 | 1.50 | 3.87 | 2,817,984 | 190,128,335 | |
2008-02-28 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 12,000 | 2,511,950 | 0.48 | 3.95 | 47,431 | 9,928,734 | |
2008-02-28 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 30,000 | 2,499,950 | 1.21 | 3.95 | 118,374 | 9,864,303 | |
2008-02-28 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 28,380 | 2,469,950 | 1.16 | 3.95 | 112,101 | 9,756,302 | |
2008-02-28 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 188,000 | 48,432,130 | 0.39 | 3.95 | 743,089 | 191,432,837 | |
2008-02-28 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 470,000 | 48,235,130 | 0.98 | 3.95 | 1,854,526 | 190,326,176 | |
2008-02-28 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 444,620 | 47,765,130 | 0.94 | 3.95 | 1,756,249 | 188,672,264 | |
2008-02-22 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 100 | 2,441,570 | 0.00 | 3.84 | 384 | 9,375,629 | |
2008-02-22 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 900 | 47,320,510 | 0.00 | 3.84 | 3,456 | 181,710,758 | |
2008-02-19 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 360 | 2,441,470 | 0.01 | 3.81 | 1,371 | 9,297,606 | |
2008-02-19 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 5,640 | 473,196,910 | 0.00 | 3.81 | 21,478 | 1,802,028,473 | |
2008-02-08 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary shares |
P - Purchase | 600 | 3,441,110 | 0.02 | 3.40 | 2,038 | 11,686,010 | |
2008-02-08 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary shares |
P - Purchase | 9,400 | 47,313,970 | 0.02 | 3.40 | 31,922 | 160,678,242 | |
2008-02-08 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 21,000 | 2,440,510 | 0.87 | 3.71 | 77,914 | 9,054,780 | |
2008-02-08 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 120 | 2,419,510 | 0.00 | 3.68 | 442 | 8,903,797 | |
2008-02-08 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 329,000 | 47,304,570 | 0.70 | 3.71 | 1,220,656 | 175,509,416 | |
2008-02-08 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary shares |
P - Purchase | 1,880 | 46,975,570 | 0.00 | 3.68 | 6,918 | 172,870,098 | |
2008-02-06 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary shares |
P - Purchase | 9,060 | 2,419,390 | 0.38 | 3.79 | 34,314 | 9,163,198 | |
2008-02-06 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary shares |
P - Purchase | 6,060 | 2,410,330 | 0.25 | 3.75 | 22,725 | 9,038,738 | |
2008-02-06 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary shares |
P - Purchase | 141,940 | 46,973,690 | 0.30 | 3.79 | 537,584 | 177,908,154 | |
2008-02-06 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary shares |
P - Purchase | 94,940 | 46,831,750 | 0.20 | 3.75 | 356,025 | 175,619,062 | |
2008-02-06 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary shares |
P - Purchase | 8,400 | 2,404,270 | 0.35 | 3.87 | 32,495 | 9,300,678 | |
2008-02-06 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary shares |
P - Purchase | 33,000 | 2,320,270 | 1.44 | 3.88 | 128,056 | 9,003,808 | |
2008-02-06 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary shares |
P - Purchase | 131,600 | 46,736,810 | 0.28 | 3.87 | 509,081 | 180,796,676 | |
2008-02-06 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary shares |
P - Purchase | 517,000 | 46,605,210 | 1.12 | 3.88 | 2,006,218 | 180,851,517 | |
2008-02-05 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 42,000 | 2,322,870 | 1.84 | 3.69 | 155,022 | 8,573,713 | |
2008-02-05 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 658,000 | 46,088,210 | 1.45 | 3.69 | 2,428,678 | 170,111,583 | |
2008-02-05 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 30,000 | 2,320,870 | 1.31 | 3.43 | 102,987 | 7,967,315 | |
2008-02-05 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 23,640 | 2,290,870 | 1.04 | 3.50 | 82,723 | 8,016,441 | |
2008-02-05 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 470,000 | 45,430,210 | 1.05 | 3.43 | 1,613,463 | 155,957,368 | |
2008-02-05 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 370,360 | 44,960,210 | 0.83 | 3.50 | 1,296,001 | 157,329,263 | |
2008-02-01 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 15,000 | 2,267,230 | 0.67 | 3.23 | 48,456 | 7,324,060 | |
2008-02-01 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 235,000 | 44,589,850 | 0.53 | 3.23 | 759,144 | 144,043,051 | |
2008-01-30 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 6,000 | 2,252,230 | 0.27 | 3.23 | 19,379 | 7,274,252 | |
2008-01-30 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 94,000 | 44,354,850 | 0.21 | 3.23 | 303,601 | 143,257,295 | |
2008-01-30 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 600 | 2,246,230 | 0.03 | 3.23 | 1,938 | 7,255,323 | |
2008-01-30 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 40,200 | 2,245,630 | 1.82 | 3.21 | 129,203 | 7,217,455 | |
2008-01-30 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 9,400 | 44,260,850 | 0.02 | 3.23 | 30,362 | 142,962,546 | |
2008-01-30 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 629,800 | 44,251,450 | 1.44 | 3.21 | 2,024,177 | 142,224,160 | |
2008-01-29 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 12,000 | 2,205,430 | 0.55 | 3.24 | 38,856 | 7,141,182 | |
2008-01-29 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 188,000 | 43,621,650 | 0.43 | 3.24 | 608,744 | 141,246,903 | |
2008-01-28 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 42,300 | 2,193,430 | 1.97 | 2.99 | 126,477 | 6,558,356 | |
2008-01-28 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 13,800 | 2,151,130 | 0.65 | 2.98 | 41,124 | 6,410,367 | |
2008-01-28 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 66,270 | 43,433,650 | 0.15 | 2.99 | 198,147 | 129,866,614 | |
2008-01-28 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 216,200 | 42,770,950 | 0.51 | 2.98 | 644,276 | 127,457,431 | |
2008-01-28 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 18,000 | 2,137,330 | 0.85 | 2.88 | 51,908 | 6,163,632 | |
2008-01-28 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 282,000 | 42,554,750 | 0.67 | 2.88 | 813,232 | 122,719,388 | |
2008-01-25 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 790 | 2,119,330 | 0.04 | 2.90 | 2,293 | 6,151,355 | |
2008-01-25 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 12,520 | 42,272,750 | 0.03 | 2.90 | 36,339 | 122,696,657 | |
2008-01-25 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 7,560 | 2,118,540 | 0.36 | 3.16 | 23,888 | 6,694,163 | |
2008-01-25 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 11,820 | 2,110,980 | 0.56 | 3.13 | 36,994 | 6,606,945 | |
2008-01-25 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 118,440 | 42,260,230 | 0.28 | 3.16 | 374,247 | 133,533,875 | |
2008-01-25 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 185,180 | 42,141,790 | 0.44 | 3.13 | 579,576 | 131,895,374 | |
2008-01-25 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 11,460 | 2,099,160 | 0.55 | 3.01 | 34,444 | 6,309,235 | |
2008-01-25 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 9,240 | 2,087,700 | 0.44 | 3.06 | 28,240 | 6,380,638 | |
2008-01-25 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 144,760 | 41,956,610 | 0.35 | 3.06 | 442,430 | 128,231,987 | |
2008-01-25 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 179,540 | 41,811,850 | 0.43 | 3.01 | 539,625 | 125,669,696 | |
2008-01-25 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 27,600 | 2,078,460 | 1.35 | 3.06 | 84,346 | 6,351,774 | |
2008-01-25 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 180 | 2,008,860 | 0.01 | 3.16 | 568 | 6,341,368 | |
2008-01-25 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 432,400 | 41,632,310 | 1.05 | 3.10 | 1,340,440 | 129,060,161 | |
2008-01-25 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 2,820 | 41,199,910 | 0.01 | 3.16 | 8,902 | 130,055,756 | |
2008-01-25 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 42,000 | 2,050,680 | 2.09 | 3.11 | 130,712 | 6,382,126 | |
2008-01-25 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 15,000 | 2,008,680 | 0.75 | 3.06 | 45,909 | 6,147,766 | |
2008-01-25 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 658,000 | 41,197,090 | 1.62 | 3.11 | 2,047,828 | 128,213,583 | |
2008-01-25 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 235,000 | 40,539,090 | 0.58 | 3.06 | 719,241 | 124,073,939 | |
2008-01-18 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 27,600 | 2,078,460 | 1.35 | 3.10 | 85,560 | 6,443,226 | |
2008-01-18 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 180 | 2,050,860 | 0.01 | 3.16 | 568 | 6,473,950 | |
2008-01-18 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 432,400 | 41,632,310 | 1.05 | 3.10 | 1,340,440 | 129,060,161 | |
2008-01-18 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 2,820 | 41,199,910 | 0.01 | 3.16 | 8,902 | 130,055,756 | |
2008-01-18 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 42,000 | 2,050,680 | 2.09 | 3.11 | 130,712 | 6,382,126 | |
2008-01-18 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 15,000 | 2,008,680 | 0.75 | 3.06 | 45,909 | 6,147,766 | |
2008-01-18 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 658,000 | 41,197,090 | 1.62 | 3.11 | 2,047,828 | 128,213,583 | |
2008-01-18 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 235,000 | 40,539,000 | 0.58 | 3.06 | 719,241 | 124,073,663 | |
2008-01-15 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 22,200 | 1,993,680 | 1.13 | 3.41 | 75,724 | 6,800,442 | |
2008-01-15 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 347,800 | 40,304,090 | 0.87 | 3.41 | 1,186,346 | 137,477,251 | |
2008-01-15 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 28,320 | 1,971,480 | 1.46 | 3.39 | 96,076 | 6,688,246 | |
2008-01-15 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 443,680 | 39,956,290 | 1.12 | 3.39 | 1,505,184 | 135,551,714 | |
2008-01-11 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 69,000 | 1,943,160 | 3.68 | 3.30 | 227,748 | 6,413,788 | |
2008-01-11 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 1,081,000 | 39,521,610 | 2.81 | 3.30 | 3,568,057 | 130,448,978 | |
2008-01-11 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 36,000 | 1,874,160 | 1.96 | 3.27 | 117,896 | 6,137,687 | |
2008-01-11 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 24,060 | 1,838,160 | 1.33 | 3.30 | 79,283 | 6,057,105 | |
2008-01-11 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 564,000 | 37,431,610 | 1.53 | 3.27 | 1,847,044 | 122,584,780 | |
2008-01-11 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 376,940 | 37,867,610 | 1.01 | 3.30 | 1,242,093 | 124,781,348 | |
2008-01-11 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 30,000 | 1,814,100 | 1.68 | 3.26 | 97,743 | 5,910,519 | |
2008-01-11 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 20,000 | 1,784,100 | 1.13 | 2.87 | 57,372 | 5,117,869 | |
2008-01-11 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 81,600 | 1,764,100 | 4.85 | 3.11 | 253,401 | 5,478,236 | |
2008-01-11 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 6,000 | 1,682,500 | 0.36 | 3.10 | 18,600 | 5,215,750 | |
2008-01-11 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 1,278,400 | 37,020,670 | 3.58 | 3.11 | 3,969,943 | 114,963,989 | |
2008-01-11 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 94,000 | 35,742,270 | 0.26 | 3.10 | 291,400 | 110,801,037 | |
2008-01-11 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 180,000 | 35,648,270 | 0.51 | 2.87 | 516,348 | 102,260,627 | |
2008-01-11 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 470,000 | 37,490,670 | 1.27 | 3.26 | 1,531,307 | 122,148,352 | |
2008-01-04 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 1,222,000 | 35,045,270 | 3.61 | 2.89 | 3,531,580 | 101,280,830 | |
2008-01-04 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 78,000 | 1,649,500 | 4.96 | 2.89 | 225,420 | 4,767,055 | |
2008-01-02 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 69,000 | 1,571,500 | 4.59 | 2.74 | 188,750 | 4,298,838 | |
2008-01-02 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 1,081,000 | 33,823,270 | 3.30 | 2.74 | 2,957,076 | 92,523,555 | |
2008-01-02 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 48,000 | 1,502,500 | 3.30 | 2.69 | 129,226 | 4,045,030 | |
2008-01-02 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 752,000 | 32,742,270 | 2.35 | 2.69 | 2,024,534 | 88,148,739 | |
2007-12-31 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 18,000 | 1,454,500 | 1.25 | 2.60 | 46,717 | 3,775,009 | |
2007-12-31 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 282,000 | 31,990,270 | 0.89 | 2.60 | 731,903 | 83,027,547 | |
2007-12-31 | 3/A | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
31,708,270 | ||||||||
2007-12-07 | 3 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
27,876,060 | ||||||||
2007-12-07 | 3 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
1,436,500 | ||||||||
2004-12-06 |
|
4 | BPA |
BIOSANTE PHARMACEUTICALS INC
Common Stock |
S - Sale | -1,315,000 | 209,100 | -86.28 | 4.72 | -6,200,225 | 985,906 | |
2004-12-06 |
|
4 | BPA |
BIOSANTE PHARMACEUTICALS INC
Common Stock |
S - Sale | -50,000 | 1,524,100 | -3.18 | 4.55 | -227,500 | 6,934,655 | |
2004-12-06 |
|
4 | BPA |
BIOSANTE PHARMACEUTICALS INC
Common Stock |
S - Sale | -30,000 | 1,574,100 | -1.87 | 4.35 | -130,500 | 6,847,335 | |
2004-12-06 |
|
4 | BPA |
BIOSANTE PHARMACEUTICALS INC
Common Stock |
S - Sale | -273,550 | 1,604,100 | -14.57 | 4.47 | -1,222,221 | 7,167,119 | |
2004-12-06 |
|
4 | BPA |
BIOSANTE PHARMACEUTICALS INC
Common Stock |
P - Purchase | 2,000 | 1,877,650 | 0.11 | 3.98 | 7,960 | 7,473,047 | |
2004-12-06 |
|
4 | BPA |
BIOSANTE PHARMACEUTICALS INC
Common Stock |
S - Sale | -2,000 | 1,875,650 | -0.11 | 4.47 | -8,936 | 8,380,404 | |
2004-12-06 |
|
4 | BPA |
BIOSANTE PHARMACEUTICALS INC
Common Stock |
S - Sale | -25,000 | 1,877,650 | -1.31 | 4.90 | -122,500 | 9,200,485 | |
2004-12-06 |
|
4 | BPA |
BIOSANTE PHARMACEUTICALS INC
Common Stock |
S - Sale | -70,900 | 1,902,650 | -3.59 | 4.47 | -316,781 | 8,501,040 | |
2004-12-06 |
|
4 | BPA |
BIOSANTE PHARMACEUTICALS INC
Common Stock |
S - Sale | -28,550 | 0 | -100.00 | 4.47 | -127,561 | ||
2004-10-12 |
|
4 | BPA |
BIOSANTE PHARMACEUTICALS INC
Common Stock |
P - Purchase | 14,900 | 1,973,550 | 0.76 | 9.87 | 146,991 | 19,469,465 | |
2004-10-12 |
|
4 | BPA |
BIOSANTE PHARMACEUTICALS INC
Common Stock |
P - Purchase | 1,000 | 27,950 | 3.71 | 9.87 | 9,865 | 275,732 | |
2004-10-08 |
|
4 | BPA |
BIOSANTE PHARMACEUTICALS INC
Common Stock |
P - Purchase | 9,000 | 1,958,650 | 0.46 | 10.11 | 90,964 | 19,796,271 | |
2004-10-08 |
|
4 | BPA |
BIOSANTE PHARMACEUTICALS INC
Common Stock |
P - Purchase | 1,000 | 26,950 | 3.85 | 10.11 | 10,107 | 272,386 | |
2004-10-08 |
|
4 | BPA |
BIOSANTE PHARMACEUTICALS INC
Common Stock |
P - Purchase | 9,000 | 1,949,650 | 0.46 | 9.90 | 89,112 | 19,304,070 | |
2004-10-08 |
|
4 | BPA |
BIOSANTE PHARMACEUTICALS INC
Common Stock |
P - Purchase | 1,000 | 25,950 | 4.01 | 9.90 | 9,901 | 256,939 | |
2004-10-06 |
|
4 | BPA |
BIOSANTE PHARMACEUTICALS INC
Common Stock |
P - Purchase | 15,800 | 1,940,650 | 0.82 | 9.90 | 156,417 | 19,212,047 | |
2004-10-06 |
|
4 | BPA |
BIOSANTE PHARMACEUTICALS INC
Common Stock |
P - Purchase | 1,700 | 24,950 | 7.31 | 9.90 | 16,830 | 247,000 | |
2004-10-06 |
|
4 | BPA |
BIOSANTE PHARMACEUTICALS INC
Common Stock |
P - Purchase | 13,100 | 1,924,850 | 0.69 | 9.72 | 127,341 | 18,710,889 | |
2004-10-06 |
|
4 | BPA |
BIOSANTE PHARMACEUTICALS INC
Common Stock |
P - Purchase | 1,400 | 23,250 | 6.41 | 9.72 | 13,609 | 226,006 | |
2004-10-04 |
|
4 | BPA |
BIOSANTE PHARMACEUTICALS INC
Common Stock |
P - Purchase | 19,400 | 1,911,750 | 1.03 | 9.59 | 186,046 | 18,333,682 | |
2004-10-04 |
|
4 | BPA |
BIOSANTE PHARMACEUTICALS INC
Common Stock |
P - Purchase | 2,100 | 21,850 | 10.63 | 9.59 | 20,139 | 209,542 | |
2004-10-04 |
|
4 | BPA |
BIOSANTE PHARMACEUTICALS INC
Common Stock |
P - Purchase | 9,000 | 1,892,350 | 0.48 | 8.96 | 80,680 | 16,963,972 | |
2004-10-04 |
|
4 | BPA |
BIOSANTE PHARMACEUTICALS INC
Common Stock |
P - Purchase | 1,000 | 19,750 | 5.33 | 8.96 | 8,964 | 177,049 | |
2004-09-16 |
|
4 | BPA |
BIOSANTE PHARMACEUTICALS INC
Common Stock |
P - Purchase | 22,100 | 1,883,350 | 1.19 | 7.69 | 169,843 | 14,473,921 | |
2004-09-16 |
|
4 | BPA |
BIOSANTE PHARMACEUTICALS INC
Common Stock |
P - Purchase | 2,400 | 18,750 | 14.68 | 7.69 | 18,444 | 144,098 | |
2004-09-15 |
|
4 | BPA |
BIOSANTE PHARMACEUTICALS INC
Common Stock |
P - Purchase | 23,400 | 1,861,250 | 1.27 | 7.17 | 167,734 | 13,341,626 | |
2004-09-15 |
|
4 | BPA |
BIOSANTE PHARMACEUTICALS INC
Common Stock |
P - Purchase | 2,500 | 16,350 | 18.05 | 7.17 | 17,920 | 117,198 | |
2004-09-13 |
|
4 | BPA |
BIOSANTE PHARMACEUTICALS INC
Common Stock |
P - Purchase | 4,300 | 1,837,850 | 0.23 | 6.85 | 29,455 | 12,589,272 | |
2004-09-13 |
|
4 | BPA |
BIOSANTE PHARMACEUTICALS INC
Common Stock |
P - Purchase | 400 | 13,850 | 2.97 | 6.85 | 2,740 | 94,872 | |
2004-09-01 |
|
4 | BPA |
BIOSANTE PHARMACEUTICALS INC
Common Stock |
P - Purchase | 9,000 | 1,833,550 | 0.49 | 6.84 | 61,563 | 12,542,032 | |
2004-09-01 |
|
4 | BPA |
BIOSANTE PHARMACEUTICALS INC
Common Stock |
P - Purchase | 9,000 | 1,824,550 | 0.50 | 6.84 | 61,537 | 12,475,178 | |
2004-09-01 |
|
4 | BPA |
BIOSANTE PHARMACEUTICALS INC
Common Stock |
P - Purchase | 1,000 | 13,450 | 8.03 | 6.84 | 6,837 | 91,963 | |
2004-08-20 |
|
4 | BPA |
BIOSANTE PHARMACEUTICALS INC
Common Stock |
P - Purchase | 700 | 12,450 | 5.96 | 5.84 | 4,091 | 72,765 | |
2004-08-20 |
|
4 | BPA |
BIOSANTE PHARMACEUTICALS INC
Common Stock |
P - Purchase | 6,200 | 1,815,550 | 0.34 | 5.84 | 36,237 | 10,611,164 | |
2004-08-20 |
|
4 | BPA |
BIOSANTE PHARMACEUTICALS INC
Common Stock |
P - Purchase | 4,500 | 11,750 | 62.07 | 5.83 | 26,214 | 68,447 | |
2004-08-20 |
|
4 | BPA |
BIOSANTE PHARMACEUTICALS INC
Common Stock |
P - Purchase | 40,500 | 1,809,350 | 2.29 | 5.83 | 235,925 | 10,540,007 | |
2004-08-19 |
|
4 | BPA |
BIOSANTE PHARMACEUTICALS INC
Common Stock |
S - Sale | -200 | 7,250 | -2.68 | 5.50 | -1,100 | 39,875 | |
2004-08-19 |
|
4 | BPA |
BIOSANTE PHARMACEUTICALS INC
Common Stock |
P - Purchase | 200 | 7,450 | 2.76 | 5.10 | 1,020 | 37,995 | |
2004-08-16 |
|
4 | BPA |
BIOSANTE PHARMACEUTICALS INC
Common Stock |
P - Purchase | 2,500 | 1,768,850 | 0.14 | 4.75 | 11,875 | 8,402,038 | |
2004-08-13 |
|
4 | BPA |
BIOSANTE PHARMACEUTICALS INC
Common Stock |
P - Purchase | 2,300 | 7,250 | 46.46 | 4.72 | 10,850 | 34,202 | |
2004-08-13 |
|
4 | BPA |
BIOSANTE PHARMACEUTICALS INC
Common Stock |
P - Purchase | 21,300 | 1,766,350 | 1.22 | 4.72 | 100,483 | 8,332,756 | |
2004-07-21 |
|
4 | BPA |
BIOSANTE PHARMACEUTICALS INC
Common Stock |
P - Purchase | 2,800 | 4,950 | 130.23 | 5.67 | 15,889 | 28,090 | |
2004-07-21 |
|
4 | BPA |
BIOSANTE PHARMACEUTICALS INC
Common Stock |
P - Purchase | 25,652 | 1,745,050 | 1.49 | 5.67 | 145,567 | 9,902,635 | |
2004-07-19 |
|
4 | BPA |
BIOSANTE PHARMACEUTICALS INC
Common Stock |
P - Purchase | 1,400 | 2,150 | 186.67 | 5.89 | 8,242 | 12,657 | |
2004-07-19 |
|
4 | BPA |
BIOSANTE PHARMACEUTICALS INC
Common Stock |
P - Purchase | 12,648 | 1,719,398 | 0.74 | 5.89 | 74,468 | 10,123,300 | |
2004-07-19 |
|
4 | BPA |
BIOSANTE PHARMACEUTICALS INC
Common Stock |
P - Purchase | 750 | 750 | 5.96 | 4,472 | 4,472 | ||
2004-07-19 |
|
4 | BPA |
BIOSANTE PHARMACEUTICALS INC
Common Stock |
P - Purchase | 6,750 | 1,706,750 | 0.40 | 5.96 | 40,252 | 10,177,862 | |
2004-05-18 |
|
4/A | BPA |
BIOSANTE PHARMACEUTICALS INC
Warrants |
P - Purchase | 97,500 | 97,500 | |||||
2004-05-18 |
|
4/A | BPA |
BIOSANTE PHARMACEUTICALS INC
Common Stock |
P - Purchase | 650,000 | 1,700,000 | 61.90 | 6.00 | 3,900,000 | 10,200,000 | |
2004-05-12 |
|
4 | BPA |
BIOSANTE PHARMACEUTICALS INC
Common Stock |
P - Purchase | 650,000 | 1,700,000 | 61.90 | 6.00 | 3,900,000 | 10,200,000 | |
2004-02-12 | 3 | ANTR.OB |
ANTARES PHARMA INC
Common Stock, $0.01 par value per share |
2,700,000 | ||||||||
2004-02-05 |
|
4 | BPA |
BIOSANTE PHARMACEUTICALS INC
Common Stock |
S - Sale | -87,400 | 1,050,000 | -7.68 | 6.44 | -562,576 | 6,758,640 | |
2004-01-23 |
|
4 | BPA |
BIOSANTE PHARMACEUTICALS INC
Common Stock |
S - Sale | -35,000 | 1,137,400 | -2.99 | 5.62 | -196,700 | 6,392,188 | |
2004-01-23 |
|
4 | BPA |
BIOSANTE PHARMACEUTICALS INC
Common Stock |
S - Sale | -100,000 | 1,172,400 | -7.86 | 5.68 | -568,000 | 6,659,232 | |
2004-01-23 |
|
4 | BPA |
BIOSANTE PHARMACEUTICALS INC
Common Stock |
S - Sale | -5,000 | 1,272,400 | -0.39 | 5.65 | -28,250 | 7,189,060 | |
2004-01-23 |
|
4 | BPA |
BIOSANTE PHARMACEUTICALS INC
Common Stock |
S - Sale | -15,000 | 1,277,400 | -1.16 | 5.84 | -87,600 | 7,460,016 | |
2004-01-23 |
|
4 | BPA |
BIOSANTE PHARMACEUTICALS INC
Common Stock |
S - Sale | -100,000 | 1,292,400 | -7.18 | 5.66 | -566,000 | 7,314,984 | |
2003-08-13 | 3 | BISP.OB |
BIOSANTE PHARMACEUTICALS INC
Common Stock, par value $0.0001 |
225,000 | ||||||||
2003-08-13 | 3 | BISP.OB |
BIOSANTE PHARMACEUTICALS INC
Common Stock, par value $0.0001 |
1,392,400 |